Science.gov

Sample records for artificial heart devices

  1. High reliability linear drive device for artificial hearts

    NASA Astrophysics Data System (ADS)

    Ji, Jinghua; Zhao, Wenxiang; Liu, Guohai; Shen, Yue; Wang, Fangqun

    2012-04-01

    In this paper, a new high reliability linear drive device, termed as stator-permanent-magnet tubular oscillating actuator (SPM-TOA), is proposed for artificial hearts (AHs). The key is to incorporate the concept of two independent phases into this linear AH device, hence achieving high reliability operation. The fault-tolerant teeth are employed to provide the desired decoupling phases in magnetic circuit. Also, as the magnets and the coils are located in the stator, the proposed SPM-TOA takes the definite advantages of robust mover and direct-drive capability. By using the time-stepping finite element method, the electromagnetic characteristics of the proposed SPM-TOA are analyzed, including magnetic field distributions, flux linkages, back- electromotive forces (back-EMFs) self- and mutual inductances, as well as cogging and thrust forces. The results confirm that the proposed SPM-TOA meets the dimension, weight, and force requirements of the AH drive device.

  2. Fatal Acanthamoeba Encephalitis in a Patient With a Total Artificial Heart (Syncardia) Device

    PubMed Central

    Tan, Susanna K.; Gajurel, Kiran; Tung, Christie; Albers, Gregory; Deresinski, Stan; Montoya, Jose G.; Sheikh, Ahmad Y.; Banerjee, Dipanjan; Ha, Richard

    2014-01-01

    Acanthamoeba encephalitis is an uncommon but often fatal infection complication. Here we report the first case of Acanthamoeba encephalitis in a patient with a Total Artificial Heart device. PMID:25734127

  3. Fatal acanthamoeba encephalitis in a patient with a total artificial heart (syncardia) device.

    PubMed

    Tan, Susanna K; Gajurel, Kiran; Tung, Christie; Albers, Gregory; Deresinski, Stan; Montoya, Jose G; Sheikh, Ahmad Y; Banerjee, Dipanjan; Ha, Richard

    2014-09-01

    Acanthamoeba encephalitis is an uncommon but often fatal infection complication. Here we report the first case of Acanthamoeba encephalitis in a patient with a Total Artificial Heart device. PMID:25734127

  4. Artificial heart and assist devices: directions, needs, costs, societal and ethical issues.

    PubMed

    Van Citters, R L; Bauer, C B; Christopherson, L K; Eberhart, R C; Eddy, D M; Frye, R L; Jonsen, A R; Keller, K H; Levine, R J; McGoon, D C

    1985-11-01

    A Working Group appointed by the Director of the National Heart, Lung, and Blood Institute (NHBLI) has reviewed the current status of mechanical circulatory support systems (MCSS), and has examined the potential need for such devices, their cost, and certain societal and ethical issues related to their use. The media have reported the limited clinical investigative use of pneumatically energized total artificial hearts (which actually replace the patient's heart) and left ventricular assist devices (which support or replace the function of the left ventricle by pumping blood from the left heart to the aorta with the patient's heart in place). However, electrically energized systems, which will allow full implantation, permit relatively normal everyday activity, and involve battery exchange or recharge two or three times a day, are currently approaching long-term validation in animals prior to clinical testing. Such long-term left ventricular assist devices have been the primary goal of the NHLBI targeted artificial heart program. Although the ventricular assist device is regarded as an important step in the sequence of MCSS development, the Working Group believes that a fully implantable, long-term, total artificial heart will be a clinical necessity and recommends that the mission of the targeted program include the development of such systems. Past estimates of the potential usage of artificial hearts have been reviewed in the context of advances in medical care and in the prevention of cardiovascular disease. In addition, a retrospective analysis of needs was carried out within a defined population. The resulting projection of 17,000-35,000 cases annually, in patients below age 70, falls within the general range of earlier estimates, but is highly sensitive to many variables. In the absence of an actual base of data and experience with MCSS, projection of costs and prognoses was carried out using explicit sets of assumptions. The total cost of a left ventricular

  5. The total artificial heart

    PubMed Central

    Cook, Jason A.; Shah, Keyur B.; Quader, Mohammed A.; Cooke, Richard H.; Kasirajan, Vigneshwar; Rao, Kris K.; Smallfield, Melissa C.; Tchoukina, Inna

    2015-01-01

    The total artificial heart (TAH) is a form of mechanical circulatory support in which the patient’s native ventricles and valves are explanted and replaced by a pneumatically powered artificial heart. Currently, the TAH is approved for use in end-stage biventricular heart failure as a bridge to heart transplantation. However, with an increasing global burden of cardiovascular disease and congestive heart failure, the number of patients with end-stage heart failure awaiting heart transplantation now far exceeds the number of available hearts. As a result, the use of mechanical circulatory support, including the TAH and left ventricular assist device (LVAD), is growing exponentially. The LVAD is already widely used as destination therapy, and destination therapy for the TAH is under investigation. While most patients requiring mechanical circulatory support are effectively treated with LVADs, there is a subset of patients with concurrent right ventricular failure or major structural barriers to LVAD placement in whom TAH may be more appropriate. The history, indications, surgical implantation, post device management, outcomes, complications, and future direction of the TAH are discussed in this review. PMID:26793338

  6. Wearable air supply for pneumatic artificial hearts and ventricular assist devices.

    PubMed

    Sipin, A J; Fabrey, W J; Smith, S H; Doussourd, J D; Olsen, D B

    1992-08-01

    An experimental wearable air supply for pneumatic artificial hearts and ventricular assist devices has been built and tested. The unit eliminates the need for tethering to a large, stationery driver. The miniaturized air supply is designed for ambulatory patients with implanted pulsatile pneumatic total artificial hearts (TAH) or pneumatic left-ventricular assist devices (LVAD), to permit mobility in clinical and home settings. The device has major short-term utility as a supply for pneumatic TAH or VAD bridges in patients awaiting heart transplants. The system design for the wearable driver includes a novel, fast rotary compressor, driven by a brushless direct current (DC) motor to supply air to the ventricle through an electromagnetically actuated directional valve, all controlled by a microcomputer. Stroke volume from 0 to 200 cc; pulse rate from 60 to 160 bpm, and duty cycle from 33% to 50% are selected on a keyboard, and the selected or measured parameters can be shown on a liquid crystal display. For control of delivery from a single ventricular assist device, stroke volume is controlled by variation of compressor speed. In the wearable air supply for a TAH, a single compressor drives both ventricles alternately through a double-acting directional valve. Air volume delivered to the left ventricle is adjusted by variation of compressor speed, and air volume to the right ventricle by variation of ejection time. The effect on blood flow rate of the lower impedance to the right ventricle is compensated by provision of a two-stage compressor, in which a single stage drives the right ventricle, and both stages connected in parallel drive the left ventricle. The overall dimensions of the prototype air supply for driving either a TAH or LVAD are 4.5 by 7.8 by 4.5 inches, including an emergency battery with a duration of 15 to 30 min depending on load. The weight is presently 5.5 lb, but this will be reduced in a production design and for a dedicated LVAD air supply

  7. Artificial heart for humanoid robot

    NASA Astrophysics Data System (ADS)

    Potnuru, Akshay; Wu, Lianjun; Tadesse, Yonas

    2014-03-01

    A soft robotic device inspired by the pumping action of a biological heart is presented in this study. Developing artificial heart to a humanoid robot enables us to make a better biomedical device for ultimate use in humans. As technology continues to become more advanced, the methods in which we implement high performance and biomimetic artificial organs is getting nearer each day. In this paper, we present the design and development of a soft artificial heart that can be used in a humanoid robot and simulate the functions of a human heart using shape memory alloy technology. The robotic heart is designed to pump a blood-like fluid to parts of the robot such as the face to simulate someone blushing or when someone is angry by the use of elastomeric substrates and certain features for the transport of fluids.

  8. The total artificial heart.

    PubMed

    Meyer, A; Slaughter, M

    2011-09-01

    In the 1960s, cardiac surgeons and biomedical engineers pioneered the development of total artificial hearts (TAH) for the treatment of left and right heart failure. As we mark the 10th anniversary of the first implantation of the AbioCor device, the use of TAH has been limited, having failed to reach its envisioned potential and promise as an alternative therapy to heart transplantation. The Syncardia/CardioWest device, originally developed 30 years ago as the Jarvik TAH and later renamed the CardioWest TAH, continues to be used clinically in over 50 centers within the US and Europe having supported over 900 patients worldwide. Syncardia continues to develop TAH technology as evidenced by their recent introduction of a new portable pneumatic driver that enables patients to be discharged from the hospital. In contrast to TAH devices, continuous flow ventricular assist devices (VAD) have made tremendous technological strides and are rapidly gaining widespread clinical acceptance. The VAD technology has demonstrated extraordinary safety and reliability records through evolving technologies, advanced biocompatible materials, and improved patient management. Subsequently, the number of TAH implantations remains low compared to the growth in LVAD implants. Nonetheless, the Syncardia/CardioWest TAH remains an important and viable option for patients with severe biventricular failure and end organ dysfunction. Overall, a 79% survival rate has been achieved in patients supported with a Syncardia/CardioWest TAH as bridge-to-transplantation. In this review article, a brief history on the evolution of TAH devices, their current use and emerging use of evolving continuous flow VAD technology as chronic biventricular and TAH device systems are presented. PMID:21775941

  9. Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients.

    PubMed

    Ramirez, Angeleah; Riley, Jeffrey B; Joyce, Lyle D

    2016-03-01

    To prevent thrombotic or bleeding events in patients receiving a total artificial heart (TAH), agents have been used to avoid adverse events. The purpose of this article is to outline the adoption and results of a multi-targeted antithrombotic clinical procedure guideline (CPG) for TAH patients. Based on literature review of TAH anticoagulation and multiple case series, a CPG was designed to prescribe the use of multiple pharmacological agents. Total blood loss, Thromboelastograph(®) (TEG), and platelet light-transmission aggregometry (LTA) measurements were conducted on 13 TAH patients during the first 2 weeks of support in our institution. Target values and actual medians for postimplant days 1, 3, 7, and 14 were calculated for kaolinheparinase TEG, kaolin TEG, LTA, and estimated blood loss. Protocol guidelines were followed and anticoagulation management reduced bleeding and prevented thrombus formation as well as thromboembolic events in TAH patients postimplantation. The patients in this study were susceptible to a variety of possible complications such as mechanical device issues, thrombotic events, infection, and bleeding. Among them all it was clear that patients were at most risk for bleeding, particularly on postoperative days 1 through 3. However, bleeding was reduced into postoperative days 3 and 7, indicating that acceptable hemostasis was achieved with the anticoagulation protocol. The multidisciplinary, multi-targeted anticoagulation clinical procedure guideline was successful to maintain adequate antithrombotic therapy for TAH patients. PMID:27134306

  10. Polish artificial heart program.

    PubMed

    El Fray, Miroslawa; Czugala, Monika

    2012-01-01

    Despite significant advances in the development of artificial heart substitutes, anthrombogenic materials and surfaces remain to be the main challenge for implants, which can prevent thrombosis that leads to rejection. The goal of material engineering is essentially to design polymeric materials of high durability and optimal thrombogenicity in mechanical heart prosthesis, being developed recently in a frame of the polish artificial heart program. For these reasons, various surface modifications are being continuously developed for a 'gold standard' material, which is a polyurethane (PU) thermoplastic elastomer and they will be shortly reviewed. However, new polymeric materials can meet medical word's attention if they are able to provide similar or better characteristics in term of bulk and surface properties. Specifically, if they will show appropriate surface topography, which is the most influential in determining the response of live tissues toward biomaterials. Nanostructured polyester thermoplastic elastomers of high biodurability as an alternative to PU materials for artificial heart are challenging new materials, and they will be discussed briefly. PMID:22110047

  11. Computation of incompressible viscous flows through artificial heart devices with moving boundaries

    NASA Technical Reports Server (NTRS)

    Kiris, Cetin; Rogers, Stuart; Kwak, Dochan; Chang, I.-DEE

    1991-01-01

    The extension of computational fluid dynamics techniques to artificial heart flow simulations is illustrated. Unsteady incompressible Navier-Stokes equations written in 3-D generalized curvilinear coordinates are solved iteratively at each physical time step until the incompressibility condition is satisfied. The solution method is based on the pseudo compressibility approach and uses an implicit upwind differencing scheme together with the Gauss-Seidel line relaxation method. The efficiency and robustness of the time accurate formulation of the algorithm are tested by computing the flow through model geometries. A channel flow with a moving indentation is computed and validated with experimental measurements and other numerical solutions. In order to handle the geometric complexity and the moving boundary problems, a zonal method and an overlapping grid embedding scheme are used, respectively. Steady state solutions for the flow through a tilting disk heart valve was compared against experimental measurements. Good agreement was obtained. The flow computation during the valve opening and closing is carried out to illustrate the moving boundary capability.

  12. Total artificial hearts: past, present, and future.

    PubMed

    Cohn, William E; Timms, Daniel L; Frazier, O H

    2015-10-01

    A practical artificial heart has been sought for >50 years. An increasing number of people succumb to heart disease each year, but the number of hearts available for transplantation remains small. Early total artificial hearts mimicked the pumping action of the native heart. These positive-displacement pumps could provide adequate haemodynamic support and maintain the human circulation for short periods, but large size and limited durability adversely affected recipients' quality of life. Subsequent research into left ventricular assist devices led to the use of continuous-flow blood pumps with rotating impellers. Researchers have attempted to integrate this technology into modern total artificial hearts with moderate clinical success. The importance of pulsatile circulation remains unclear. Future research is, therefore, needed into positive-displacement and rotary total artificial hearts. PMID:26031698

  13. An electric artificial heart for clinical use.

    PubMed

    Pierce, W S; Rosenberg, G; Snyder, A J; Pae, W E; Donachy, J H; Waldhausen, J A

    1990-09-01

    Advances in microelectronics, high-strength magnets, and control system design now make replacement of the heart using an implantable, electrically powered pump feasible. The device described herein is a compact, dual pusher plate unit with valved polyurethane sac-type ventricles positioned at either end. The power unit consists of a small, brushless direct current motor and a motion translator. A microprocessor control system is used to regulate heart beat rate and provide left-right output balance. Bench studies lasting for as long as 1 year have been performed. Heart replacement with the electric heart has been performed in 18 calves since 1984. The longest survivor lived for more than 7 months. Among the causes of termination were component failure, thromboembolic complications, and bleeding. No major problem has been identified that precludes prolonged use of the electric heart. In the future the patient with end-stage heart disease will have an electric artificial heart as one therapeutic option. PMID:2396885

  14. Computational Hemodynamics Involving Artificial Devices

    NASA Technical Reports Server (NTRS)

    Kwak, Dochan; Kiris, Cetin; Feiereisen, William (Technical Monitor)

    2001-01-01

    This paper reports the progress being made towards developing complete blood flow simulation capability in human, especially, in the presence of artificial devices such as valves and ventricular assist devices. Devices modeling poses unique challenges different from computing the blood flow in natural hearts and arteries. There are many elements needed such as flow solvers, geometry modeling including flexible walls, moving boundary procedures and physiological characterization of blood. As a first step, computational technology developed for aerospace applications was extended in the recent past to the analysis and development of mechanical devices. The blood flow in these devices is practically incompressible and Newtonian, and thus various incompressible Navier-Stokes solution procedures can be selected depending on the choice of formulations, variables and numerical schemes. Two primitive variable formulations used are discussed as well as the overset grid approach to handle complex moving geometry. This procedure has been applied to several artificial devices. Among these, recent progress made in developing DeBakey axial flow blood pump will be presented from computational point of view. Computational and clinical issues will be discussed in detail as well as additional work needed.

  15. Management of a malfunctioning left ventricle in an artificial heart.

    PubMed

    Gaykowski, R; Blaylock, R C; Murray, K D; Nielsen, S D; Olsen, D B

    1985-02-01

    Artificial heart research is carried out in the United States, Europe, Japan, Argentina and the Soviet Union, and prolonged survival has been achieved in animals, which has increased the interest of the media and public in this field. Although recent advances are promising, device malfunction remains an obstacle to overcome in most laboratories. Relying on noninvasive monitoring techniques we were able to diagnose and correct artificial heart malfunction safely using surgical techniques employed during the heart implantation. PMID:3843611

  16. Devices in Heart Failure

    PubMed Central

    Munir, Shahzeb M.; Bogaev, Roberta C.; Sobash, Ed; Shankar, K. J.; Gondi, Sreedevi; Stupin, Igor V.; Robertson, Jillian; Brewer, M. Alan; Casscells, S. Ward; Delgado, Reynolds M.; Ahmed, Amany

    2008-01-01

    Congestive heart failure has long been one of the most serious medical conditions in the United States; in fact, in the United States alone, heart failure accounts for 6.5 million days of hospitalization each year. One important goal of heart-failure therapy is to inhibit the progression of congestive heart failure through pharmacologic and device-based therapies. Therefore, there have been efforts to develop device-based therapies aimed at improving cardiac reserve and optimizing pump function to meet metabolic requirements. The course of congestive heart failure is often worsened by other conditions, including new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ damage, and therapeutic refractoriness, that have an impact on outcomes. The onset of such conditions is sometimes heralded by subtle pathophysiologic changes, and the timely identification of these changes may promote the use of preventive measures. Consequently, device-based methods could in the future have an important role in the timely identification of the subtle pathophysiologic changes associated with congestive heart failure. PMID:18612451

  17. SynCardia: the total artificial heart

    PubMed Central

    Anyanwu, Anelechi; Zucchetta, Fabio; Gerosa, Gino

    2014-01-01

    The SynCardia total artificial heart (TAH) currently provides the most definitive option for patients with biventricular failure who are not candidates for isolated left ventricular (LV) assist device placement. The techniques for implantation are adaptable to almost all patients with advanced heart failure, including those with severe biventricular cardiomyopathy, complex congenital heart disease, failed LV assist devices, failed transplantations, and acquired structural heart defects that have failed or are not amenable to conventional surgical treatment. Over the years, the implantation technique has evolved in order to minimize the surgical invasiveness of the procedure, in anticipation of additional future surgery. Meticulous hemostasis with double layer sutures, use of Gore-Tex sheets around the TAH and the pericardial cavity, and use of tissue expanders to avoid contraction of pericardial cavity around the device are discussed in detail in the following report. Additionally, we will provide our experience with implantation of TAH in various challenging scenarios, such as patients with a small chest cavity, congenital heart defects, and simultaneous use of extracorporeal membrane oxygenation (ECMO). PMID:25512904

  18. SynCardia: the total artificial heart.

    PubMed

    Torregrossa, Gianluca; Anyanwu, Anelechi; Zucchetta, Fabio; Gerosa, Gino

    2014-11-01

    The SynCardia total artificial heart (TAH) currently provides the most definitive option for patients with biventricular failure who are not candidates for isolated left ventricular (LV) assist device placement. The techniques for implantation are adaptable to almost all patients with advanced heart failure, including those with severe biventricular cardiomyopathy, complex congenital heart disease, failed LV assist devices, failed transplantations, and acquired structural heart defects that have failed or are not amenable to conventional surgical treatment. Over the years, the implantation technique has evolved in order to minimize the surgical invasiveness of the procedure, in anticipation of additional future surgery. Meticulous hemostasis with double layer sutures, use of Gore-Tex sheets around the TAH and the pericardial cavity, and use of tissue expanders to avoid contraction of pericardial cavity around the device are discussed in detail in the following report. Additionally, we will provide our experience with implantation of TAH in various challenging scenarios, such as patients with a small chest cavity, congenital heart defects, and simultaneous use of extracorporeal membrane oxygenation (ECMO). PMID:25512904

  19. Implantation of Total Artificial Heart in Congenital Heart Disease

    PubMed Central

    Adachi, Iki; Morales, David S. L.

    2014-01-01

    In patients with end-stage heart failure (HF), a total artificial heart (TAH) may be implanted as a bridge to cardiac transplant. However, in congenital heart disease (CHD), the malformed heart presents a challenge to TAH implantation. In the case presented here, a 17 year-old patient with congenital transposition of the great arteries (CCTGA) experienced progressively worsening HF due to his congenital condition. He was hospitalized multiple times and received an implantable cardioverter defibrillator (ICD). However, his condition soon deteriorated to end-stage HF with multisystem organ failure. Due to the patient's grave clinical condition and the presence of complex cardiac lesions, the decision was made to proceed with a TAH. The abnormal arrangement of the patient's ventricles and great arteries required modifications to the TAH during implantation. With the TAH in place, the patient was able to return home and regain strength and physical well-being while awaiting a donor heart. He was successfully bridged to heart transplantation 5 months after receiving the device. This report highlights the TAH is feasible even in patients with structurally abnormal hearts, with technical modification. PMID:25078059

  20. Total Artificial Heart and Physical Therapy Management

    PubMed Central

    Nicholson, Clare

    2010-01-01

    Purpose: To describe the total artificial heart (TAH) device as a bridge to heart transplantation (BTT), and related physical therapy management, while comparisons to left ventricular assist devices (LVAD) are made. Summary: The SynCardia CardioWest Temporary TAH System is the only TAH approved by the Food and Drug Administration (FDA), Health Canada and Consultants Europe (CE) for BTT. CardioWest implantation involves cardiectomy thus avoiding pulmonary hypertension, right heart failure, inotropic or anti-arrhythmic agents, myocardial and valve related problems. CardioWest has a fixed beat rate and cardiac output is dependent upon venous return and preload. Both TAH and LVADs are adaptive with exercise, increasing cardiac output during activities, allowing for conditioning to occur peripherally. Left ventricular assist devices have portable drivers permitting discharge home, while the CardioWest's large driver console necessitates inpatient therapy. Exercise progression, positioning, and monitoring of exercise intolerance are similar with LVAD and TAH. Ventricular fill volumes in TAH dictate cardiac output and require close attention. Cardiectomy in TAH prevents electrocardiography, telemetry, and native pulse rate monitoring. Conclusion: While mechanical differences exist between TAH and LVAD, physical therapists can provide evidence-based treatment for patients with TAH using previously established guidelines for patients with heart failure and mechanical circulatory support. PMID:20520759

  1. AN INNOVATIVE, SENSORLESS, PULSATILE, CONTINUOUS-FLOW TOTAL ARTIFICIAL HEART: DEVICE DESIGN AND INITIAL IN VITRO STUDY

    PubMed Central

    Fukamachi, Kiyotaka; Horvath, David J.; Massiello, Alex L.; Fumoto, Hideyuki; Horai, Tetsuya; Rao, Santosh; Golding, Leonard A. R.

    2009-01-01

    Background We are developing a very small, innovative, continuous-flow total artificial heart (CFTAH) that passively self-balances left and right pump flows and atrial pressures without sensors. This report details the CFTAH design concept and our initial in vitro data. Methods System performance of the CFTAH was evaluated using a mock circulatory loop to determine the range of systemic and pulmonary vascular resistances (SVR and PVR) over which the design goal of a maximum absolute atrial pressure difference of 10 mm Hg is achieved for a steady-state flow condition. Pump speed was then modulated at 2,600 ± 900 rpm to induce flow and arterial pressure pulsation to evaluate the effects of speed pulsations on the system performance. An automatic control mode was also evaluated. Results Using only passive self-regulation, pump flows were balanced and absolute atrial pressure differences were maintained below 10 mm Hg over a range of SVR (750-2,750 dyne·sec·cm-5) and PVR (135-600 dyne·sec·cm-5) values far exceeding normal levels. The magnitude of induced speed pulsatility affected relative left/right performance, allowing for an additional active control to improve balanced flow and pressure. The automatic control mode adjusted pump speed to achieve targeted pump flows based on sensorless calculations of SVR and CFTAH flow. Conclusions The initial in vitro testing of the CFTAH with a single, valveless, continuous-flow pump demonstrated its passive self-regulation of flows and atrial pressures and a new automatic control mode. PMID:19782599

  2. [Power units of implanted artificial heart and assisted circulation system].

    PubMed

    Kiselev, Iu M; Kremnev, V A; Sadov, V V; Spiridonov, V A

    1976-01-01

    The existing and presently planned systems of power supply for an artificially implanted heart and assisted circulation devices are reviewed. A comparative analysis as to their conformability to biological, functional and technical demands placed on the implanted systems is given. In an implanted artificial heart and assisted circulation systems most promising is shown to be the use of nuclear fuel as a source of power and as converters -- that of thermal engines with gas and steam cycle. PMID:1025440

  3. Actuator device for artificial leg

    NASA Technical Reports Server (NTRS)

    Burch, J. L. (Inventor)

    1976-01-01

    An actuator device is described for moving an artificial leg of a person having a prosthesis replacing an entire leg and hip joint. The device includes a first articulated hip joint assembly carried by the natural leg and a second articulated hip joint assembly carried by the prosthesis whereby energy from the movement of the natural leg is transferred by a compressible fluid from the first hip joint assembly to the second hip joint assembly for moving the artificial leg.

  4. Computed Flow Through An Artificial Heart Valve

    NASA Technical Reports Server (NTRS)

    Rogers, Stewart E.; Kwak, Dochan; Kiris, Cetin; Chang, I-Dee

    1994-01-01

    Report discusses computations of blood flow through prosthetic tilting disk valve. Computational procedure developed in simulation used to design better artificial hearts and valves by reducing or eliminating following adverse flow characteristics: large pressure losses, which prevent hearts from working efficiently; separated and secondary flows, which causes clotting; and high turbulent shear stresses, which damages red blood cells. Report reiterates and expands upon part of NASA technical memorandum "Computed Flow Through an Artificial Heart and Valve" (ARC-12983). Also based partly on research described in "Numerical Simulation of Flow Through an Artificial Heart" (ARC-12478).

  5. Atrial septum defect closure device in a beating heart, from the perspective of a researcher in artificial organs.

    PubMed

    Tomizawa, Yasuko

    2012-12-01

    Transcatheter closure of atrial septum defect (ASD) with a closure device is increasing, but the history of clinical use of this procedure is still short, and the efficacy and long-term safety remain unproved. The total number of closure devices implanted throughout the world has not been counted accurately. Therefore, the probability of complications occurring after implantation is uncertain. Device-related complications that occur suddenly late after implantation are life-threatening, and quite often necessitate emergency surgical intervention. In Japanese medical journals, authors reporting closure devices have mentioned no complications and problems in their facilities. Detailed studies of device-related complications and device removal have not been reported in Japan. In fact, this literature search found an unexpectedly large number of reports of various adverse events from many overseas countries. When follow-up duration is short and the number of patients is small, the incidence of complications cannot be determined. Rare complications may emerge in a large series with a long observation period. Consequently, the actual number of incidents related to ASD closure devices is possibly several times higher than the number reported. Guidelines for long-term patient management for patients with an implanted closure device are necessary and post-marketing surveillance is appropriate. Development of a national database, a worldwide registration system, and continuous information disclosure will improve the quality of treatment. The devices currently available are not ideal in view of reports of late complications requiring urgent surgery and the need for life-long follow-up. An ideal device should be free from complications during life, and reliability is indispensable. PMID:22729293

  6. The need for artificial hearts.

    PubMed Central

    Westaby, S.

    1996-01-01

    Chronic immunosuppression, allograft coronary disease, and restricted availability of donor organs continue to limit the scope of cardiac transplantation. Meanwhile increasingly favourable experience with implantable blood pumps used as a bridge to transplant has reintroduced the concept of permanent mechanical cardiac support. Existing models (for example, the Thermo Cardiosystems Heartmate device) are now used for such support in patients who are not candidates for transplantation. Miniaturised axial flow pumps such as the Jarvik 2000 fit within the failed left ventricle and provide an exciting prospect for the treatment of heart failure in the future. Preliminary experience suggests that the "offloaded" left ventricle may recover. Mechanical blood pumps can be used before the onset of multisystem failure and removed if the myocardium recovers. This "bridge to recovery" concept should be tested in patients with recoverable cardiomyopathy and those with coronary disease and poor left ventricular function where an implantable pump can be used in conjunction with myocardial revascularisation. Images PMID:8868975

  7. What Is a Total Artificial Heart?

    MedlinePlus

    ... that the CardioWest is connected to an outside power source and the AbioCor isn't. The CardioWest ... run from inside the chest to an outside power source. Normal Heart and CardioWest Total Artificial Heart ...

  8. Design and performance of heart assist or artificial heart control systems

    NASA Technical Reports Server (NTRS)

    Webb, J. A., Jr.; Gebben, V. D.

    1978-01-01

    The factors leading to the design of a controlled driving system for either a heart assist pump or artificial heart are discussed. The system provides square pressure waveform to drive a pneumatic-type blood pump. For assist usage the system uses an R-wave detector circuit that can detect the R-wave of the electrocardiogram in the presence of electrical disturbances. This circuit provides a signal useful for synchronizing an assist pump with the natural heart. It synchronizes a square wave circuit, the output of which is converted into square waveforms of pneumatic pressure suitable for driving both assist device and artificial heart. The pressure levels of the driving waveforms are controlled by means of feedback channels to maintain physiological regulation of the artificial heart's output flow. A more compact system that could achieve similar regulatory characteristics is also discussed.

  9. Implantation of the syncardia total artificial heart.

    PubMed

    Tang, Daniel G; Shah, Keyur B; Hess, Micheal L; Kasirajan, Vigneshwar

    2014-01-01

    With advances in technology, the use of mechanical circulatory support devices for end stage heart failure has rapidly increased. The vast majority of such patients are generally well served by left ventricular assist devices (LVADs). However, a subset of patients with late stage biventricular failure or other significant anatomic lesions are not adequately treated by isolated left ventricular mechanical support. Examples of concomitant cardiac pathology that may be better treated by resection and TAH replacement includes: post infarction ventricular septal defect, aortic root aneurysm / dissection, cardiac allograft failure, massive ventricular thrombus, refractory malignant arrhythmias (independent of filling pressures), hypertrophic / restrictive cardiomyopathy, and complex congenital heart disease. Patients often present with cardiogenic shock and multi system organ dysfunction. Excision of both ventricles and orthotopic replacement with a total artificial heart (TAH) is an effective, albeit extreme, therapy for rapid restoration of blood flow and resuscitation. Perioperative management is focused on end organ resuscitation and physical rehabilitation. In addition to the usual concerns of infection, bleeding, and thromboembolism common to all mechanically supported patients, TAH patients face unique risks with regard to renal failure and anemia. Supplementation of the abrupt decrease in brain natriuretic peptide following ventriculectomy appears to have protective renal effects. Anemia following TAH implantation can be profound and persistent. Nonetheless, the anemia is generally well tolerated and transfusion are limited to avoid HLA sensitization. Until recently, TAH patients were confined as inpatients tethered to a 500 lb pneumatic console driver. Recent introduction of a backpack sized portable driver (currently under clinical trial) has enabled patients to be discharged home and even return to work. Despite the profound presentation of these sick

  10. Implantation of the Syncardia Total Artificial Heart

    PubMed Central

    Tang, Daniel G.; Shah, Keyur B.; Hess, Micheal L.; Kasirajan, Vigneshwar

    2014-01-01

    With advances in technology, the use of mechanical circulatory support devices for end stage heart failure has rapidly increased. The vast majority of such patients are generally well served by left ventricular assist devices (LVADs). However, a subset of patients with late stage biventricular failure or other significant anatomic lesions are not adequately treated by isolated left ventricular mechanical support. Examples of concomitant cardiac pathology that may be better treated by resection and TAH replacement includes: post infarction ventricular septal defect, aortic root aneurysm / dissection, cardiac allograft failure, massive ventricular thrombus, refractory malignant arrhythmias (independent of filling pressures), hypertrophic / restrictive cardiomyopathy, and complex congenital heart disease. Patients often present with cardiogenic shock and multi system organ dysfunction. Excision of both ventricles and orthotopic replacement with a total artificial heart (TAH) is an effective, albeit extreme, therapy for rapid restoration of blood flow and resuscitation. Perioperative management is focused on end organ resuscitation and physical rehabilitation. In addition to the usual concerns of infection, bleeding, and thromboembolism common to all mechanically supported patients, TAH patients face unique risks with regard to renal failure and anemia. Supplementation of the abrupt decrease in brain natriuretic peptide following ventriculectomy appears to have protective renal effects. Anemia following TAH implantation can be profound and persistent. Nonetheless, the anemia is generally well tolerated and transfusion are limited to avoid HLA sensitization. Until recently, TAH patients were confined as inpatients tethered to a 500 lb pneumatic console driver. Recent introduction of a backpack sized portable driver (currently under clinical trial) has enabled patients to be discharged home and even return to work. Despite the profound presentation of these sick

  11. Artificial Heart and Self-making

    NASA Astrophysics Data System (ADS)

    Imachi, Kou

    Artificial heart (AH) study has been started in 1957. After the accomplishments of various difficulties, the AH can become to use clinically as a postcardiotomy cardiac assist or bridge to heart transplantation. However, there remain many obstacles to realize an implantable total artificial heart. The history of AH was the self-making. Although self-making is important in all the experimental sciences, it is the most important factor to develop AH. In this paper, the author would like to introduce the present status of AH and the importance of self-making.

  12. FLUID MECHANICS OF ARTIFICIAL HEART VALVES

    PubMed Central

    Dasi, Lakshmi P; Simon, Helene A; Sucosky, Philippe; Yoganathan, Ajit P

    2009-01-01

    SUMMARY 1. Artificial heart valves have been in use for over five decades to replace diseased heart valves. Since the first heart valve replacement performed with a caged-ball valve, more than 50 valve designs have been developed, differing principally in valve geometry, number of leaflets and material. To date, all artificial heart valves are plagued with complications associated with haemolysis, coagulation for mechanical heart valves and leaflet tearing for tissue-based valve prosthesis. For mechanical heart valves, these complications are believed to be associated with non-physiological blood flow patterns. 2. In the present review, we provide a bird’s-eye view of fluid mechanics for the major artificial heart valve types and highlight how the engineering approach has shaped this rapidly diversifying area of research. 3. Mechanical heart valve designs have evolved significantly, with the most recent designs providing relatively superior haemodynamics with very low aerodynamic resistance. However, high shearing of blood cells and platelets still pose significant design challenges and patients must undergo life-long anticoagulation therapy. Bioprosthetic or tissue valves do not require anticoagulants due to their distinct similarity to the native valve geometry and haemodynamics, but many of these valves fail structurally within the first 10–15 years of implantation. 4. These shortcomings have directed present and future research in three main directions in attempts to design superior artificial valves: (i) engineering living tissue heart valves; (ii) development of advanced computational tools; and (iii) blood experiments to establish the link between flow and blood damage. PMID:19220329

  13. Implanted artificial heart with radioisotope power source.

    PubMed

    Shumakov, V I; Griaznov, G M; Zhemchuzhnikov, G N; Kiselev, I M; Osipov, A P

    1983-02-01

    An atomic artificial heart for orthotopic implantation was developed with the following characteristics: volume, 1.2 L; weight, 1.5 kg; radioisotope power, 45 W; operating life, up to 5 years; hemodynamics, similar to natural hemodynamics. The artificial heart includes a thermal drive with systems for regulating power, feeding steam into the cylinders, return of the condensate to the steam generator, and delivery of power to the ventricles and heat container. The artificial heart is placed in an artificial pericardium partially filled with physiologic solution. It uses a steam engine with two operating cylinders that separately drive the left and right ventricles. There is no electronic control system in the proposed design. The operation of the heat engine is controlled, with preservation of autoregulation by the vascular system of the body. The separate drives for the ventricles is of primary importance as it provides for operation of the artificial heart through control of cardiac activity by venous return. Experimental testing on a hydromechanical bench demonstrated effective autoregulation. PMID:6838394

  14. Successful heart transplant after 1374 days living with a total artificial heart.

    PubMed

    Gerosa, Gino; Gallo, Michele; Bottio, Tomaso; Tarzia, Vincenzo

    2016-04-01

    The CardioWest Total Artificial Heart (CW-TAH) has been approved as a temporary device for bridge to cardiac transplantation and is under investigation for destination therapy by US Food and Drug Administration (FDA). We herein report the longest worldwide survival out of hospital (1374 days) of a patient supported with Cardio West Total Artificial Heart (CW-TAH). This experience is intended as a proof of concept of using CW-TAH as the destination therapy in patients with biventricular failure. PMID:26819291

  15. THEORETICAL DESIGN CONSIDERATIONS AND PHYSIOLOGIC PERFORMANCE CRITERIA FOR AN IMPROVED INTRACORPOREAL (ABDOMINAL) ELECTRICALLY ACTUATED LONG-TERM LEFT VENTRICULAR ASSIST DEVICE (“E-TYPE” ALVAD) OR PARTIAL ARTIFICIAL HEART

    PubMed Central

    Igo, Stephen R.; Hibbs, C. Wayne; Fuqua, John M.; Trono, Ruben; Edmonds, Charles H.; Norman, John C.

    1978-01-01

    Our laboratories are engaged in the design of a clinically-oriented electrically actuated long-term intracorporeal (abdominal) left ventricular assist device (“E-type” ALVAD) or partial artificial heart. This infradiaphragmatic blood pump is designed to be powered by implantable electrical to mechanical energy converter systems. The following analyses were undertaken to: [List: see text] The proposed “E-type” ALVAD should be capable of pumping 4-7 liters per minute at heart rates of 75-100 beats per minute during rest, and 10 liters per minute at rates of 120 beats per minute during moderate exercise. These performance levels should be exceeded with a maximum device stroke volume of 85-90 ml and a mean pump inflow (filling) impedance of ≤ 0.072 gm/sec/cm−5. Images PMID:15216070

  16. Computed Flow Through An Artificial Heart And Valve

    NASA Technical Reports Server (NTRS)

    Rogers, Stuart E.; Kwak, Dochan; Kiris, Cetin; Chang, I-Dee

    1994-01-01

    NASA technical memorandum discusses computations of flow of blood through artificial heart and through tilting-disk artificial heart valve. Represents further progress in research described in "Numerical Simulation of Flow Through an Artificial Heart" (ARC-12478). One purpose of research to exploit advanced techniques of computational fluid dynamics and capabilities of supercomputers to gain understanding of complicated internal flows of viscous, essentially incompressible fluids like blood. Another to use understanding to design better artificial hearts and valves.

  17. Demikhov's "Mechanical Heart": The Circumstances Surrounding Creation of the World's First Implantable Total Artificial Heart in 1937.

    PubMed

    Glyantsev, Sergey P; Tchantchaleishvili, Vakhtang; Bockeria, Leo A

    2016-01-01

    The world's first implantable total artificial heart was designed by Vladimir Demikhov as a fourth year biology student in Voronezh, Soviet Union, in 1937. As a prototype of his device, Demikhov must have used an apparatus for extracorporeal blood circulation invented by Sergei Bryukhonenko of Moscow. The device was the size of a dog's native heart and consisted of two diaphragm pumps brought into motion by an electric motor. A dog with an implanted device lived for 2.5 hours. In addition to having the prototype, the preconditions for Demikhov's artificial heart creation were his manual dexterity, expertise in animal physiology, and his mechanistic worldview. PMID:26501917

  18. Liver failure in total artificial heart therapy

    PubMed Central

    Dimitriou, Alexandros Merkourios; Dapunt, Otto; Knez, Igor; Wasler, Andrae; Oberwalder, Peter; Koerfer, Reiner; Tenderich, Gero

    2016-01-01

    Background Congestive hepatopathy (CH) and acute liver failure (ALF) are common among biventricular heart failure patients. We sought to evaluate the impact of total artificial heart (TAH) therapy on hepatic function and associated clinical outcomes. Methods A total of 31 patients received a Syncardia Total Artificial Heart. Preoperatively 17 patients exhibited normal liver function or mild hepatic derangements that were clinically insignificant and did not qualify as acute or chronic liver failure, 5 patients exhibited ALF and 9 various hepatic derangements owing to CH. Liver associated mortality and postoperative course of liver values were prospectively documented and retrospectively analyzed. Results Liver associated mortality in normal liver function, ALF and CH cases was 0%, 20% (P=0.03) and 44.4% (P=0.0008) respectively. 1/17 (5.8%) patients with a normal liver function developed an ALF, 4/5 (80%) patients with an ALF experienced a markedly improvement of hepatic function and 6/9 (66.6%) patients with CH a significant deterioration. Conclusions TAH therapy results in recovery of hepatic function in ALF cases. Patients with CH prior to surgery form a high risk group with increased liver associated mortality. PMID:27499942

  19. Expanding Applicability of Total Artificial Heart Therapy: The 50-cc SynCardia Total Artificial Heart.

    PubMed

    Spiliopoulos, Sotirios; Dimitriou, Alexandros Merkourios; Guersoy, Dilek; Koerfer, Reiner; Tenderich, Gero

    2015-09-01

    The 50-cc SynCardia total artificial heart is designed to facilitate orthotopic replacement of the native ventricles in patients with a body surface area below 1.7 m(2) in need of long-term circulatory support as a result of end-stage biventricular heart failure. We describe the implementation of this technology in a female patient with irreversible cardiogenic shock on the grounds of acute myocardial infarction and chronic ischemic cardiomyopathy. PMID:26354668

  20. An intelligent remote monitoring system for artificial heart.

    PubMed

    Choi, Jaesoon; Park, Jun W; Chung, Jinhan; Min, Byoung G

    2005-12-01

    A web-based database system for intelligent remote monitoring of an artificial heart has been developed. It is important for patients with an artificial heart implant to be discharged from the hospital after an appropriate stabilization period for better recovery and quality of life. Reliable continuous remote monitoring systems for these patients with life support devices are gaining practical meaning. The authors have developed a remote monitoring system for this purpose that consists of a portable/desktop monitoring terminal, a database for continuous recording of patient and device status, a web-based data access system with which clinicians can access real-time patient and device status data and past history data, and an intelligent diagnosis algorithm module that noninvasively estimates blood pump output and makes automatic classification of the device status. The system has been tested with data generation emulators installed on remote sites for simulation study, and in two cases of animal experiments conducted at remote facilities. The system showed acceptable functionality and reliability. The intelligence algorithm also showed acceptable practicality in an application to animal experiment data. PMID:16379373

  1. Anatomy of the bovine ascending aorta and brachiocephalic artery found unfavorable for total artificial heart implant.

    PubMed

    Karimov, Jamshid H; Sunagawa, Gengo; Such, Kimberly A; Sale, Shiva; Golding, Leonard A R; Moazami, Nader; Fukamachi, Kiyotaka

    2015-12-01

    The biocompatibility assessment of the Cleveland Clinic continuous-flow total artificial heart is an important part of the device developmental program. Surgical and postoperative management are key factors in achieving optimal outcomes. However, the presence of vascular anatomical abnormalities in experimental animal models is often unpredictable and may worsen the expected outcomes. We report a technical impediment encountered during total artificial heart implantation complicated by unfavorable bovine anatomy of the ascending aorta and brachiocephalic arterial trunk. PMID:26105105

  2. Parallel application of extracorporeal membrane oxygenation and the CardioWest total artificial heart as a bridge to transplant.

    PubMed

    Anderson, Eric; Jaroszewski, Dawn; Pierce, Christopher; DeValeria, Patrick; Arabia, Francisco

    2009-11-01

    Circulatory assist devices are an increasingly common method of treating patients with refractory cardiogenic shock. We describe a patient who was a heart transplant candidate with biventricular failure who underwent CardioWest total artificial heart-temporary (SynCardia Inc, Tucson, AZ) implantation with extracorporeal membrane oxygenation to manage the patient's subsequent respiratory failure. After respiratory and hemodynamic stabilization, the CardioWest total artificial heart-temporary served as a successful 62-day bridge-to-heart transplantation. PMID:19853137

  3. Automatic Emboli Detection System for the Artificial Heart

    NASA Astrophysics Data System (ADS)

    Steifer, T.; Lewandowski, M.; Karwat, P.; Gawlikowski, M.

    In spite of the progress in material engineering and ventricular assist devices construction, thromboembolism remains the most crucial problem in mechanical heart supporting systems. Therefore, the ability to monitor the patient's blood for clot formation should be considered an important factor in development of heart supporting systems. The well-known methods for automatic embolus detection are based on the monitoring of the ultrasound Doppler signal. A working system utilizing ultrasound Doppler is being developed for the purpose of flow estimation and emboli detection in the clinical artificial heart ReligaHeart EXT. Thesystem will be based on the existing dual channel multi-gate Doppler device with RF digital processing. A specially developed clamp-on cannula probe, equipped with 2 - 4 MHz piezoceramic transducers, enables easy system setup. We present the issuesrelated to the development of automatic emboli detection via Doppler measurements. We consider several algorithms for the flow estimation and emboli detection. We discuss their efficiency and confront them with the requirements of our experimental setup. Theoretical considerations are then met with preliminary experimental findings from a) flow studies with blood mimicking fluid and b) in-vitro flow studies with animal blood. Finally, we discuss some more methodological issues - we consider several possible approaches to the problem of verification of the accuracy of the detection system.

  4. Total artificial heart freedom driver in a patient with end-stage biventricular heart failure.

    PubMed

    Friedline, Kristin; Hassinger, Pamela

    2012-04-01

    Approximately 5.7 million people in the United States have a diagnosis of heart failure, and more than 3,100 patients are awaiting a heart transplant. A temporary total artificial heart (TAH-t, SynCardia Systems Inc, Tucson, Arizona) is approved by the US Food and Drug Administration (FDA) as a bridge to transplant in patients at risk of dying of biventricular heart failure. Currently, TAH-t recipients awaiting transplant are hospital-bound and attached to a large pneumatic driver. In 2010, the FDA gave conditional approval for an Investigational Device Exemption clinical study of the portable Freedom driver (SynCardia). This case report describes a 61-year-old man admitted with acute decompensated heart failure, which progressively worsened, eventually requiring implantation of a TAH-t. Following stabilization, the patient was switched to the Freedom driver. After the patient and his wife proved competence in managing the device, they were able to take several daylong excursions outside the hospital. The patient considered discharge from the hospital while awaiting a transplant but ultimately received a heart transplant while still an inpatient. Higher rates of survival to transplant have already been proved with the TAH-t. Potential benefits for the portable Freedom driver include increased mobility, decreased cost, and improved quality of life. PMID:22586879

  5. Development of a totally implantable artificial heart.

    PubMed

    Rowles, J R; Khanwilkar, P S; Diegel, P D; Hansen, A C; Bearnson, G B; Smith, K D; Tatsumi, E; Olsen, D B

    1992-01-01

    The first generation of an integrated, totally implantable electrohydraulic total artificial heart was designed for long-term cardiac replacement. The system consists of an elliptical blood pump with an interatrial shunt, Medtronic-Hall 27 mm and 25 mm inflow and outflow valves, respectively, an energy converter consisting of an axial-flow, hydraulic pump driven by a brushless DC motor, and an electronics system with transcutaneous energy transmission and telemetry. Energy is supplied by internal nickel-cadmium rechargeable batteries that supply power for 20 min and external silver-zinc batteries that are designed to supply energy to run the system for 5 hr. The blood pump consists of a single layer diaphragm cast from Biolon, with joined right and left ventricles sharing a common base. The dynamic stroke volume is 84 ml, and maximum cardiac output is 9.2 L/min at a heart rate of 110 beats/min on the mock circulation. A 4.3 mm diameter interatrial shunt is used to balance the volumetrically coupled ventricles. The energy converter pumps hydraulic fluid alternately between ventricles, with controlled, active filling in one ventricle during the systolic phase of the other ventricle. Internal or external controllers adjust the heart rate and motor speed to maintain normal atrial filling pressures and full stroke. Electromagnetic induction is used to transfer energy through the skin and a bidirectional infrared data link incorporated within the transcutaneous energy transmission coils is used to transmit information. The entire system is being assembled and refined for long-term animal implant studies. PMID:1457955

  6. Numerical Simulation Of Flow Through An Artificial Heart

    NASA Technical Reports Server (NTRS)

    Rogers, Stuart; Kutler, Paul; Kwak, Dochan; Kiris, Centin

    1991-01-01

    Research in both artificial hearts and fluid dynamics benefits from computational studies. Algorithm that implements Navier-Stokes equations of flow extended to simulate flow of viscous, incompressible blood through articifial heart. Ability to compute details of such flow important for two reasons: internal flows with moving boundaries of academic interest in their own right, and many of deficiencies of artificial hearts attributable to dynamics of flow.

  7. Durability testing of a completely implantable electric total artificial heart.

    PubMed

    Zapanta, Conrad M; Snyder, Alan J; Weiss, William J; Cleary, Thomas J; Reibson, John D; Rawhouser, Marjorie A; Lewis, Jeffrey P; Pierce, William S; Rosenberg, Gerson

    2005-01-01

    In vitro durability testing was conducted on the Penn State/3M electric total artificial heart (ETAH) to determine device durability and to evaluate device failures. A specialized mock circulatory loop was developed for this testing. Customized software continuously acquired data during the test period, and failures were analyzed using FMEA (failure modes and effects analysis) and FMECA (failure modes, effects, and criticality analysis) principles. Redesigns were implemented when appropriate. Reliability growth principles were then applied to calculate the 1 and 2 year reliability. The 1 and 2 year reliability of the Penn State/3M ETAH was shown to be 96.1% and 59.9%, respectively, at 80% confidence. PMID:15968950

  8. Present and future perspectives on total artificial hearts

    PubMed Central

    Gerosa, Gino; Scuri, Silvia; Iop, Laura

    2014-01-01

    Due to shortages in donor organ availability, advanced heart-failure patients are at high risk of further decompensation and often death while awaiting transplantation. This shortage has led to the development of effective mechanical circulatory support (MCS). Currently, various implantable ventricular-assist devices (VADs) are able to provide temporary or long-term circulatory support for many end-stage heart-failure patients. Implantation of a total artificial heart (TAH) currently represents the surgical treatment option for patients requiring biventricular MCS as a bridge to transplant (BTT) or destination therapy (DT). However, the clinical applicability of available versions of positive displacement pumps is limited by their size and associated complications. Application of advanced technology is aimed at solving some of these issues, attempting to develop a new generation of smaller and more effective TAHs to suit a wider patient population. Particular targets for improvement include modifications to the biocompatibility of device designs and materials in order to decrease hemorrhagic and thromboembolic complications. Meanwhile, new systems to power implanted driving units which are fully operational without interruption of skin barriers represent a potential means of decreasing the risk of infections. In this review, we will discuss the history of the TAH, its development and clinical application, the implications of the existing technological solutions, published outcomes and the future outlook for TAHs. PMID:25512901

  9. Present and future perspectives on total artificial hearts.

    PubMed

    Gerosa, Gino; Scuri, Silvia; Iop, Laura; Torregrossa, Gianluca

    2014-11-01

    Due to shortages in donor organ availability, advanced heart-failure patients are at high risk of further decompensation and often death while awaiting transplantation. This shortage has led to the development of effective mechanical circulatory support (MCS). Currently, various implantable ventricular-assist devices (VADs) are able to provide temporary or long-term circulatory support for many end-stage heart-failure patients. Implantation of a total artificial heart (TAH) currently represents the surgical treatment option for patients requiring biventricular MCS as a bridge to transplant (BTT) or destination therapy (DT). However, the clinical applicability of available versions of positive displacement pumps is limited by their size and associated complications. Application of advanced technology is aimed at solving some of these issues, attempting to develop a new generation of smaller and more effective TAHs to suit a wider patient population. Particular targets for improvement include modifications to the biocompatibility of device designs and materials in order to decrease hemorrhagic and thromboembolic complications. Meanwhile, new systems to power implanted driving units which are fully operational without interruption of skin barriers represent a potential means of decreasing the risk of infections. In this review, we will discuss the history of the TAH, its development and clinical application, the implications of the existing technological solutions, published outcomes and the future outlook for TAHs. PMID:25512901

  10. Simultaneous heart and kidney transplantation after bridging with the CardioWest total artificial heart.

    PubMed

    Jaroszewski, Dawn E; Pierce, Christopher C; Staley, Linda L; Wong, Raymond; Scott, Robert R; Steidley, Eric E; Gopalan, Radha S; DeValeria, Patrick; Lanza, Louis; Mulligan, David; Arabia, Francisco A

    2009-10-01

    End-stage renal failure is often considered a relative contraindication for total artificial heart implantation due to the increased risk of mortality after transplantation. We report the successful treatment of a patient having heart and renal failure with the CardioWest (SynCardia Inc, Tucson, AZ) total artificial heart for bridge-to-cardiac transplantation of a heart and kidney. PMID:19766830

  11. Heart failure - surgeries and devices

    MedlinePlus

    ... surgery; Cardiomyopathy - surgery; HF - surgery; Intra-aortic balloon pumps - heart failure; IABP - heart failure; Catheter based assist ... is weakened, gets too large, and does not pump blood very well, you are at high risk ...

  12. [Caecal volvulus after heart surgery with artificial circulation].

    PubMed

    Korostelev, A N; Kuznetsov, A M; Chzhao, A V

    2016-01-01

    Presented herein is a description of a rare complication, i.e. caecal volvulus, after heart surgery. This case report illustrates difficulty of diagnosis of abdominal organs complications after artificial circulation and necessity of active surgical policy. PMID:27336350

  13. Development of a totally implantable total artificial heart controller.

    PubMed

    Lee, S H; Choi, W W; Min, B G

    1991-01-01

    Using a one chip microcontroller, 87C196 (One chip EPROM), and an erasable and programmable logic device (EPLD), an implantable control system to drive a pendulum type electromechanical total artificial heart was developed. This control system consists of four parts: a main management system, a motor driver with power regulator, a state monitoring system, and a communication portion. The main system has a speed detector, proportional and integral (PI) control, pulse width modulation (PWM) generation, serial communication, and an analog data processor. Two kinds of power system are used, separated by eight photocoupler arrays to improve system stability. When the performance of each compartment was compared with that of the previously used Z80 microprocessor based control system, good correspondence was shown. Logic power consumption was reduced to one third that of the previous controller. Using mock circulation tests, the overall performance of the control system was evaluated. PMID:1751254

  14. Percutaneous Endoscopic Gastrostomy Tube in a Syncardia™ Total Artificial Heart.

    PubMed

    Prasad, Amit; Singbartl, Kai; Boone, Jacqueline; Soleimani, Behzad; Zeriouh, Mohamad; Loebe, M; Koerner, Michael; Oei, J Elisabeth; Brehm, Christoph E; Ghodsizad, Ali

    2016-01-01

    As a bridge to transplant, the Syncardia™ total artificial heart (TAH) is an option for patients who are not candidates for left ventricular assist devices (LVAD) due to right ventricular failure. The need for nutritional support in these patients is essential for a favorable outcome. Low body mass indexes and albumin levels have been associated with increased morbidity and mortality in cardiac surgery patients [Alverdy 2003]. It is not uncommon for postoperative patients to have difficulty in consuming enough calories after surgery, which is further complicated by a hypermetabolic demand due to surgical stress. Enteral nutrition has typically been favored for gut mucosal integrity and bacterial flora [Alverdy 2003] [Engleman 1999]. We describe the need for prolonged enteral nutritional support in a TAH patient that was accomplished with a percutaneous endoscopic gastrostomy (PEG) tube. PMID:26913678

  15. Factors affecting survival in total artificial heart recipients before transplantation.

    PubMed

    Kawaguchi, A T; Gandjbakhch, I; Pavie, A; Muneretto, C; Solis, E; Bors, V; Leger, P; Vaissier, E; Levasseur, J P; Szefner, J

    1990-11-01

    To identify factors affecting the successful bridge to transplantation, experience with 32 recipients of the Jarvik-7 artificial heart was reviewed. Between patients with and without a successful bridge, there were no significant differences in preoperative hepatorenal function or postoperative hemodynamics, but there were significant differences in body size. When recipients were divided according to body surface areas of less than or greater than 1.8 m2, the smaller patients more frequently developed respirator dependence (73% vs. 18%, p less than 0.01), renal failure (53% vs. 18%, p less than 0.05), and hepatic failure and sepsis, resulting in less frequent qualification for transplantation (20% vs. 65%, p less than 0.05). There were no successful bridge operations in seven patients with body surface areas of less than 1.7 m2, and only one success in nine patients who were less than 170 cm in height, despite use of a smaller stroke volume model. The smaller patients had poorer ventricular filling, which was largely compensated for by the drive controls set for significantly longer diastole and higher vacuum, resulting in similar hemodynamics between the groups. The results suggest that device fitting as manifested by body size is an important factor affecting major organ recovery and subsequent transplantation in recipients of the Jarvik-7 artificial heart. A paracorporeal device may be advisable for patients with body surface areas of less than 1.8 m2 or who were less than 175 cm in height until an even smaller model with a better fit in the thorax becomes available. PMID:2225424

  16. Antithrombotic Therapy for the CardioWest Temporary Total Artificial Heart

    PubMed Central

    Ensor, Christopher R.; Cahoon, William D.; Crouch, Michael A.; Katlaps, Gundars J.; Hess, Michael L.; Cooke, Richard H.; Gunnerson, Kyle J.; Kasirajan, Vigneshwar

    2010-01-01

    The CardioWest™ temporary total artificial heart serves as a viable bridge to orthotopic heart transplantation in patients who are experiencing end-stage refractory biventricular heart failure. This device is associated with a low, albeit still substantial, risk of thrombosis. Platelet interactions with artificial surfaces are complex and result in continuous activation of contact proteins despite therapeutic anticoagulation. We searched the medical literature (publication dates, January 1962–October 2009) in order to evaluate means of mitigating adverse events that have occurred after implantation of the CardioWest temporary total artificial heart. We conclude that the use of a multitargeted antithrombotic approach, involving anticoagulation (bivalirudin and warfarin) and antiplatelet therapy (dipyridamole and aspirin), can mitigate the procoagulative effects of mechanical circulatory assist devices, particularly those that are associated with the CardioWest temporary total artificial heart. Careful monitoring with use of a variant multisystem approach, involving efficacy tests (thrombelastography and light transmittance aggregometry), safety tests (laboratory analyses), and warfarin genomics, may maximize the therapeutic actions and minimize the bleeding risks that are associated with the multitargeted antithrombotic approach. The development and monitoring of individualized antithrombotic regimens require that informed health professionals appreciate the complexities and grasp the hazards that are associated with these therapies. PMID:20401285

  17. Control system for an artificial heart

    NASA Technical Reports Server (NTRS)

    Gebben, V. D.; Webb, J. A., Jr.

    1970-01-01

    Inexpensive industrial pneumatic components are combined to produce control system to drive sac-type heart-assistance blood pump with controlled pulsatile pressure that makes pump rate of flow sensitive to venous /atrial/ pressure, while stroke is centered about set operating point and pump is synchronized with natural heart.

  18. Testing of Safety-Critical Software Embedded in an Artificial Heart

    NASA Astrophysics Data System (ADS)

    Cha, Sungdeok; Jeong, Sehun; Yoo, Junbeom; Kim, Young-Gab

    Software is being used more frequently to control medical devices such as artificial heart or robotic surgery system. While much of software safety issues in such systems are similar to other safety-critical systems (e.g., nuclear power plants), domain-specific properties may warrant development of customized techniques to demonstrate fitness of the system on patients. In this paper, we report results of a preliminary analysis done on software controlling a Hybrid Ventricular Assist Device (H-VAD) developed by Korea Artificial Organ Centre (KAOC). It is a state-of-the-art artificial heart which completed animal testing phase. We performed software testing in in-vitro experiments and animal experiments. An abnormal behaviour, never detected during extensive in-vitro analysis and animal testing, was found.

  19. Past and Present of Total Artificial Heart Therapy: A Success Story

    PubMed Central

    Samak, Mostafa; Fatullayev, Javid; Sabashnikov, Anton; Zeriouh, Mohamed; Rahmanian, Parwis B.; Choi, Yeong-Hoon; Wippermann, Jens; Wahlers, Thorsten; Schmack, Bastian; Ruhparwar, Arjang; Dohmen, Pascal M.; Karck, Matthias; Popov, Aron-Frederik; Simon, André R.; Weymann, Alexander

    2015-01-01

    The totally artificial heart (TAH) is among the most prominent medical innovations of the 21st century, especially due to the increasing population with end-stage heart failure. The progressive course of the disease, its resistance to conventional therapy, and the scarcity of hearts available for transplantation were the prime impetus for developing a TAH, especially when other options of mechanical circulatory assist devices are exhausted. In this review, we narrate the history of TAH, give an overview of its technology, and address the pros and cons of the currently available TAH models in light of published clinical experience. PMID:26343363

  20. Design of a hydraulic analog of the circulatory system for evaluating artificial hearts.

    PubMed

    Donovan, F M

    1975-01-01

    A major problem in improving artificial heart designs is the absence of methods for accurate in vitro testing of artificial heart systems. A mock circulatory system has been constructed which hydraulically simulates the systemic and pulmonary circulations of the normal human. The device is constructed of 1/2 in. acrylic sheet and has overall dimensions of 24 in. wide, 16 in. tall, and 8 in. deep. The artificial heart to be tested is attached to the front of the device, and pumps fluid from the systemic venous chamber into the pulmonary arterial chamber and from the pulmonary venous chamber into the systemic arterial chamber. Each of the four chambers is hermetically sealed. The compliance of each chamber is determined by the volume of air trapped above the fluid in that chamber. The pulmonary and systemic resistances are set automatically by bellows-operated valves to simulate the barroreceptor response in the systemic arteries and the passive pulmonary resistance response in the pulmonary arteries. Cardiac output is measured by a turbine flowmeter in the systemic circulation. Results using the Kwan-Gett artificial heart show a good comparison between the mock circulatory system response and the calf response. PMID:1225373

  1. Total artificial heart in the pediatric patient with biventricular heart failure.

    PubMed

    Park, S S; Sanders, D B; Smith, B P; Ryan, J; Plasencia, J; Osborn, M B; Wellnitz, C M; Southard, R N; Pierce, C N; Arabia, F A; Lane, J; Frakes, D; Velez, D A; Pophal, S G; Nigro, J J

    2014-01-01

    Mechanical circulatory support emerged for the pediatric population in the late 1980s as a bridge to cardiac transplantation. The Total Artificial Heart (TAH-t) (SynCardia Systems Inc., Tuscon, AZ) has been approved for compassionate use by the Food and Drug Administration for patients with end-stage biventricular heart failure as a bridge to heart transplantation since 1985 and has had FDA approval since 2004. However, of the 1,061 patients placed on the TAH-t, only 21 (2%) were under the age 18. SynCardia Systems, Inc. recommends a minimum patient body surface area (BSA) of 1.7 m(2), thus, limiting pediatric application of this device. This unique case report shares this pediatric institution's first experience with the TAH-t. A 14-year-old male was admitted with dilated cardiomyopathy and severe biventricular heart failure. The patient rapidly decompensated, requiring extracorporeal life support. An echocardiogram revealed severe biventricular dysfunction and diffuse clot formation in the left ventricle and outflow tract. The decision was made to transition to biventricular assist device. The biventricular failure and clot formation helped guide the team to the TAH-t, in spite of a BSA (1.5 m(2)) below the recommendation of 1.7 m(2). A computed tomography (CT) scan of the thorax, in conjunction with a novel three-dimensional (3D) modeling system and team, assisted in determining appropriate fit. Chest CT and 3D modeling following implantation were utilized to determine all major vascular structures were unobstructed and the bronchi were open. The virtual 3D model confirmed appropriate device fit with no evidence of compression to the left pulmonary veins. The postoperative course was complicated by a left lung opacification. The left lung anomalies proved to be atelectasis and improved with aggressive recruitment maneuvers. The patient was supported for 11 days prior to transplantation. Chest CT and 3D modeling were crucial in assessing whether the device would

  2. Elective Inactivation of Total Artificial Heart Technology in Non-Futile Situations: Inpatients, Outpatients and Research Participants

    ERIC Educational Resources Information Center

    Bramstedt, Katrina A.

    2004-01-01

    Total artificial heart technology as a potential clinical therapy raises the issue of elective device inactivation in both futile and non-futile situations. This article explores elective device inactivation in non-futile situations. In reply to such requests for inactivation, the medical team should reflect on the individual's decision-making…

  3. Total Artificial Heart, Augmented by Venovenous Extracorporeal Membrane Oxygenation.

    PubMed

    Lick, Scott D; Tran, Phat L; Kazui, Toshinobu; Smith, Richard G; Khalpey, Zain I

    2016-01-01

    Shortly after SynCardia total artificial heart (TAH) implant, venovenous extracorporeal membrane oxygenation (ECMO) via a 31 Fr Avalon cannula was used for profound hypoxic lung dysfunction. Immediately after starting ECMO, TAH flow increased by 1.5-2.0 L/min, presumably because of augmented TAH filling by the ECMO jet. PMID:26771394

  4. Inspection of an artificial heart by the neutron radiography technique

    NASA Astrophysics Data System (ADS)

    Pugliesi, R.; Geraldo, L. P.; Andrade, M. L. G.; Menezes, M. O.,; Pereira, M. A. S.; Maizato, M. J. S.

    1999-11-01

    The neutron radiography technique was employed to inspect an artificial heart prototype which is being developed to provide blood circulation for patients expecting heart transplant surgery. The radiographs have been obtained by the direct method with a gadolinium converter screen along with the double coated Kodak-AA emulsion film. The artificial heart consists of a flexible plastic membrane located inside a welded metallic cavity, which is employed for blood pumping purposes. The main objective of the present inspection was to identify possible damages in this plastic membrane, produced during the welding process of the metallic cavity. The obtained radiographs were digitized as well as analysed in a PC and the improved images clearly identify several damages in the plastic membrane, suggesting changes in the welding process.

  5. Use of Bivalirudin for Anticoagulation during Implantation of Total Artificial Heart

    PubMed Central

    Federman, Myke; Dragomer, Douglas; Grant, Stuart; Reemtsen, Brian; Biniwale, Reshma

    2014-01-01

    Abstract: Heparin-induced thrombocytopenia presents a challenge for anticoagulation techniques during cardiac surgery and ventricular assist device implantation. Bivalirudin is currently recommended for use during cardiopulmonary bypass for patients with heparin-induced thrombocytopenia but requires the use of special techniques to avoid blood stagnation. We report the successful use of bivalirudin during cardiopulmonary bypass for implantation of the Total Artificial Heart with late operative bleeding likely resulting from heavy cell saver use. PMID:25208436

  6. Fluid dynamics of heart assist device

    NASA Technical Reports Server (NTRS)

    Jones, R. T.

    1976-01-01

    Certain hemodynamic phenomena that arise in connection with the use of artificial blood pumping devices are reviewed. Among these are: (1) Flows produced by collapsing bulbs; (2) the impedance presented by the aorta; (3) limiting velocities and instability of flow in elastic vessels; (4) effectiveness of valveless arterio-arterial pumps, and (5) wave reflection phenomena and instabilities associated with the intra-aortic balloon pump.

  7. Experiences with a sac-type artificial heart

    PubMed Central

    Morris, David T.; Couves, Cecil M.

    1971-01-01

    A total replacement artificial heart is described having in vitro performance satisfying human requirements up to and including moderate work. The in vitro design has been modified to make its implantation into the chests of experimental animals technically feasible. The heart has been tested in vivo for up to six hours, and has been found to provide the experimental animals with adequate blood flow and pressures. Preliminary tests have shown major problems of air embolism and red blood cell hemolysis. The heart design and technique of implantation are undergoing further improvement. Performance will be more comprehensively examined with the use of larger experimental animals in order more accurately to evaluate the heart's potential. ImagesFIG. 1FIG. 2FIG. 3FIG. 4FIG. 5FIG. 6FIG. 7FIG. 8FIG. 9FIG. 10 PMID:5112120

  8. Total Artificial Heart Implantation after Excision of Right Ventricular Angiosarcoma.

    PubMed

    Bruckner, Brian A; Abu Saleh, Walid K; Al Jabbari, Odeaa; Copeland, Jack G; Estep, Jerry D; Loebe, Matthias; Reardon, Michael J

    2016-06-01

    Primary cardiac sarcomas, although rare, are aggressive and lethal, requiring thorough surgical resection and adjuvant chemotherapy for the best possible outcome. We report the case of a 32-year-old woman who underwent total artificial heart implantation for right-sided heart failure caused by right ventricular angiosarcoma. For the first several weeks in intensive care, the patient recovered uneventfully. However, a postoperative liver biopsy indicated hepatocellular injury consistent with preoperative chemotherapy. She developed continuing liver failure, from which she died despite good cardiac function. PMID:27303244

  9. Total Artificial Heart Implantation after Excision of Right Ventricular Angiosarcoma

    PubMed Central

    Abu Saleh, Walid K.; Al Jabbari, Odeaa; Copeland, Jack G.; Estep, Jerry D.; Loebe, Matthias; Reardon, Michael J.

    2016-01-01

    Primary cardiac sarcomas, although rare, are aggressive and lethal, requiring thorough surgical resection and adjuvant chemotherapy for the best possible outcome. We report the case of a 32-year-old woman who underwent total artificial heart implantation for right-sided heart failure caused by right ventricular angiosarcoma. For the first several weeks in intensive care, the patient recovered uneventfully. However, a postoperative liver biopsy indicated hepatocellular injury consistent with preoperative chemotherapy. She developed continuing liver failure, from which she died despite good cardiac function. PMID:27303244

  10. The Thoratec system implanted as a modified total artificial heart: the Bad Oeynhausen technique.

    PubMed

    Arusoglu, Latif; Reiss, Nils; Morshuis, Michiel; Schoenbrodt, Michael; Hakim-Meibodi, Kavous; Gummert, Jan

    2010-12-01

    The CardioWest™ total artificial heart (SynCardia Systems, Tuscon, AZ, USA) is the only FDA-approved total artificial heart determined as a bridge to human heart transplantation for patients dying of biventricular heart failure. Implantation provides immediate hemodynamic restoration and clinical stabilization, leading to end-organ recovery and thus eventually allowing cardiac transplantation. Occasionally, implantation of a total artificial heart is not feasible for anatomical reasons. For this patient group, we have developed an alternative technique using the paracorporeal Thoratec biventricular support system (Thoratec, Pleasanton, CA, USA) as a modified total artificial heart. A detailed description of the implantation technique is presented. PMID:21169150

  11. Numerical Simulation of Flow Through an Artificial Heart

    NASA Technical Reports Server (NTRS)

    Rogers, Stuart E.; Kutler, Paul; Kwak, Dochan; Kiris, Cetin

    1989-01-01

    A solution procedure was developed that solves the unsteady, incompressible Navier-Stokes equations, and was used to numerically simulate viscous incompressible flow through a model of the Pennsylvania State artificial heart. The solution algorithm is based on the artificial compressibility method, and uses flux-difference splitting to upwind the convective terms; a line-relaxation scheme is used to solve the equations. The time-accuracy of the method is obtained by iteratively solving the equations at each physical time step. The artificial heart geometry involves a piston-type action with a moving solid wall. A single H-grid is fit inside the heart chamber. The grid is continuously compressed and expanded with a constant number of grid points to accommodate the moving piston. The computational domain ends at the valve openings where nonreflective boundary conditions based on the method of characteristics are applied. Although a number of simplifing assumptions were made regarding the geometry, the computational results agreed reasonably well with an experimental picture. The computer time requirements for this flow simulation, however, are quite extensive. Computational study of this type of geometry would benefit greatly from improvements in computer hardware speed and algorithm efficiency enhancements.

  12. Devices in heart failure: potential methods for device-based monitoring of congestive heart failure.

    PubMed

    Munir, Shahzeb M; Bogaev, Roberta C; Sobash, Ed; Shankar, K J; Gondi, Sreedevi; Stupin, Igor V; Robertson, Jillian; Brewer, M Alan; Casscells, S Ward; Delgado, Reynolds M; Ahmed, Amany

    2008-01-01

    Congestive heart failure has long been one of the most serious medical conditions in the United States; in fact, in the United States alone, heart failure accounts for 6.5 million days of hospitalization each year. One important goal of heart-failure therapy is to inhibit the progression of congestive heart failure through pharmacologic and device-based therapies. Therefore, there have been efforts to develop device-based therapies aimed at improving cardiac reserve and optimizing pump function to meet metabolic requirements. The course of congestive heart failure is often worsened by other conditions, including new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ damage, and therapeutic refractoriness, that have an impact on outcomes. The onset of such conditions is sometimes heralded by subtle pathophysiologic changes, and the timely identification of these changes may promote the use of preventive measures. Consequently, device-based methods could in the future have an important role in the timely identification of the subtle pathophysiologic changes associated with congestive heart failure. PMID:18612451

  13. Animal Experiments of the Helical Flow Total Artificial Heart.

    PubMed

    Abe, Yusuke; Isoyama, Takashi; Saito, Itsuro; Inoue, Yusuke; Ishii, Kohei; Sato, Masami; Hara, Shintaro; Yurimoto, Terumi; Li, Xinyang; Murakami, Haruka; Ariyoshi, Koki; Kawase, Yukino; Ono, Toshiya; Fukazawa, Kyoko; Ishihara, Kazuhiko

    2015-08-01

    Severe cardiac failure patients require a total artificial heart (TAH) to save life. To realize a TAH that can fit a body of small stature and has high performance, high durability, good anatomical fitting, good blood compatibility, and physiological control, we have been developing the helical flow TAH (HFTAH) with two helical flow pumps with hydrodynamic levitation impeller. Animal experiments of the HFTAH were conducted to perform in vivo studies. The HFTAH was implanted in 13 adult female goats weighing 45.0-64.0 kg. After surgery, neither anti-coagulant nor anti-platelet medication was given systemically. The HFTAH was usually driven with a quasi-pulsatile mode. The 1/R control or ΔP control was applied to control the circulation. The ΔP control is a new method using simplified equation of the 1/R control. The HFTAH could be implanted in all goats with good anatomical fitting. Two goats survived for a long time (100 and 68 days). Major causes of termination were device failure and surgical complications. In the device failure, trouble with hydrodynamic bearing was conspicuous. In the two long-term survived goats, experiments were terminated with bearing instability that was probably caused by the suction effect. In these goats, hemolysis occurred on postoperative day 88 and 44, which was considered to be relevant to the bearing trouble. Thrombus was found at the broken right bearing of the 100-day survived goat. However, antithrombogenicity of the pump is expected to be good unless bearing trouble occurs. In two long-term survived goats, the 1/R control or ΔP control worked appropriately to prevent the elevation of right atrial pressure. In both goats, hemodynamic parameters changed with the condition of the animals, liver and kidney functions remained almost normal except when recovering from surgery and during hemolysis, and total protein recovered 2 weeks after surgery. Although instability of the hydrodynamic bearing should be improved, performance of

  14. Computational flow visualization in vibrating flow pump type artificial heart by unstructured grid.

    PubMed

    Kato, Takuma; Kawano, Satoyuki; Nakahashi, Kazuhiro; Yambe, Tomoyuki; Nitta, Shin-ichi; Hashimoto, Hiroyuki

    2003-01-01

    Computational flow visualization in the casing of vibrating flow pump (VFP) was made for various conditions based on the novel techniques of fluid dynamics. VFP type artificial heart can generate the oscillated flow and can be applied to the left ventricular assist device. Flow pattern of blood in an artificial heart is closely connected to mechanical performance and serious biomechanical problems such as hemolysis and blood coagulation. To effectively design the VFP for a left ventricular assist device, the numerical codes for solving Navier-Stokes equations were developed for three-dimensional blood flow based on the finite volume method. Furthermore, the simulation techniques based on the artificial compressibility method and the unstructured grid were also developed here. The numerical calculations were based on the precise configurations and the flow conditions of the prototype device. From the viewpoint of computational fluid dynamics (CFD), the detailed discussion of flow patterns in the casing of VFP, which were closely connected with hemolysis and blood coagulation, was made and the computational results were visualized by the use of the recent technique of computational graphics. Some useful design data of VFP were presented. PMID:12534712

  15. Robust motor speed control under time varying loads in moving actuator type artificial heart (AnyHeart).

    PubMed

    Lee, J J; Kim, W E; Choi, J; Park, J W; Chung, J; Nam, K; Park, S K; Son, H S; Sun, K; Min, B G

    2004-09-01

    The Moving Actuator type artificial heart(AnyHeart) as well as many other artificial hearts uses a motor as its power source. For controllability of control parameters such as pump rate, pump output, blood pressure profile and flow form, the precise motor speed control is important. However, because the implantable device has limited carrying capacity of hardware components in size and number, applying diverse motor control methods are not possible. In addition, the existing PI (Proportional-Integral) motor controller does not show satisfactory performance. A new controller that is sufficiently robust for the changes of load and physical system parameters has been designed and tested. The robust speed controller is based on the sliding mode control method that is applicable to a system of which the ranges of uncertainty in physical parameters are known. In a mock circulation system test, the actual speed showed good tracking characteristics in respect to the reference speed. Fast follow-up characteristics were also observed under high afterload and speed conditions. The speed error, current and power consumption were reduced by about 40%. The proposed control technique overcomes the limitations of the PI controller, and makes important improvements in both performance and stability. PMID:15521219

  16. Artificial heart for humanoid robot using coiled SMA actuators

    NASA Astrophysics Data System (ADS)

    Potnuru, Akshay; Tadesse, Yonas

    2015-03-01

    Previously, we have presented the design and characterization of artificial heart using cylindrical shape memory alloy (SMA) actuators for humanoids [1]. The robotic heart was primarily designed to pump a blood-like fluid to parts of the robot such as the face to simulate blushing or anger by the use of elastomeric substrates for the transport of fluids. It can also be used for other applications. In this paper, we present an improved design by using high strain coiled SMAs and a novel pumping mechanism that uses sequential actuation to create peristalsis-like motions, and hence pump the fluid. Various placements of actuators will be investigated with respect to the silicone elastomeric body. This new approach provides a better performance in terms of the fluid volume pumped.

  17. The evolving role of the total artificial heart in the management of end-stage congenital heart disease and adolescents.

    PubMed

    Ryan, Thomas D; Jefferies, John L; Zafar, Farhan; Lorts, Angela; Morales, David L S

    2015-01-01

    Advances in medical therapies have yielded improvement in morbidity and a decrease in mortality for patients with congenital heart disease, both surgically palliated and uncorrected. An unintended consequence is a cohort of adolescent and adult patients with heart failure who require alternative therapies. One intriguing option is placement of a total artificial heart (TAH) either as a bridge to transplant or as a destination therapy. Of the 1091 Jarvik-7 type TAH (Symbion, CardioWest and SynCardia) placed between 1985 and 2012, only 24 have been performed in patients with congenital heart disease, and a total of 51 were placed in patients younger than 21. At our institution, the SynCardia TAH was implanted in a 19-year-old patient with cardiac allograft failure because of chronic rejection and related multisystem organ failure including need for hemodialysis. Over the next year, she was nutritionally and physically rehabilitated, as were her end organs, allowing her to come off dialysis, achieve normal renal function and eventually be successfully transplanted. Given the continued growth of adolescent and adult congenital heart disease populations with end-stage heart failure, the TAH may offer therapeutic options where previously there were few. In addition, smaller devices such as the SynCardia 50/50 will open the door for applications in smaller children. The Freedom Driver offers the chance for patients to leave the hospital with a TAH, as does the AbioCor, which is a fully implantable TAH option. In this report, we review the history of the TAH and potential applications in adolescent patients and congenital heart disease. PMID:25248044

  18. Post-explant visualization of thrombi in outflow grafts and their junction to a continuous-flow total artificial heart using a high-definition miniaturized camera.

    PubMed

    Karimov, Jamshid H; Horvath, David; Sunagawa, Gengo; Byram, Nicole; Moazami, Nader; Golding, Leonard A R; Fukamachi, Kiyotaka

    2015-12-01

    Post-explant evaluation of the continuous-flow total artificial heart in preclinical studies can be extremely challenging because of the device's unique architecture. Determining the exact location of tissue regeneration, neointima formation, and thrombus is particularly important. In this report, we describe our first successful experience with visualizing the Cleveland Clinic continuous-flow total artificial heart using a custom-made high-definition miniature camera. PMID:25939428

  19. A hybrid mock circulation loop for a total artificial heart.

    PubMed

    Nestler, Frank; Bradley, Andrew P; Wilson, Stephen J; Timms, Daniel L; Frazier, O Howard; Cohn, William E

    2014-09-01

    Rotary blood pumps are emerging as a viable technology for total artificial hearts, and the development of physiological control algorithms is accelerated with new evaluation environments. In this article, we present a novel hybrid mock circulation loop (HMCL) designed specifically for evaluation of rotary total artificial hearts (rTAH). The rTAH is operated in the physical domain while all vasculature elements are embedded in the numerical domain, thus combining the strengths of both approaches: fast and easy exchange of the vasculature model together with improved controllability of the pump. Parameters, such as vascular resistance, compliance, and blood volume, can be varied dynamically in silico during operation. A hydraulic-numeric interface creates a real-time feedback loop between the physical and numerical domains. The HMCL uses computer-controlled resistance valves as actuators, thereby reducing the size and number of hydraulic elements. Experimental results demonstrate a stable interaction over a wide operational range and a high degree of flexibility. Therefore, we demonstrate that the newly created design environment can play an integral part in the hydraulic design, control development, and durability testing of rTAHs. PMID:25234760

  20. Vacuum generation in pneumatic artificial heart drives with a specially designed ejector system.

    PubMed

    Schima, H; Huber, L; Spitaler, F

    1990-06-01

    To improve the filling characteristics of pneumatically driven membrane artificial hearts (AHs), a vacuum is applied during diastole. This paper describes an ejector system for AH-drivers based on the Venturi effect, which was designed for this purpose. It provides vacuums of more than -40 mmHg at flow rates up to 50 l/min requiring a supplying primary gas pressure of less than 150 kPa (1140 mmHg). Under normal working conditions, the necessary supply flow was less than 5l/min. The device is small, cheap, quiet and fail-safe, and has been evaluated successfully in experimental and clinical use. PMID:2357149

  1. Results with an anticoagulation protocol in 99 SynCardia total artificial heart recipients.

    PubMed

    Copeland, Jack; Copeland, Hannah; Nolan, Paul; Gustafson, Monica; Slepian, Marvin; Smith, Richard

    2013-01-01

    For 15 years, we employed a consistent anticoagulation protocol in 99 consecutive SynCardia Systems total artificial heart (TAH) recipients. Thromboelastography and platelet aggregation studies were used for evaluating and modulating therapy with dipyridamole, pentoxiphylline, aspirin, and heparin. Partial thromboplastin times, international normalized ratios, and platelet counts were also followed. After the second post-implant day in patients who were free of endo-device infection (97 patients), the embolic stroke incidence was 0.08 per patient year. This included 23.6 patient years of device support. There were no spontaneous hemorrhagic strokes. Two patients had endo-device infections and both had strokes. Postimplantation bleeding was seen in 20% of patients. All but two of these were within the first postoperative week. In all, 4% of patients had gastrointestinal bleeding. We did not observe heparin-induced thrombocytopenia in any patient. We conclude that stroke rates on TAH support have been low, and recommend this protocol. PMID:23644607

  2. Pathogenesis of various forms of infection in artificial hearts.

    PubMed

    Dobsák, Petr; Vasků, Jaromir; Janci;k, Jiri;; Eicher, Jean Christophe; Wotke, Jiri;

    2003-05-01

    Implanted biomaterials are often inevitably attacked by the bacterial infection. So far this problem has not been sufficiently explained and solved. It represents an 'evergreen' in the artificial heart research. Infection of biomaterials is a completely new clinical entity that profoundly differs from the common clinical course of various kinds of infections and their treatment. These infections are persistent; they resist host defense mechanisms and antibiotic therapy because the nature of these microorganisms has changed due to their protection by the biofilm of some bacteria on the surfaces of implanted biomaterials. In our 66 long-term experiments with total artificial heart (TAH) in 25 animals, the infection and sepsis were the main causes of death. The different organs, attacked by the bacterial and septic complications, varied from case to case as the predominant organs, the function of which ceased to be compatible with further survival. The main foci where the infection started were also very variable. The artificial hearts used in these 25 calves were predominantly of TNS-BRNO-VII type (19 animals), TNS-BRNO-II type (4 animals) and of ROSTOCK TAH type (2 animals). The decrease of the immune defense in the TAH recipients of different intensity was evident during the course of infectious process and simultaneously, the virulence and resistance of the microorganisms against antibiotics substantially increased. The activity of the infectious agents was often combined with increased blood coagulation and thrombi formation. In 5 calves hemolytic and hemorrhagic episodes were observed, and in 15 calves without simultaneous anti-calcification treatment, a primary calcification of driving diaphragms was observed. A common dystrophic calcification sometimes complicated septic thrombogenesis. The tactics of the antibiotic therapy differed according to the results of hemocultivation tests and body temperature and was often supported by the stimulation of the immune

  3. HeartWare left ventricular assist device for the treatment of advanced heart failure.

    PubMed

    Hanke, Jasmin S; Rojas, Sebastian V; Avsar, Murat; Bara, Christoph; Ismail, Issam; Haverich, Axel; Schmitto, Jan D

    2016-01-01

    The importance of mechanical circulatory support in the therapy of advanced heart failure is steadily growing. The rapid developments in the field of mechanical support are characterized by continuous miniaturization and enhanced performance of the assist devices, providing increased pump durability and prolonged patient survival. The HeartWare left ventricular assist device system (HeartWare Inc., Framingham, MA, USA) is a mechanical ventricular assist device with over 8000 implantations worldwide. Compared with other available assist devices it is smaller in size and used in a broad range of patients. The possibility of minimally invasive procedures is one of the major benefits of the device - allowing implants and explants, as well as exchanges of the device with reduced surgical impact. We present here a review of the existing literature on the treatment of advanced heart failure using the HeartWare left ventricular assist device system. PMID:26597386

  4. The Syncardia(™) total artificial heart: in vivo, in vitro, and computational modeling studies.

    PubMed

    Slepian, Marvin J; Alemu, Yared; Girdhar, Gaurav; Soares, João Silva; Smith, Richard G; Einav, Shmuel; Bluestein, Danny

    2013-01-18

    The SynCardia(™) total artificial heart (TAH) is the only FDA-approved TAH in the world. The SynCardia(™) TAH is a pneumatically driven, pulsatile system capable of flows of >9L/min. The TAH is indicated for use as a bridge to transplantation (BTT) in patients at imminent risk of death from non-reversible bi-ventricular failure. In the Pivotal US approval trial the TAH achieved a BTT rate of >79%. Recently a multi-center, post-market approval study similarly demonstrated a comparable BTT rate. A major milestone was recently achieved for the TAH, with over 1100 TAHs having been implanted to date, with the bulk of implantation occurring at an ever increasing rate in the past few years. The TAH is most commonly utilized to save the lives of patients dying from end-stage bi-ventricular heart failure associated with ischemic or non-ischemic dilated cardiomyopathy. Beyond progressive chronic heart failure, the TAH has demonstrated great efficacy in supporting patients with acute irreversible heart failure associated with massive acute myocardial infarction. In recent years several diverse clinical scenarios have also proven to be well served by the TAH including severe heart failure associated with advanced congenital heart disease. failed or burned-out transplants, infiltrative and restrictive cardiomyopathies and failed ventricular assist devices. Looking to the future a major unmet need remains in providing total heart support for children and small adults. As such, the present TAH design must be scaled to fit the smaller patient, while providing equivalent, if not superior flow characteristics, shear profiles and overall device thrombogenicity. To aid in the development of a new "pediatric," TAH an engineering methodology known as "Device Thrombogenicity Emulation (DTE)", that we have recently developed and described, is being employed. Recently, to further our engineering understanding of the TAH, as steps towards next generation designs we have: (1) assessed of

  5. The Syncardia™ total artificial heart: in vivo, in vitro, and computational modeling studies

    PubMed Central

    Slepian, Marvin J.; Alemu, Yared; Soares, João Silva; Smith, Richard G.; Einav, Shmuel; Bluestein, Danny

    2014-01-01

    The SynCardia™ total artificial heart (TAH) is the only FDA-approved TAH in the world. The SynCardia™ TAH is a pneumatically driven, pulsatile system capable of flows of >9 L/min. The TAH is indicated for use as a bridge to transplantation (BTT) in patients at imminent risk of death from non-reversible bi-ventricular failure. In the Pivotal US approval trial the TAH achieved a BTT rate of >79%. Recently a multi-center, post-market approval study similarly demonstrated a comparable BTT rate. A major milestone was recently achieved for the TAH, with over 1100 TAHs having been implanted to date, with the bulk of implantation occurring at an ever increasing rate in the past few years. The TAH is most commonly utilized to save the lives of patients dying from end-stage bi-ventricular heart failure associated with ischemic or non-ischemic dilated cardiomyopathy. Beyond progressive chronic heart failure, the TAH has demonstrated great efficacy in supporting patients with acute irreversible heart failure associated with massive acute myocardial infarction. In recent years several diverse clinical scenarios have also proven to be well served by the TAH including severe heart failure associated with advanced congenital heart disease. failed or burned-out transplants, infiltrative and restrictive cardiomyopathies and failed ventricular assist devices. Looking to the future a major unmet need remains in providing total heart support for children and small adults. As such, the present TAH design must be scaled to fit the smaller patient, while providing equivalent, if not superior flow characteristics, shear profiles and overall device thrombogenicity. To aid in the development of a new “pediatric,” TAH an engineering methodology known as “Device Thrombogenicity Emulation (DTE)”, that we have recently developed and described, is being employed. Recently, to further our engineering understanding of the TAH, as steps towards next generation designs we have: (1

  6. Hemodynamic support with percutaneous devices in patients with heart failure.

    PubMed

    Kapur, Navin K; Esposito, Michele

    2015-04-01

    The use of surgically implanted durable mechanical circulatory support (MCS) in high-risk patients with heart failure is declining and short-term, nondurable MCS device use is growing. Percutaneously delivered MCS options for advanced heart failure include the intra-aortic balloon pump, Impella axial flow catheter, TandemHeart centrifugal pump, and venoarterial extracorporeal membrane oxygenation. Nondurable MCS devices have unique implantation characteristics and hemodynamic effects. Algorithms and guidelines for optimal nondurable MCS device selection do not exist. Emerging technologies and applications will address the need for improved left ventricular unloading using lower-profile devices, longer-term ambulatory support, and the potential for myocardial recovery. PMID:25834971

  7. Artificial Heart Rejects High Tech? Lessens Learnt from Non-pulsatile VAD with Straight Impeller Vanes

    PubMed Central

    Qian, Kun-xi

    2007-01-01

    Despite the progresses in developing pulsatile impeller pump and impeller total heart, as well as in applying streamlined impeller vanes, the best results in application of artificial heart pumps have been achieved by nonpulsatile univentricular assist pump with straight impeller vanes until now. It seems all efforts and successes have been done in vain because artificial heart rejects Hi-Tech! This paper recalls some important achievements in R&D of artificial heart in past 25 years and shares author’s experiences with the readers. PMID:19662125

  8. Role of total artificial heart in the management of heart transplant rejection and retransplantation: case report and review.

    PubMed

    Kalya, Anantharam; Jaroszewski, Dawn; Pajaro, Octavio; Scott, Robert; Gopalan, Radha; Kasper, Diane; Arabia, Francisco

    2013-01-01

    Cardiac allograft rejection and failure may require mechanical circulatory support as bridge-to-retransplantation. Prognosis in this patient group is poor and implantable ventricular assist devices have had limited success due to organ failure associated with the high dose immunosuppression required to treat ongoing rejection. We present a case from our institution and the world-wide experience utilizing the SynCardia CardioWest Total Artificial Heart (TAH-t; SynCardia Systems, Inc., Tucson, AZ, USA) for replacement of the failing graft, recovery of patient and end-organ failure with ultimate bridge to retransplantation. We present our experience and review of world-wide experience for use of TAH-t in this type patient. PMID:23725400

  9. First North American 50 cc Total Artificial Heart Experience: Conversion from a 70 cc Total Artificial Heart.

    PubMed

    Khalpey, Zain; Kazui, Toshinobu; Ferng, Alice S; Connell, Alana; Tran, Phat L; Meyer, Mark; Rawashdeh, Badi; Smith, Richard G; Sweitzer, Nancy K; Friedman, Mark; Lick, Scott; Slepian, Marvin J; Copeland, Jack G

    2016-01-01

    The 70 cc total artificial heart (TAH) has been utilized as bridge to transplant (BTT) for biventricular failure. However, the utilization of 70 cc TAH has been limited to large patients for the low output from the pulmonary as well as systemic vein compression after chest closure. Therefore, the 50 cc TAH was developed by SynCardia (Tucson, AZ) to accommodate smaller chest cavity. We report the first TAH exchange from a 70 to 50 cc due to a fit difficulty. The patient failed to be closed with a 70 cc TAH, although the patient met the conventional 70 cc TAH fit criteria. We successfully closed the chest with a 50 cc TAH. PMID:26809081

  10. Effective ultraviolet irradiance measurements from artificial tanning devices in Greece.

    PubMed

    Petri, Aspasia; Karabetsos, Efthymios

    2015-12-01

    Artificial tanning remains very popular worldwide, despite the International Agency for Research on Cancer classification of ultraviolet (UV) radiation from sunbeds as 'carcinogenic to humans'. Greek Atomic Energy Commission has initiated a surveillance action of the artificial tanning devices in Greece in order to record the effective irradiance levels from the sunbeds and to inform and synchronise the domestic artificial tanning business sector with the requirements of the European Standard EN 60335-2-27:2010. In this direction, in situ measurements of UV emissions from sunbeds in solaria businesses all over Greece were performed from October 2013 until July 2014, with a radiometer and a portable single-monochromator spectrophotometer. Analysis of the measurements' results revealed that effective irradiance in ∼60 % of the measured sunbeds exceeded the 0.3 W m(-2) limit value set by EN 60335-2-27:2010 and only 20 % of the devices could be categorised as UV type 3. PMID:25468991

  11. A first step beyond traditional boundaries: destination therapy with the SynCardia total artificial heart.

    PubMed

    Spiliopoulos, Sotirios; Koerfer, Reiner; Tenderich, Gero

    2014-06-01

    The SynCardia total artificial heart is currently used as a bridge to transplantation therapy in cases of irreversible, acute or chronic, biventricular heart failure. We describe the implementation of this technology in the context of destination therapy in a patient with an end-stage heart failure on grounds of primary amyloidosis. PMID:24632422

  12. That giant whirring sound you hear is either an artificial heart or Louisville's Jewish Hospital cashing in on being first.

    PubMed

    Romano, M

    2001-09-10

    For Jewish Hospital in Louisville, Ky., a modest-looking device made of titanium and plastic could be the ticket to healthcare's big leagues. Earlier this summer the hospital was the first to implant the AbioCor artificial heart, and it's been riding a wave of media acclaim ever since. Hospital President Doug Shaw hopes the facility can cash in on its successes. PMID:11573357

  13. Devices and circuits for nanoelectronic implementation of artificial neural networks

    NASA Astrophysics Data System (ADS)

    Turel, Ozgur

    Biological neural networks perform complicated information processing tasks at speeds better than conventional computers based on conventional algorithms. This has inspired researchers to look into the way these networks function, and propose artificial networks that mimic their behavior. Unfortunately, most artificial neural networks, either software or hardware, do not provide either the speed or the complexity of a human brain. Nanoelectronics, with high density and low power dissipation that it provides, may be used in developing more efficient artificial neural networks. This work consists of two major contributions in this direction. First is the proposal of the CMOL concept, hybrid CMOS-molecular hardware [1-8]. CMOL may circumvent most of the problems in posed by molecular devices, such as low yield, vet provide high active device density, ˜1012/cm 2. The second contribution is CrossNets, artificial neural networks that are based on CMOL. We showed that CrossNets, with their fault tolerance, exceptional speed (˜ 4 to 6 orders of magnitude faster than biological neural networks) can perform any task any artificial neural network can perform. Moreover, there is a hope that if their integration scale is increased to that of human cerebral cortex (˜ 1010 neurons and ˜ 1014 synapses), they may be capable of performing more advanced tasks.

  14. Results with SynCardia total artificial heart beyond 1 year.

    PubMed

    Torregrossa, Gianluca; Morshuis, Michiel; Varghese, Robin; Hosseinian, Leila; Vida, Vladimiro; Tarzia, Vincenzo; Loforte, Antonio; Duveau, Daniel; Arabia, Francisco; Leprince, Pascal; Kasirajan, Vigneshwa; Beyersdorf, Friedhelm; Musumeci, Francesco; Hetzer, Roland; Krabatsch, Thoamas; Gummert, Jan; Copeland, Jack; Gerosa, Gino

    2014-01-01

    Mechanical circulatory support devices have been increasingly used for long-term support. We reviewed outcomes in all patients supported with a SynCardia total artificial heart (TAH) for more than 1 year to assess its safety in long-term support. As of December 2011, all 47 patients who received the TAH from 10 centers worldwide were included in this retrospective study. Clinical data were collected on survival, infections, thromboembolic and hemorrhagic events, device failures, and antithrombotic therapy. The mean age of patients was 50 ± 1.57 years, the median support time was 554 days (range 365-1373 days). The primary diagnosis was dilated cardiomiopathy in 23 patients, ischemic in 15, and "other" in 9. After a minimum of 1 year of support, 34 patients (72%) were successfully transplanted, 12 patients (24%) died while on device support, and 1 patient (2%) is still supported. Five patients (10%) had a device failure reported. Major complications were as follows: systemic infections in 25 patients (53%), driveline infections in 13 patients (27%), thromboembolic events in 9 patients (19%), and hemorrhagic events in 7 patients (14%). SynCardia TAH has proven to be a reliable and effective device in replacing the entire heart. In patients who reached a minimum of 1 year of support, device failure rate is acceptable and only in two cases was the leading cause of death. Infections and hemorrhagic events were the major causes of death. Patients who remain supported beyond 1 year are still likely to survive to transplantation. PMID:25158888

  15. Total Artificial Heart as Bridge to Heart Transplantation in Chagas Cardiomyopathy: Case Report.

    PubMed

    Ruzza, A; Czer, L S C; De Robertis, M; Luthringer, D; Moriguchi, J; Kobashigawa, J; Trento, A; Arabia, F

    2016-01-01

    Chagas disease (CD) is becoming an increasingly recognized cause of dilated cardiomyopathy outside of Latin America, where it is endemic, due to population shifts and migration. Heart transplantation (HTx) is a therapeutic option for end-stage cardiomyopathy due to CD, but may be considered a relative contraindication due to potential reactivation of the causative organism with immunosuppression therapy. The total artificial heart (TAH) can provide mechanical circulatory support in decompensated patients with severe biventricular dysfunction until the time of HTx, while avoiding immunosuppressive therapy and removing the organ most affected by the causative organism. We report herein a patient with CD and severe biventricular dysfunction, who had mechanical circulatory support with a TAH for more than 6 months, followed by successful orthotopic HTx and treatment with benznidazole for 3 months. The patient had no evidence of recurrent disease in the transplanted heart based on endomyocardial biopsy up to 1 year post-transplantation, and remains alive more than 30 months after insertion of a TAH and 24 months after HTx. PMID:26915885

  16. Development of an Electrohydraulic Total Artificial Heart System

    NASA Astrophysics Data System (ADS)

    Homma, Akihiko; Taenaka, Yoshiyuki; Tatsumi, Eisuke; Takewa, Yoshiaki; Mizuno, Toshihide; Shioya, Kyoko; Lee, Hwan Sung; Tsukiya, Tomonori; Kakuta, Yukihide; Katagiri, Nobumasa; Nishinaka, Tomohiro; Koshiji, Kohji

    An electrohydraulic total artificial heart (EHTAH) system has been developed. The EHTAH system consists of diaphragm-type blood pumps, an electrohydraulic actuator, an internal control unit, a transcutaneous energy transfer system (TETS), a transcutaneous optical telemetry system (TOTS), and an internal battery. The reciprocating rotation of the impeller generates oil pressure which drives the blood pumps at alternating intervals. The blood pumps and the actuator were successfully integrated into the pump unit without oil conduits. As a result of miniaturizing the blood pumps and the actuator, the displacement volume and weight of the EHTAH system decreased to 872 ml and 2492g, respectively. Furthermore, the maximum flow rate and efficiency increased up to 12 L/min and 15.4%. The pump units and the EHTAH systems were successfully implanted in 36 calves weighing from 55 to 87kg. In the longest case, the ca1f with the pump unit survived for 87 days and the calf with the EHTAH system survived for 70 days. The EHTAH system was powered by the TETS, and was powered everyday by the internal battery for 40 minutes. These results indicate that the EHTAH system has the potential to become a fully implantable cardiac replacement system.

  17. About the Operation: Heart Transplant

    MedlinePlus

    ... Short gut syndrome Living with Devices Artificial hearts LVADS ICDs Pacemakers Hemodialysis Peritoneal dialysis About Organ Allocation ... because the new heart can act as an assist device if complications occur. Your physician can explain ...

  18. Supramolecular photochemistry applied to artificial photosynthesis and molecular logic devices.

    PubMed

    Gust, Devens

    2015-01-01

    Supramolecular photochemical systems consist of photochemically active components such as chromophores, electron donors or electron acceptors that are associated via non-covalent or covalent interactions and that interact in some functional way. Examples of interactions are singlet-singlet energy transfer, triplet-triplet energy transfer, photoinduced electron transfer, quantum coherence and spin-spin magnetic interactions. Supramolecular photochemical "devices" may have applications in areas such as solar energy conversion, molecular logic, computation and data storage, biomedicine, sensing, imaging, and displays. This short review illustrates supramolecular photochemistry with examples drawn from artificial photosynthesis, molecular logic, analog photochemical devices and models for avian magnetic orientation. PMID:26515930

  19. Heart failure analysis dashboard for patient's remote monitoring combining multiple artificial intelligence technologies.

    PubMed

    Guidi, G; Pettenati, M C; Miniati, R; Iadanza, E

    2012-01-01

    In this paper we describe an Heart Failure analysis Dashboard that, combined with a handy device for the automatic acquisition of a set of patient's clinical parameters, allows to support telemonitoring functions. The Dashboard's intelligent core is a Computer Decision Support System designed to assist the clinical decision of non-specialist caring personnel, and it is based on three functional parts: Diagnosis, Prognosis, and Follow-up management. Four Artificial Intelligence-based techniques are compared for providing diagnosis function: a Neural Network, a Support Vector Machine, a Classification Tree and a Fuzzy Expert System whose rules are produced by a Genetic Algorithm. State of the art algorithms are used to support a score-based prognosis function. The patient's Follow-up is used to refine the diagnosis. PMID:23366362

  20. Incompressible viscous flow computations for the pump components and the artificial heart

    NASA Technical Reports Server (NTRS)

    Kiris, Cetin

    1992-01-01

    A finite-difference, three-dimensional incompressible Navier-Stokes formulation to calculate the flow through turbopump components is utilized. The solution method is based on the pseudocompressibility approach and uses an implicit-upwind differencing scheme together with the Gauss-Seidel line relaxation method. Both steady and unsteady flow calculations can be performed using the current algorithm. In this work, the equations are solved in steadily rotating reference frames by using the steady-state formulation in order to simulate the flow through a turbopump inducer. Eddy viscosity is computed by using an algebraic mixing-length turbulence model. Numerical results are compared with experimental measurements and a good agreement is found between the two. Included in the appendix is a paper on incompressible viscous flow through artificial heart devices with moving boundaries. Time-accurate calculations, such as impeller and diffusor interaction, will be reported in future work.

  1. Sleep and wake phase of heart beat dynamics by artificial insymmetrised patterns

    NASA Astrophysics Data System (ADS)

    Dudkowska, A.; Makowiec, D.

    2004-05-01

    In order to determine differences between healthy patients and patients with congestive heart failure we apply the artificial insymmetrised pattern (AIP) method. The AIP method by exploring a human eye ability to extract regularities and read symmetries in a dot pattern, serves a tool for qualitative discrimination of heart rate states.

  2. Hemodynamics of a functional centrifugal-flow total artificial heart with functional atrial contraction in goats.

    PubMed

    Shiga, Takuya; Shiraishi, Yasuyuki; Sano, Kyosuke; Taira, Yasunori; Tsuboko, Yusuke; Yamada, Akihiro; Miura, Hidekazu; Katahira, Shintaro; Akiyama, Masatoshi; Saiki, Yoshikatsu; Yambe, Tomoyuki

    2016-03-01

    Implantation of a total artificial heart (TAH) is one of the therapeutic options for the treatment of patients with end-stage biventricular heart failure. There is no report on the hemodynamics of the functional centrifugal-flow TAH with functional atrial contraction (fCFTAH). We evaluated the effects of pulsatile flow by atrial contraction in acute animal models. The goats received fCFTAH that we created from two centrifugal-flow ventricular assist devices. Some hemodynamic parameters maintained acceptable levels: heart rate 115.5 ± 26.3 bpm, aortic pressure 83.5 ± 10.1 mmHg, left atrial pressure 18.0 ± 5.9 mmHg, pulmonary pressure 28.5 ± 9.7 mmHg, right atrial pressure 13.6 ± 5.2 mmHg, pump flow 4.0 ± 1.1 L/min (left) 3.9 ± 1.1 L/min (right), and cardiac index 2.13 ± 0.14 L/min/m(2). fCFTAH with atrial contraction was able to maintain the TAH circulation by forming a pulsatile flow in acute animal experiments. Taking the left and right flow rate balance using the low internal pressure loss of the VAD pumps may be easier than by other pumps having considerable internal pressure loss. We showed that the remnant atrial contraction effected the flow rate change of the centrifugal pump, and the atrial contraction waves reflected the heart rate. These results indicate that remnant atria had the possibility to preserve autonomic function in fCFTAH. We may control fCFTAH by reflecting the autonomic function, which is estimated with the flow rate change of the centrifugal pump. PMID:26198448

  3. A mock circulatory loop for designing and evaluating total artificial hearts.

    PubMed

    Love, Holley C; Timms, Daniel L; Nestler, Frank; Frazier, O H; Cohn, William E

    2014-01-01

    A mock circulatory loop was constructed to facilitate total artificial heart development. The loop includes many novel features such as a pressure-regulated tank to simulate exercise conditions, controllable systemic and pulmonary vascular resistance to create left-right flow imbalances as seen in postural change and breathing, and a left atrial suction valve. Dual HeartMate II pumps and the BiVACOR® rotary total artificial heart were used to generate pressure and flow data characterizing the flow loop. PMID:25571281

  4. [Telemedicine and wireless devices in heart failure].

    PubMed

    Billeci, Lucia; Guerriero, Lorenzo; L'Abbate, Antonio; Pioggia, Giovanni; Tartarisco, Gennaro; Trivella, Maria Giovanna

    2014-05-01

    Telemedicine has the potential to constitute the central element of the future primary care and become an effective means of prevention and early warning of acute exacerbation of chronic diseases. Up to now, the application of telemedicine has found a variety of difficulties, regarding the types and methods of acquisition and transmission of biological signals, the acceptance and cooperation of the patient, etc. The latest technological developments involve the combined use of wireless technologies and smartphones, for the collection and the transmission of data, and specific softwares for their automatic analysis. This paper examines some of the critical aspects in the application of new technologies for heart failure remote management. PMID:24873944

  5. Human Fitting Studies of Cleveland Clinic Continuous-Flow Total Artificial Heart

    PubMed Central

    Karimov, Jamshid H.; Steffen, Robert J.; Byram, Nicole; Sunagawa, Gengo; Horvath, David; Cruz, Vincent; Golding, Leonard A.R.; Fukamachi, Kiyotaka; Moazami, Nader

    2015-01-01

    Implantation of mechanical circulatory support devices is challenging, especially in patients with a small chest cavity. We evaluated how well the Cleveland Clinic continuous-flow total artificial heart (CFTAH) fit the anatomy of patients about to receive a heart transplant. A mock pump model of the CFTAH was rapid-prototyped using biocompatible materials. The model was brought to the operative table, and the direction, length, and angulation of the inflow/outflow ports and outflow conduits were evaluated after the recipient's ventricles had been resected. Thoracic cavity measurements were based on preoperative computed tomographic data. The CFTAH fit well in all five patients (height, 170 ± 9 cm; weight, 75 ± 24 kg). Body surface area was 1.9 ± 0.3 m2 (range, 1.6-2.1 m2). The required inflow and outflow port orientation of both the left and right housings appeared consistent with the current version of the CFTAH implanted in calves. The left outflow conduit remained straight, but the right outflow direction necessitated a 73 ± 22 degree angulation to prevent potential kinking when crossing over the connected left outflow. These data support the fact that our design achieves the proper anatomical relationship of the CFTAH to a patient's native vessels. PMID:25806613

  6. Ultimate test bench for pediatric biventricular assist device based on artificial muscles.

    PubMed

    Muradbegovic, Mirza; Taub, Steven; Rizzo, Elena; von Segesser, Ludwig K; Tozzi, Piergiorgio

    2011-01-01

    Ventricular assist devices (VADs) are used in treatment for terminal heart failure or as a bridge to transplantation. We created biVAD using the artificial muscles (AMs) that supports both ventricles at the same time. We developed the test bench (TB) as the in vitro evaluating system to enable the measurement of performance. The biVAD exerts different pressure between left and right ventricle like the heart physiologically does. The heart model based on child's heart was constructed in silicone. This model was fitted with the biVAD. Two pipettes containing water with an ultrasonic sensor placed on top of each and attached to ventricles reproduced the preload and the after load of each ventricle by the real-time measurement of the fluid height variation proportionally to the exerted pressure. The LabVIEW software extrapolated the displaced volume and the pressure generated by each side of our biVAD. The development of a standardized protocol permitted the validation of the TB for in vitro evaluation, measurement of the performances of the AM biVAD herein, and reproducibility of data. PMID:21229806

  7. Artificial Muscle Devices: Innovations and Prospects for Fecal Incontinence Treatment.

    PubMed

    Fattorini, Elisa; Brusa, Tobia; Gingert, Christian; Hieber, Simone E; Leung, Vanessa; Osmani, Bekim; Dominietto, Marco D; Büchler, Philippe; Hetzer, Franc; Müller, Bert

    2016-05-01

    Fecal incontinence describes the involuntary loss of bowel content, which is responsible for stigmatization and social exclusion. It affects about 45% of retirement home residents and overall more than 12% of the adult population. Severe fecal incontinence can be treated by the implantation of an artificial sphincter. Currently available implants, however, are not part of everyday surgery due to long-term re-operation rates of 95% and definitive explantation rates of 40%. Such figures suggest that the implants fail to reproduce the capabilities of the natural sphincter. This article reviews the artificial sphincters on the market and under development, presents their physical principles of operation and critically analyzes their performance. We highlight the geometrical and mechanical parameters crucial for the design of an artificial fecal sphincter and propose more advanced mechanisms of action for a biomimetic device with sensory feedback. Dielectric electro-active polymer actuators are especially attractive because of their versatility, response time, reaction forces, and energy consumption. The availability of such technology will enable fast pressure adaption comparable to the natural feedback mechanism, so that tissue atrophy and erosion can be avoided while maintaining continence during daily activities. PMID:26926695

  8. Application of a PExSim for modeling a POLVAD artificial heart and the human circulatory system with left ventricle assistance

    NASA Astrophysics Data System (ADS)

    Siewnicka, Alicja; Fajdek, Bartlomiej; Janiszowski, Krzysztof

    2010-01-01

    This paper presents a model of the human circulatory system with the possible addition of a parallel assist device, which was developed for the purpose of artificial heart monitoring. Information about an identification experiment of an extracorporeal ventricle assist device POLVAD is included. The modelling methods applied and the corresponding functional blocks in a PExSim package are presented. The results of the simulation for physiological conditions, left ventricle failure and pathological conditions with parallel assistance are included.

  9. Total Artificial Heart Bridge to Transplantation for a Patient With Occult Intracardiac Malignancy: Case Report.

    PubMed

    Reich, H; Czer, L; Bannykh, S; De Robertis, M; Wolin, E; Amersi, F; Moriguchi, J; Kobashigawa, J; Arabia, F

    2015-09-01

    Malignancy is the leading cause of long-term morbidity and mortality after heart and other solid organ transplantation; therefore, great emphasis is placed on pre- and post-transplantation cancer screening. Even with meticulous screening during evaluation for heart transplant candidacy, an occult cancer may not be apparent. Here, we share the case of a 51-year-old man with refractory heart failure who underwent total artificial heart implantation as a bridge to transplantation with the surprise finding of an isolated deposit of metastatic carcinoid tumor nested within a left ventricular papillary muscle in his explanted heart. The primary ileal carcinoid tumor was identified and resected completely. After remaining cancer-free for 14 months, he was listed for heart transplantation and was transplanted 2 months later. He is currently 3.5 months out from heart transplantation and doing well, without evidence of recurring malignancy. PMID:26361702

  10. [Thermodynamic principles and physiologic criteria for the use of heat engines to drive the ventricles of an artificial heart].

    PubMed

    Kiselev, Iu M; Mordashev, V M; Osipov, A P; Shumakov, V I

    1990-01-01

    The authors review the thermodynamic bases and physiological limitations of the applicability of thermal engines for driving artificial heart ventricles. Show that the thermodynamic characteristics of Stirling and Brighton cycles do not make it possible to effectively use cycle-based engines in the artificial heart. A steam engine operating in accordance with the Rankine cycle may be regarded as an optimum type engine for that purpose. Demonstrate that according to the rules of physiology, use should be made of a separate driving of artificial heart ventricles by two independently operating steam engines. Provide the characteristics of the Soviet artificial heart "MIKRON" acceptable for implantation into the orthotopic position. PMID:2215181

  11. Design and Evolution of the Asporto Heart Preservation Device.

    PubMed

    Rivard, Andrew L

    2015-06-01

    The Asporto Heart Preservation Device is a system providing perfusion of cardioplegia to the donor heart using a computer-controlled peristaltic pump in a thermoelectrically cooled and insulated container. In 1998, a user interface was developed at the University of Minnesota consisting of a touch screen and battery-backed microcontroller. Power was supplied by a 120 VAC to 12 VDC converter. An upgrade to the insulated cooler and microcontroller occurred in 2002, which was followed by proof of concept experimental pre-clinical transplants and tests demonstrating the efficacy of the device with isolated donor hearts. During the period between 2002 and 2006, a variety of donor organ containers were developed, modified, and tested to provide an optimal sterile environment and fluid path. Parallel development paths encompass formalized design specifications for final prototypes of the touch screen/microcontroller, organ container, and thermoelectric cooler. PMID:26405361

  12. Design and Evolution of the Asporto Heart Preservation Device

    PubMed Central

    Rivard, Andrew L.

    2015-01-01

    Abstract: The Asporto Heart Preservation Device is a system providing perfusion of cardioplegia to the donor heart using a computer-controlled peristaltic pump in a thermoelectrically cooled and insulated container. In 1998, a user interface was developed at the University of Minnesota consisting of a touch screen and battery-backed microcontroller. Power was supplied by a 120 VAC to 12 VDC converter. An upgrade to the insulated cooler and microcontroller occurred in 2002, which was followed by proof of concept experimental pre-clinical transplants and tests demonstrating the efficacy of the device with isolated donor hearts. During the period between 2002 and 2006, a variety of donor organ containers were developed, modified, and tested to provide an optimal sterile environment and fluid path. Parallel development paths encompass formalized design specifications for final prototypes of the touch screen/microcontroller, organ container, and thermoelectric cooler. PMID:26405361

  13. Spare Dying Patients Electric Shocks from Heart Device, Docs Say

    MedlinePlus

    ... FAQs Contact Us Health Topics Drugs & Supplements Videos & Tools Español You Are Here: Home → Latest Health News → Article URL of this page: https://www.nlm.nih.gov/medlineplus/news/fullstory_157958.html Spare Dying Patients Electric Shocks From Heart Device, Docs Say Many unaware ...

  14. Mock circulation loop to investigate hemolysis in a pulsatile total artificial heart.

    PubMed

    Gräf, Felix; Finocchiaro, Thomas; Laumen, Marco; Mager, Ilona; Steinseifer, Ulrich

    2015-05-01

    Hemocompatibility of blood pumps is a crucial parameter that has to be ensured prior to in vivo testing. In contrast to rotary blood pumps, a standard for testing a pulsatile total artificial heart (TAH) has not yet been established. Therefore, a new mock circulation loop was designed to investigate hemolysis in the left ventricle of the ReinHeart TAH. Its main features are a high hemocompatibility, physiological conditions, a low priming volume, and the conduction of blood through a closed tubing system. The mock circulation loop consists of a noninvasive pressure chamber, an aortic compliance chamber, and an atrium directly connected to the ventricle. As a control pump, the clinically approved Medos-HIA ventricular assist device (VAD) was used. The pumps were operated at 120 beats per minute with an aortic pressure of 120 to 80 mm Hg and a mean atrial pressure of 10 mm Hg, generating an output flow of about 5 L/min. Heparinized porcine blood was used. A series of six identical tests were performed. A test method was established that is comparable to ASTM F 1841, which is standard practice for the assessment of hemolysis in continuous-flow blood pumps. The average normalized index of hemolysis (NIH) values of the VAD and the ReinHeart TAH were 0.018 g/100 L and 0.03 g/100 L, respectively. The standard deviation of the NIH was 0.0033 for the VAD and 0.0034 for the TAH. Furthermore, a single test with a BPX-80 Bio-Pump was performed to verify that the hemolysis induced by the mock circulation loop was negligible. The performed tests showed a good reproducibility and statistical significance. The mock circulation loop and test protocol developed in this study are valid methods to investigate the hemolysis induced by a pulsatile blood pump. PMID:25586541

  15. What to Expect After Total Artificial Heart Surgery

    MedlinePlus

    ... Emotional Issues Getting a TAH may cause fear, anxiety, and stress. If you're waiting for a heart transplant, ... from family and friends also can help relieve stress and anxiety. Let your loved ones know how you feel ...

  16. Towards Optimization of a Novel Trileaflet Polymeric Prosthetic Heart Valve Via Device Thrombogenicity Emulation (DTE)

    PubMed Central

    Claiborne, Thomas E.; Xenos, Michalis; Sheriff, Jawaad; Chiu, Wei-Che; Soares, Joao; Alemu, Yared; Gupta, Shikha; Judex, Stefan; Slepian, Marvin J.; Bluestein, Danny

    2013-01-01

    Aortic stenosis the is most prevalent and life threatening form of valvular heart disease. It is primarily treated via open-heart surgical valve replacement with either a tissue or mechanical prosthetic heart valve (PHV), each prone to degradation and thrombosis, respectively. Polymeric PHVs may be optimized to eliminate these complications, and they may be more suitable for the new transcatheter aortic valve replacement (TAVR) procedure and in devices like the Total Artificial Heart. However, the development of polymer PHVs has been hampered by persistent in vivo calcification, degradation, and thrombosis. To address these issues, we have developed a novel surgically implantable polymer PHV comprised of a new thermoset polyolefin called xSIBS, in which key parameters were optimized for superior functionality via our Device Thrombogenicity Emulation (DTE) methodology. In this parametric study, we compared our homogeneous optimized polymer PHV to a prior composite polymer PHV and to a benchmark tissue valve. Our results show significantly improved hemodynamics and reduced thrombogenicity in the optimized polymer PHV compared to the other valves. These results indicate that our new design may not require anticoagulants and may be more durable than its predecessor, and validates the improvement, towards optimization, of this novel polymeric PHV design. PMID:23644615

  17. A Study on the Mechanism for Cavitation in the Mechanical Heart Valves with an Electrohydraulic Total Artificial Heart

    NASA Astrophysics Data System (ADS)

    Lee, Hwansung; Tsukiya, Tomonori; Homma, Akihiko; Kamimura, Tadayuki; Tatsumi, Eisuke; Taenaka, Yoshiyuki; Kitamura, Soichiro

    It has been conceived that the mechanical heart valves mounted in an artificial heart close much faster than in vivo use, resulting in cavitation bubbles formation. In this study, the mechanisms for cavitation in mechanical heart valves (MHVs) is investigated with monoleaflet and bileaflet valves in the mitral position with an electrohydraulic total artificial heart (EHTAH). The valve-closing velocity and pressure-drop through the valve were done, and a high-speed video camera was employed to investigate the mechanism for MHVs cavitation. The valve-closing velocity and pressure-drop of the bileaflet valves were less than that of the monoleaflet valves. Most of the cavitation bubbles in the monoleaflet valves were observed next to the edge of the valve stop and the inner side of the leaflet. With the bileaflet valves, cavitation bubbles were concentrated along the leaflet tip. Also, the number density of cavitation bubbles in the bileaflet valves was less than that of the monoleaflet valves. The number density of cavitation bubbles increased with an increase in the valve-closing velocity and the valve stop area. It is established that squeeze flow holds the key to cavitation in the mechanical heart valve. In a viewpoint of squeeze flow, the bileaflet valve with slow valve-closing velocity and small valve stop area, is safer to prevent of blood cell damage than the monoleaflet valves.

  18. Novel device-based interventional strategies for advanced heart failure.

    PubMed

    Toth, Gabor G; Vanderheyden, Marc; Bartunek, Jozef

    2016-01-01

    While heart failure is one of the leading causes of mortality and morbidity, our tools to provide ultimate treatment solutions are still limited. Recent developments in new devices are designed to fill this therapeutic gap. The scope of this review is to focus on two particular targets, namely (1) left ventricular geometric restoration and (2) atrial depressurization. (1) Reduction of the wall stress by shrinking the ventricular cavity has been traditionally attempted surgically. Recently, the Parachute device (CardioKinetix Inc., Menlo Park, CA, USA) has been introduced to restore ventricular geometry and cardiac mechanics. The intervention aims to partition distal dysfunctional segments that are non-contributory to the ventricular mechanics and forward cardiac output. (2) Diastolic heart failure is characterized by abnormal relaxation and chamber stiffness. The main therapeutic goal achieved should be the reduction of afterload and diastolic pressure load. Recently, new catheter-based approaches were proposed to reduce left atrial pressure and ventricular decompression: the InterAtrial Shunt Device (IASD™) (Corvia Medical Inc., Tewksbury, MA, USA) and the V-Wave Shunt (V-Wave Ltd, Or Akiva, Israel). Both are designed to create a controlled atrial septal defect in symptomatic patients with heart failure. While the assist devices are aimed at end-stage heart failure, emerging device-based percutaneous or minimal invasive techniques comprise a wide spectrum of innovative concepts that target ventricular remodeling, cardiac contractility or neuro-humoral modulation. The clinical adoption is in the early stages of the initial feasibility and safety studies, and clinical evidence needs to be gathered in appropriately designed clinical trials. PMID:26966444

  19. Novel device-based interventional strategies for advanced heart failure

    PubMed Central

    Vanderheyden, Marc; Bartunek, Jozef

    2016-01-01

    While heart failure is one of the leading causes of mortality and morbidity, our tools to provide ultimate treatment solutions are still limited. Recent developments in new devices are designed to fill this therapeutic gap. The scope of this review is to focus on two particular targets, namely (1) left ventricular geometric restoration and (2) atrial depressurization. (1) Reduction of the wall stress by shrinking the ventricular cavity has been traditionally attempted surgically. Recently, the Parachute device (CardioKinetix Inc., Menlo Park, CA, USA) has been introduced to restore ventricular geometry and cardiac mechanics. The intervention aims to partition distal dysfunctional segments that are non-contributory to the ventricular mechanics and forward cardiac output. (2) Diastolic heart failure is characterized by abnormal relaxation and chamber stiffness. The main therapeutic goal achieved should be the reduction of afterload and diastolic pressure load. Recently, new catheter-based approaches were proposed to reduce left atrial pressure and ventricular decompression: the InterAtrial Shunt Device (IASD™) (Corvia Medical Inc., Tewksbury, MA, USA) and the V-Wave Shunt (V-Wave Ltd, Or Akiva, Israel). Both are designed to create a controlled atrial septal defect in symptomatic patients with heart failure. While the assist devices are aimed at end-stage heart failure, emerging device-based percutaneous or minimal invasive techniques comprise a wide spectrum of innovative concepts that target ventricular remodeling, cardiac contractility or neuro-humoral modulation. The clinical adoption is in the early stages of the initial feasibility and safety studies, and clinical evidence needs to be gathered in appropriately designed clinical trials. PMID:26966444

  20. Artificial vision approach to the understanding of heart motion.

    PubMed

    Coppini, G; Demi, M; Calamai, R; Valli, G

    1992-07-01

    To overcome the major drawbacks of conventional descriptive methods, we have developed a computer vision approach to aid understanding of heart motion from a series of sequential X-ray images. The computation is addressed of local descriptors of the heart pumping function from ventricular contours. Physical constraints are exploited such as spatial smoothness of the displacement field and shape correspondence between ventricular boundaries during the beat. A computational method is proposed for the estimation of the displacement field of the left ventricular boundary. Moreover, the spatial arrangement of the estimated motion field is rendered explicit so that it may be utilized in the medical clinic (or for high-level symbolic processing). This is achieved using a grouping criterion which allows the clustering of contiguous points of the left ventricular outline into curve segments which have homogeneous motion properties. PMID:1513138

  1. Device monitoring strategies in acute heart failure syndromes.

    PubMed

    Samara, Michael A; Tang, W H Wilson

    2011-09-01

    Acute heart failure syndromes (AHFS) represent the most common discharge diagnoses in adults over age 65 and translate into dramatically increased heart failure-associated morbidity and mortality. Conventional approaches to the early detection of pulmonary and systemic congestion have been shown to be of limited sensitivity. Despite their proven efficacy, disease management and structured telephone support programs have failed to achieve widespread use in part due to their resource intensiveness and reliance upon motivated patients. While once thought to hold great promise, results from recent prospective studies on telemonitoring strategies have proven disappointing. Implantable devices with their capacity to monitor electrophysiologic and hemodynamic parameters over long periods of time and with minimal reliance on patient participation may provide solutions to some of these problems. Conventional electrophysiologic parameters and intrathoracic impedance data are currently available in the growing population of heart failure patients with equipped devices. A variety of implantable hemodynamic monitors are currently under investigation. How best to integrate these devices into a systematic approach to the management of patients before, during, and after AHFS is yet to be established. PMID:21424278

  2. Progress on the Design and Development of the Continuous-Flow Total Artificial Heart

    PubMed Central

    Kobayashi, Mariko; Horvath, David J.; Mielke, Nicole; Shiose, Akira; Kuban, Barry; Goodin, Mark; Fukamachi, Kiyotaka; Golding, Leonard A. R.

    2013-01-01

    Cleveland Clinic’s continuous-flow total artificial heart has one motor and one rotating assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the rotating assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump’s speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ± 10 mm Hg for a wide range of SVR/PVR (systemic/pulmonary vascular resistance) ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development. PMID:22747979

  3. Development of Eddy Current Sensor systems in artificial heart for noncontact gap sensing.

    PubMed

    Ahn, C; Kim, K; Moon, K; Jeong, K; Kim, H; Lee, J; Hwang, C; Sun, K

    2005-01-01

    The axial flow pump has been developed in Korea Artificial Organ Center. It consists of an impeller, a motor and a magnetic bearing. The magnetic bearing fully levitates the impeller not to contact with other parts of pump. However, in order to control the gap between the impeller and other parts, continuous gap sensing is necessary. The conventional gap sensors are relatively large to implant in artificial heart. Thus, the compact eddy current sensor system proper for artificial heart was developed and the performances were evaluated. It showed good results and has small size. However, the dependency of the sensor upon temperature and target material was shown also. Moreover, the output of sensor had nonlinear responses. These must be calibrated in further study. PMID:17281087

  4. Hemodynamic effects of pressure-volume relation in the atrial contraction model on the total artificial heart using centrifugal blood pumps.

    PubMed

    Shiga, Takuya; Kuroda, Takehito; Tsuboko, Yusuke; Miura, Hidekazu; Shiraishi, Yasuyuki; Yambe, Tomoyuki

    2013-01-01

    Hemodynamic effects of atrial contraction with centrifugal pump type total artificial heart is unknown. In this study, we simulated an atrial contraction in a mock model. By the driving condition with higher pressure in the mock atrial model, the load during atrial contraction increased. Based on these findings, we examined atrial contraction in the animal using adult goats. Prior to the measurement, we installed a centrifugal-type ventricular assist device (VADs), and then clamped both ventricles. We measured the hemodynamic data without ventricular contractile functions in order to obtain the effect of atrial contraction on hemodynamics under the condition of the total artificial heart (TAH) circulatory support model. We could estimate the heart rate by revolution number and voltage of pumps. There might be a possibility that we could regulate autonomic nervous response with the control of cardiac output. PMID:24110062

  5. Upscaling cardiac assist devices in decompensated heart failure: Choice of device and its timing.

    PubMed

    Mishra, Sundeep

    2016-04-01

    Advanced heart failure is a heterogeneous condition unified by a very high mortality unless right treatment is instituted at the right time. The first step is understanding the mechanism leading to instability: hemodynamic or ischemic. Right kind of therapy; drugs (ionotropic) or IABP or other cardiac assist devices should be chosen according to mechanism of insult as well as degree of insult. Drugs such as ionotropes are effective only in very early course but if the decompensation has progressed beyond a certain point device such as IABP may be effective but again only early in the course when CPO? 0.6. Beyond a certain point, even IABP may not be effective: here only Impella (2.5, CP or 5) or Tandem Heart may be effective. However, beyond a certain point CPO<0.53, even these devices may not be effective. Thus crux of the matter is choice of a right device/drug and timing of its institution. PMID:27056646

  6. Physiological Characterization of the SynCardia Total Artificial Heart in a Mock Circulation System

    PubMed Central

    Crosby, Jessica R.; DeCook, Katrina J.; Tran, Phat L.; Smith, Richard G.; Larson, Douglas F.; Khalpey, Zain I.; Burkhoff, Daniel; Slepian, Marvin J.

    2014-01-01

    The SynCardia total artificial heart (TAH) has emerged as an effective, life-saving bi-ventricular replacement system for a wide variety of patients with end-stage heart failure. While the clinical performance of the TAH is established, modern physiologic characterization, in terms of elastance behavior and pressure-volume characterization has not been defined. Herein we examine the TAH in terms of elastance using a non-ejecting left-ventricle, and then characterize the pressure-volume relationship of the TAH by varying preload and afterload parameters using a Donovan Mock Circulatory System. We demonstrate that the TAH does not operate with time-varying elastance, differing from the human heart. Further, we show that the TAH has a pressure-volume relationship behavior that also differs from that of the human heart. The TAH does exhibit Starling-like behavior, with output increasing via preload dependent mechanisms, without reliance on an alteration of inotropic state within the operating window of the TAH. Within our testing range, the TAH is insensitive to variations in afterload, however this insensitivity has a limit, the limit being the maximum driving pressure of the pneumatic driver. Understanding the physiology of the TAH affords insight into the functional parameters that govern artificial heart behavior providing perspective on differences compared to the human heart. PMID:25551416

  7. Physiological characterization of the SynCardia total artificial heart in a mock circulation system.

    PubMed

    Crosby, Jessica R; DeCook, Katrina J; Tran, Phat L; Smith, Richard G; Larson, Douglas F; Khalpey, Zain I; Burkhoff, Daniel; Slepian, Marvin J

    2015-01-01

    The SynCardia total artificial heart (TAH) has emerged as an effective, life-saving biventricular replacement system for a wide variety of patients with end-stage heart failure. Although the clinical performance of the TAH is established, modern physiological characterization, in terms of elastance behavior and pressure-volume (PV) characterization has not been defined. Herein, we examine the TAH in terms of elastance using a nonejecting left ventricle, and then characterize the PV relation of the TAH by varying preload and afterload parameters using a Donovan Mock Circulatory System. We demonstrate that the TAH does not operate with time-varying elastance, differing from the human heart. Furthermore, we show that the TAH has a PV relation behavior that also differs from that of the human heart. The TAH does exhibit Starling-like behavior, with output increasing via preload-dependent mechanisms, without reliance on an alteration of inotropic state within the operating window of the TAH. Within our testing range, the TAH is insensitive to variations in afterload; however, this insensitivity has a limit, the limit being the maximum driving pressure of the pneumatic driver. Understanding the physiology of the TAH affords insight into the functional parameters that govern artificial heart behavior providing perspective on differences compared with the human heart. PMID:25551416

  8. Role of Monitoring Devices in Preventing Heart Failure Admissions.

    PubMed

    McDonald, Kenneth; Wilkinson, Mark; Ledwidge, Mark

    2015-08-01

    This review aims to discuss and summarize the evidence base for devices that have a role in monitoring patients with heart failure for the purpose of attempting to prevent heart failure-related admissions. Despite contemporary heart failure service provision, many patients continue to need acute admission for decompensation. There is a clinical need for a better strategy for predicting decompensation earlier so that appropriate therapeutic interventions can be commenced sooner in order to prevent the need for acute hospital admission. Between clinical assessment visits, the contemporary approach to management is based primarily on daily home monitoring of weight by patients; while this has proved useful, it falls short. For example, substantial weight gain was seen in only 20% of ADHF admission patients according to data collected in the TEN-HMS home telemonitoring study. Monitoring devices offer the possibility of tracking additional physiological or haemodynamic parameters that may allow for earlier detection and more accurate identification of patients at risk of acute decompensation. PMID:26049264

  9. Development of Haptic Display Actuated with Magnetorheological Fluid and Artificial Muscle (HAMA Device)

    NASA Astrophysics Data System (ADS)

    Kikuchi, Satoru; Hamamoto, Kazuhiko

    To operate in Immersive Virtual Environment (IVE) with standard devices, beginners will feel difficulties to do it because they are not intuitive devices. Haptic sense is very important for intuitive operation. But existing haptic device is not suited to use in IVE for reasons of displayed sense and the size of the device itself. A device that is a portable one can only display Force-Feedback sense, and a device that can display tactile sense is impossible to be mounted on a hand. In this paper we proposed Haptic display Actuated with Magnetorheological fluid and Artificial muscle (HAMA device). It is a potable haptic device that can display Force-Feedback and tactile sense. The device is constructed of two small devices, a device for displaying Force-Feedback sense and a device for displaying tactile sence. They use Artificial Muscle and Magnetorheological fluid for an actuator. This time we developed index finger part for a trial and evaluate it.

  10. Design and construction of the artificial patient module for testing bioimpedance measuring devices

    NASA Astrophysics Data System (ADS)

    Młyńczak, Marcel; Pariaszewska, Katarzyna; Niewiadomski, Wiktor; Cybulski, Gerard

    2013-10-01

    The purpose of this study was to describe the design of the electronic module for testing bioimpedance measuring devices, for example impedance cardiographs or impedance pneumographs. Artificial Patient was conceived as an electronic equivalent of the impedance of skin-electrode interface and the impedance between electrodes - measured one. Different approaches in imitating a resistance of skin and an impedance of electrode-skin connection were presented. The module was adapted for frequently applied tetrapolar electrode configuration. Therefore the design do not enclose the elements simulating impedance between skin and receiver electrodes due to negligible effect of this impedance on the current flow through the receiver. The Artificial Patient enables testing either application generators, or receiver parts, particularly the level of noise and distortions of the signal. Use of digitally controlled potentiometer allows simulating different tissue resistances changes such as constant values, very-low-frequency and low-frequency changes corresponding to those caused by breathing or heart activity. Also it allows distorting signals in order to test algorithms of artifacts attenuation.

  11. Simulation of blood flow through an artificial heart

    NASA Technical Reports Server (NTRS)

    Kiris, Cetin; Chang, I-Dee; Rogers, Stuart E.; Kwak, Dochan

    1991-01-01

    A numerical simulation of the incompressible viscous flow through a prosthetic tilting disk heart valve is presented in order to demonstrate the current capability to model unsteady flows with moving boundaries. Both steady state and unsteady flow calculations are done by solving the incompressible Navier-Stokes equations in 3-D generalized curvilinear coordinates. In order to handle the moving boundary problems, the chimera grid embedding scheme which decomposes a complex computational domain into several simple subdomains is used. An algebraic turbulence model for internal flows is incorporated to reach the physiological values of Reynolds number. Good agreement is obtained between the numerical results and experimental measurements. It is found that the tilting disk valve causes large regions of separated flow, and regions of high shear.

  12. Expert system for heart function based on artificial neural networks and fuzzy theory

    NASA Astrophysics Data System (ADS)

    Yu, Wei; Li, Xiaoying; Yu, Daoyin; Mao, Yi; Hua, Qi

    1998-09-01

    In this paper, a computer-aided diagnosis system for heart function based on artificial neural networks and fuzzy logic is introduced. Typical parameters reflecting heart function, provided by echocardiography, were used as input of neural networks and their corresponding heart functions as output. To obtain an analytic and discrimination model closer to brain, we combined fuzzy theory with neural network technology, and input parameters are fuzzily treated. During distinguishing morbid style, we used fuzzy interval, fuzzy number and its related possibility distribution concepts, and selected appropriate operator, and so get its corresponding membership, meanwhile membership was put out of interval of linguistic to consist with language expression. The network selected was BP, and back- propagation algorithm was used to train the network. After studying the result evaluated by expert, the neural network was used to appreciate 150 testees' heart function, of which 90.7% was consistent with experts' diagnosis.

  13. Simulation of a pulsatile total artificial heart: Development of a partitioned Fluid Structure Interaction model

    NASA Astrophysics Data System (ADS)

    Sonntag, Simon J.; Kaufmann, Tim A. S.; Büsen, Martin R.; Laumen, Marco; Linde, Torsten; Schmitz-Rode, Thomas; Steinseifer, Ulrich

    2013-04-01

    Heart disease is one of the leading causes of death in the world. Due to a shortage in donor organs artificial hearts can be a bridge to transplantation or even serve as a destination therapy for patients with terminal heart insufficiency. A pusher plate driven pulsatile membrane pump, the Total Artificial Heart (TAH) ReinHeart, is currently under development at the Institute of Applied Medical Engineering of RWTH Aachen University.This paper presents the methodology of a fully coupled three-dimensional time-dependent Fluid Structure Interaction (FSI) simulation of the TAH using a commercial partitioned block-Gauss-Seidel coupling package. Partitioned coupling of the incompressible fluid with the slender flexible membrane as well as a high fluid/structure density ratio of about unity led inherently to a deterioration of the stability (‘artificial added mass instability’). The objective was to conduct a stable simulation with high accuracy of the pumping process. In order to achieve stability, a combined resistance and pressure outlet boundary condition as well as the interface artificial compressibility method was applied. An analysis of the contact algorithm and turbulence condition is presented. Independence tests are performed for the structural and the fluid mesh, the time step size and the number of pulse cycles. Because of the large deformation of the fluid domain, a variable mesh stiffness depending on certain mesh properties was specified for the fluid elements. Adaptive remeshing was avoided. Different approaches for the mesh stiffness function are compared with respect to convergence, preservation of mesh topology and mesh quality. The resulting mesh aspect ratios, mesh expansion factors and mesh orthogonalities are evaluated in detail. The membrane motion and flow distribution of the coupled simulations are compared with a top-view recording and stereo Particle Image Velocimetry (PIV) measurements, respectively, of the actual pump.

  14. Devices in the management of advanced, chronic heart failure

    PubMed Central

    Abraham, William T.; Smith, Sakima A.

    2013-01-01

    Heart failure (HF) is a global phenomenon, and the overall incidence and prevalence of the condition are steadily increasing. Medical therapies have proven efficacious, but only a small number of pharmacological options are in development. When patients cease to respond adequately to optimal medical therapy, cardiac resynchronization therapy has been shown to improve symptoms, reduce hospitalizations, promote reverse remodelling, and decrease mortality. However, challenges remain in identifying the ideal recipients for this therapy. The field of mechanical circulatory support has seen immense growth since the early 2000s, and left ventricular assist devices (LVADs) have transitioned over the past decade from large, pulsatile devices to smaller, more-compact, continuous-flow devices. Infections and haematological issues are still important areas that need to be addressed. Whereas LVADs were once approved only for ‘bridge to transplantation’, these devices are now used as destination therapy for critically ill patients with HF, allowing these individuals to return to the community. A host of novel strategies, including cardiac contractility modulation, implantable haemodynamic-monitoring devices, and phrenic and vagus nerve stimulation, are under investigation and might have an impact on the future care of patients with chronic HF. PMID:23229137

  15. INTRACORPOREAL HEAT DISSIPATION FROM A RADIOISOTOPE-POWERED ARTIFICIAL HEART

    PubMed Central

    Huffman, Fred N.; Hagen, Kenneth G.; Whalen, Robert L.; Fuqua, John M.; Norman, John C.

    1974-01-01

    The feasibility of radioisotope-fueled circulatory support systems depends on the ability of the body to dissipate the reject heat from the power source driving the blood pump as well as to tolerate chronic intracorporeal radiation. Our studies have focused on the use of the circulating blood as a heat sink. Initial in vivo heat transfer studies utilized straight tube heat exchangers (electrically and radioisotope energized) to replace a segment of the descending aorta. More recent studies have used a left ventricular assist pump as a blood-cooled heat exchanger. This approach minimizes trauma, does not increase the area of prosthetic interface with the blood, and minimizes system volume. Heat rejected from the thermal engine (vapor or gas cycle) is transported from the nuclear power source in the abdomen to the pump in the thoracic cavity via hydraulic lines. Adjacent tissue is protected from the fuel capsule temperature (900 to 1200°F) by vacuum foil insulation and polyurethane foam. The in vivo thermal management problems have been studied using a simulated thermal system (STS) which approximates the heat rejection and thermal transport mechanisms of the nuclear circulatory support systems under development by NHLI. Electric heaters simulate the reject heat from the thermal engines. These studies have been essential in establishing the location, suspension, surgical procedures, and postoperative care for implanting prototype nuclear heart assist systems in calves. The pump has a thermal impedance of 0.12°C/watt. Analysis of the STS data in terms of an electrical analog model implies a heat transfer coefficient of 4.7 × 10−3 watt/cm2°C in the abdomen compared to a value of 14.9 × 10−3 watt/cm2°C from the heat exchanger plenum into the diaphragm. Images PMID:15215968

  16. INTRACORPOREAL HEAT DISSIPATION FROM A RADIOISOTOPE-POWERED ARTIFICIAL HEART.

    PubMed

    Huffman, Fred N.; Hagen, Kenneth G.; Whalen, Robert L.; Fuqua, John M.; Norman, John C.

    1974-01-01

    The feasibility of radioisotope-fueled circulatory support systems depends on the ability of the body to dissipate the reject heat from the power source driving the blood pump as well as to tolerate chronic intracorporeal radiation. Our studies have focused on the use of the circulating blood as a heat sink. Initial in vivo heat transfer studies utilized straight tube heat exchangers (electrically and radioisotope energized) to replace a segment of the descending aorta. More recent studies have used a left ventricular assist pump as a blood-cooled heat exchanger. This approach minimizes trauma, does not increase the area of prosthetic interface with the blood, and minimizes system volume. Heat rejected from the thermal engine (vapor or gas cycle) is transported from the nuclear power source in the abdomen to the pump in the thoracic cavity via hydraulic lines. Adjacent tissue is protected from the fuel capsule temperature (900 to 1200 degrees F) by vacuum foil insulation and polyurethane foam. The in vivo thermal management problems have been studied using a simulated thermal system (STS) which approximates the heat rejection and thermal transport mechanisms of the nuclear circulatory support systems under development by NHLI. Electric heaters simulate the reject heat from the thermal engines. These studies have been essential in establishing the location, suspension, surgical procedures, and postoperative care for implanting prototype nuclear heart assist systems in calves. The pump has a thermal impedance of 0.12 degrees C/watt. Analysis of the STS data in terms of an electrical analog model implies a heat transfer coefficient of 4.7 x 10(-3) watt/cm(2) degrees C in the abdomen compared to a value of 14.9 x 10(-3) watt/cm(2) degrees C from the heat exchanger plenum into the diaphragm. PMID:15215968

  17. Development of a miniature undulation pump for the distributed artificial heart.

    PubMed

    Abe, Y; Ono, T; Isoyama, T; Mochizuki, S; Iwasaki, K; Chinzei, T; Saito, I; Kouno, A; Imachi, K

    2000-08-01

    Research of the distributed artificial heart is important not only to acquire the means of individual organ perfusion but also to clarify the characteristics of the organ and the mechanism of blood distribution. To investigate the distributed artificial heart, the miniature undulation pump was developed. The outer diameter and the thickness of the developed pump were 38 mm and 11 mm, respectively. The priming volume of the pump was 3.2 ml. The total size including the motor unit was 38 mm in diameter and 32 mm in length. The total weight was 67.5 g. The total volume was 27.5 ml. The pump was driven with pulse width modulation by using a 1 chip motor controller. More than 5 L/min of continuous output could be obtained. The results showed that the developed miniature undulation pump system had enough performance for individual organ perfusion. PMID:10971257

  18. Right heart failure post left ventricular assist device implantation

    PubMed Central

    Argiriou, Mihalis; Kolokotron, Styliani-Maria; Sakellaridis, Timothy; Argiriou, Orestis; Charitos, Christos; Katsikogiannis, Nikolaos; Kougioumtzi, Ioanna; Machairiotis, Nikolaos; Tsiouda, Theodora; Tsakiridis, Kosmas; Zarogoulidis, Konstantinos

    2014-01-01

    Right heart failure (RHF) is a frequent complication following left ventricular assist device (LVAD) implantation. The incidence of RHF complicates 20-50% (range, 9-44%) of cases and is a major factor of postoperative morbidity and mortality. Unfortunately, despite the fact that many risk factors contributing to the development of RHF after LVAD implantation have been identified, it seems to be extremely difficult to avoid them. Prevention of RHF consists of the management of the preload and the afterload of the right ventricle with optimum inotropic support. The administration of vasodilators designed to reduce pulmonary vascular resistance is standard practice in most centers. The surgical attempt of implantation of a right ventricular assist device does not always resolve the problem and is not available in all cardiac surgery centers. PMID:24672699

  19. Non-Cardiac Symptoms of Moderate to Severe Hypokalemia in a Patient with a Syncardia™ Total Artificial Heart.

    PubMed

    Prasad, Amit; Ghodsizad, Ali; Pae, Walter; Singbartl, Kai; Boone, Jacqueline; Zeriouh, M; Ruhparwar, Arjang; Loebe, M; Khorrami, G Sadat Hoesseini; Koerner, Michael M; Brehm, Christoph

    2016-01-01

    The Syncardia™ total artificial heart (TAH) is an option for patients as a bridge to transplant in those who are not candidates for left ventricular assist devices (LVAD) due to right ventricular failure. Postoperative course is highly dependent on volume status and aggressive diuresis is often necessary. One complication from aggressive diuresis is hypokalemia; however, in these patients we tolerate a lower potassium level because cardiac arrhythmias are not a concern.  However, in two separate instances non-cardiac symptoms related to severe hypokalemia occurred. These symptoms included nystagmus in one patient and agitation, tremors, and having an "out-of-body" experience in the other patient. Both these patients had resolution of symptoms with potassium replacement. PMID:26913677

  20. Early thrombus formation in patient with HeartWare left ventricular assist device presenting with acute heart failure

    PubMed Central

    Ucar, Mustafa; Karakas, Mustafa Serkan; Bayrak, Murat; Altekin, Refik Emre; Koksel, Umut; Bayezid, Omer

    2015-01-01

    Heart failure is one of the leading causes of mortality and morbidity in the world. Heart transplantation is still the gold standard therapy despite emerging treatment options. Due to the limited number of available donors, the use of ventricular assist devices has increased. However, increasing incidences of complications are observed with using these devices. In this article, surgical treatment of a huge mobile thrombus formation in an inflow cannula due to ineffective anticoagulation in a 59 year-old man who received a HeartWare ventricular assist device because of ischemic cardiomyopathy is presented. PMID:26778905

  1. Early thrombus formation in patient with HeartWare left ventricular assist device presenting with acute heart failure.

    PubMed

    Ucar, Mustafa; Karakas, Mustafa Serkan; Bayrak, Murat; Altekin, Refik Emre; Koksel, Umut; Bayezid, Omer

    2016-01-01

    Heart failure is one of the leading causes of mortality and morbidity in the world. Heart transplantation is still the gold standard therapy despite emerging treatment options. Due to the limited number of available donors, the use of ventricular assist devices has increased. However, increasing incidences of complications are observed with using these devices. In this article, surgical treatment of a huge mobile thrombus formation in an inflow cannula due to ineffective anticoagulation in a 59 year-old man who received a HeartWare ventricular assist device because of ischemic cardiomyopathy is presented. PMID:26778905

  2. Bariatric surgery for a patient with a HeartMate II ventricular assist device for destination therapy.

    PubMed

    Lockard, Kathleen L; Allen, Carrie; Lohmann, Douglas; Severyn, Donald A; Schaub, Richard D; Kauffman, Kelly E; Hodges, Jeffrey R; Woodhall, Lorna; Ramanathan, Ramesh; Teuteberg, Jeffrey J; Eckert, Chad E; Kormos, Robert L

    2013-03-01

    A patient with a HeartMate II left ventricular assist device who had a body mass index of 52 needed gastric bypass surgery in order to qualify for a heart transplant. Unlike previous experience in which the surgery was performed at the implant hospital, the gastric bypass surgery in this case was performed at a bariatric center of excellence that was a separate facility from the implant hospital. The artificial heart program of the University of Pittsburgh Medical Center worked with the bariatric center of excellence in scheduling the gastric bypass surgery using a multidisciplinary team approach at 2 hospitals to coordinate safe, high-quality patient care in a unique situation. PMID:23448817

  3. Ventricular assist devices for treatment of acute heart failure and chronic heart failure.

    PubMed

    Kirkpatrick, James N; Wieselthaler, Georg; Strueber, Martin; St John Sutton, Martin G; Rame, J Eduardo

    2015-07-01

    Despite therapeutic advances that improve longevity and quality of life, heart failure (HF) remains a relentless disease. At the end stage of HF, patients may become eligible for mechanical circulatory support (MCS) for the indications of stabilising acute cardiogenic shock or for chronic HF management. MCS use is growing rapidly in the USA and some countries of the European Union, especially in transplant-ineligible patients. In others, it remains largely a tool to stabilise patients until heart transplant. MCS comprises a heterogeneous group of temporary and durable devices which augment or replace the pumping function of one or both ventricles, with postimplant 2 year survival rivalling that of transplant in selected, lower-risk patients. In transplant-eligible and non-transplant-eligible patients, improvement in end-organ perfusion, functional capacity and quality of life have been noted. Even for optimal candidates, however, there are a host of potential complications that require constant vigilance of a coordinated care team. Recently, there has been official recognition of the importance of palliative care expertise in advance care planning preimplant and management of patients with ventricular assist devices at the end of their lives. PMID:25948420

  4. Transcutaneous Optical Information Transmission System for a Totally Implantable Artificial Heart

    NASA Astrophysics Data System (ADS)

    Yamamoto, Takahiko; Koshiji, Kohji

    A transcutaneous optical information transmission system (TOITS) offers the most promising method for noninvasively transmitting the information to control a total artificial heart (TAH). We had used light-emitting diode (LED) and photo diode (PD) with different wavelengths for full-duplex bidirectional communication in the TOITS. In this study, reduction of optical crosstalk in full-duplex bidirectional communication was investigated by using a combination of two orthogonal polarizers with the same wavelength. As a result, we confirmed that optical crosstalk could be prevented for communication through a cow's skin (3.5 mm thick) and that the signal waveform could be transmitted satisfactorily.

  5. Use of a totally artificial heart for a complex postinfarction ventricular septal defect.

    PubMed

    Knezevic, Ivan; Jelenc, Matija; Danojevic, Nenad; Racic, Manca; Poglajen, Gregor; Ksela, Jus; Androcec, Vesna; Mesar, Tomaz; Mikuz, Ursa; Vrtovec, Bojan

    2013-06-01

    The incidence of cardiac rupture complicating myocardial infarction has declined since the introduction of thrombolytic therapy. Despite the advances in the management of myocardial infarction, cardiac rupture remains an important cause of death among infarction-related fatalities. We discuss a patient who presented to our hospital with myocardial infarction and who subsequently developed a complex ventricular septal rupture, for which surgical repair was not feasible. Implantation of a CardioWest Total Artificial Heart (SynCardia Systems) allowed for immediate hemodynamic stabilization and served as a bridge to transplantation. PMID:23803241

  6. Cutting the fat: artificial muscle oscillators for lighter, cheaper, and slimmer devices

    NASA Astrophysics Data System (ADS)

    O'Brien, Benjamin M.; Rosset, Samuel; Shea, Herbert R.; Anderson, Iain A.

    2012-04-01

    Artificial muscles based on dielectric elastomers show enormous promise for a wide range of applications and are slowly moving from the lab to industry. One problem for industrial uptake is the expensive, rigid, heavy and bulky high voltage driver, sensor and control circuitry that artificial muscle devices currently require. One recent development, the Dielectric Elastomer Switch(es) (DES), shows promise for substantially reducing auxiliary circuitry and helping to mature the technology. DES are piezoresistive elements that can be used to form logic, driver, and sensor circuitry. One particularly useful feature of DES is their ability to embed oscillatory behaviour directly into an artificial muscle device. In this paper we will focus on how DES oscillators can break down the barriers to industrial adoption for artificial muscle devices. We have developed an improved artificial muscle ring oscillator and applied it to form a mechanosensitive conveyor. The free running oscillator ran at 4.4 Hz for 1056 cycles before failing due to electrode degradation. With better materials artificial muscle oscillators could open the door to robots with increased power to weight ratios, simple-to-control peristaltic pumps, and commercially viable artificial muscle motors.

  7. Measurement and reconstruction of the leaflet geometry for a pericardial artificial heart valve.

    PubMed

    Jiang, Hongjun; Campbell, Gord; Xi, Fengfeng

    2005-03-01

    This paper describes the measurement and reconstruction of the leaflet geometry for a pericardial heart valve. Tasks involved include mapping the leaflet geometries by laser digitizing and reconstructing the 3D freeform leaflet surface based on a laser scanned profile. The challenge is to design a prosthetic valve that maximizes the benefits offered to the recipient as compared to the normally operating naturally-occurring valve. This research was prompted by the fact that artificial heart valve bioprostheses do not provide long life durability comparable to the natural heart valve, together with the anticipated benefits associated with defining the valve geometries, especially the leaflet geometries for the bioprosthetic and human valves, in order to create a replicate valve fabricated from synthetic materials. Our method applies the concept of reverse engineering in order to reconstruct the freeform surface geometry. A Brown & Shape coordinate measuring machine (CMM) equipped with a HyMARC laser-digitizing system was used to measure the leaflet profiles of a Baxter Carpentier-Edwards pericardial heart valve. The computer software, Polyworks was used to pre-process the raw data obtained from the scanning, which included merging images, eliminating duplicate points, and adding interpolated points. Three methods, creating a mesh model from cloud points, creating a freeform surface from cloud points, and generating a freeform surface by B-splines are presented in this paper to reconstruct the freeform leaflet surface. The mesh model created using Polyworks can be used for rapid prototyping and visualization. To fit a freeform surface to cloud points is straightforward but the rendering of a smooth surface is usually unpredictable. A surface fitted by a group of B-splines fitted to cloud points was found to be much smoother. This method offers the possibility of manually adjusting the surface curvature, locally. However, the process is complex and requires additional

  8. 3D Printing to Guide Ventricular Assist Device Placement in Adults With Congenital Heart Disease and Heart Failure.

    PubMed

    Farooqi, Kanwal M; Saeed, Omar; Zaidi, Ali; Sanz, Javier; Nielsen, James C; Hsu, Daphne T; Jorde, Ulrich P

    2016-04-01

    As the population of adults with congenital heart disease continues to grow, so does the number of these patients with heart failure. Ventricular assist devices are underutilized in adults with congenital heart disease due to their complex anatomic arrangements and physiology. Advanced imaging techniques that may increase the utilization of mechanical circulatory support in this population must be explored. Three-dimensional printing offers individualized structural models that would enable pre-surgical planning of cannula and device placement in adults with congenital cardiac disease and heart failure who are candidates for such therapies. We present a review of relevant cardiac anomalies, cases in which such models could be utilized, and some background on the cost and procedure associated with this process. PMID:27033018

  9. Thromboresistance comparison of the HeartMate II ventricular assist device with the device thrombogenicity emulation- optimized HeartAssist 5 VAD.

    PubMed

    Chiu, Wei-Che; Girdhar, Gaurav; Xenos, Michalis; Alemu, Yared; Soares, Jõao S; Einav, Shmuel; Slepian, Marvin; Bluestein, Danny

    2014-02-01

    Approximately 7.5 × 106 patients in the US currently suffer from end-stage heart failure. The FDA has recently approved the designations of the Thoratec HeartMate II ventricular assist device (VAD) for both bridge-to-transplant and destination therapy (DT) due to its mechanical durability and improved hemodynamics. However, incidence of pump thrombosis and thromboembolic events remains high, and the life-long complex pharmacological regimens are mandatory in its VAD recipients. We have previously successfully applied our device thrombogenicity emulation (DTE) methodology for optimizing device thromboresistance to the Micromed Debakey VAD, and demonstrated that optimizing device features implicated in exposing blood to elevated shear stresses and exposure times significantly reduces shear-induced platelet activation and significantly improves the device thromboresistance. In the present study, we compared the thrombogenicity of the FDA-approved HeartMate II VAD with the DTE-optimized Debakey VAD (now labeled HeartAssist 5). With quantitative probability density functions of the stress accumulation along large number of platelet trajectories within each device which were extracted from numerical flow simulations in each device, and through measurements of platelet activation rates in recirculation flow loops, we specifically show that: (a) Platelets flowing through the HeartAssist 5 are exposed to significantly lower stress accumulation that lead to platelet activation than the HeartMate II, especially at the impeller-shroud gap regions (b) Thrombus formation patterns observed in the HeartMate II are absent in the HeartAssist 5 (c) Platelet activation rates (PAR) measured in vitro with the VADs mounted in recirculation flow-loops show a 2.5-fold significantly higher PAR value for the HeartMate II. This head to head thrombogenic performance comparative study of the two VADs, one optimized with the DTE methodology and one FDA-approved, demonstrates the efficacy of

  10. Research on micro-structure and hemo-compatibility of the artificial heart valve surface

    NASA Astrophysics Data System (ADS)

    Ye, Xia; Shao, Yun-liang; Zhou, Ming; Li, Jian; Cai, Lan

    2009-04-01

    In order to seek the method to improve the hemo-compatibility of artificial mechanical heart valve, the surface of rabbit's heart valve was observed using the scanning electron microscopy (SEM). The results showed that the dual-scale structure which consists of cobblestones-like structure of 8 μm in underside diameter and 3 μm in height, and the fine cilia of about 150 nm in diameter, was helpful to the hemo-compatibility of the heart valve. Therefore, the polydimethylsiloxane (PDMS) surface with hierarchical micro-structure was fabricated using femtosecond laser fabrication technique and soft lithography. At the same time, the tests of apparent contact angle and platelet adhesion on both smooth and textured PDMS surfaces were carried out to study their wettability and hemo-compatibility. The results demonstrated that the surface with textured structure displayed more excellent wettabililty and anti-coagulation property than that of smooth surface. The apparent contact angle of textured surface enhanced from 113.1° to 163.6° and the amount of adsorbed platelet on such surface was fewer, no distortion and no activation were found.

  11. Three-dimentional simulation of flow-induced platelet activation in artificial heart valves

    NASA Astrophysics Data System (ADS)

    Hedayat, Mohammadali; Asgharzadeh, Hafez; Borazjani, Iman

    2015-11-01

    Since the advent of heart valve, several valve types such as mechanical and bio-prosthetic valves have been designed. Mechanical Heart Valves (MHV) are durable but suffer from thromboembolic complications that caused by shear-induced platelet activation near the valve region. Bio-prosthetic Heart Valves (BHV) are known for better hemodynamics. However, they usually have a short average life time. Realistic simulations of heart valves in combination with platelet activation models can lead to a better understanding of the potential risk of thrombus formation in such devices. In this study, an Eulerian approach is developed to calculate the platelet activation in three-dimensional simulations of flow through MHV and BHV using a parallel overset-curvilinear immersed boundary technique. A curvilinear body-fitted grid is used for the flow simulation through the anatomic aorta, while the sharp-interface immersed boundary method is used for simulation of the Left Ventricle (LV) with prescribed motion. In addition, dynamics of valves were calculated numerically using under-relaxed strong-coupling algorithm. Finally, the platelet activation results for BMV and MHV are compared with each other.

  12. Progress of artificial pancreas devices toward clinical use: the first outpatient studies

    PubMed Central

    Russell, Steven J.

    2015-01-01

    Purpose of review This article describes recent progress in the automated control of glycemia in type 1 diabetes with artificial pancreas devices that combine continuous glucose monitoring with automated decision-making and insulin delivery. Recent findings After a gestation period of closely supervised feasibility studies in research centers, the last 2 years have seen publication of studies testing these devices in outpatient environments, and many more such studies are ongoing. The most basic form of automation, suspension of insulin delivery for actual or predicted hypoglycemia, has been shown to be effective and well tolerated, and a first-generation device has actually reached the market. Artificial pancreas devices that actively dose insulin fall into two categories, those that dose insulin alone and those that also use glucagon to prevent and treat hypoglycemia (bihormonal artificial pancreas). Initial outpatient clinical trials have shown that both strategies can improve glycemic management in comparison with patient-controlled insulin pump therapy, but only the bihormonal strategy has been tested without restrictions on exercise. Summary Artificial pancreas technology has the potential to reduce acute and chronic complications of diabetes and mitigate the burden of diabetes self-management. Successful outpatient studies bring these technologies one step closer to availability for patients. PMID:25692927

  13. Feasibility of a nickel-metal hydride battery for totally implantable artificial hearts.

    PubMed

    Okamoto, E; Yoshida, T; Fujiyoshi, M; Shimanaka, M; Takeuchi, A; Mitamura, Y; Mikami, T

    1996-01-01

    An implantable rechargeable battery is one of the key technologies for totally implantable artificial hearts. The nickel-metal hydride (Ni-MH) battery is promising for its high energy density of 1.5-2.0 times that of a nickel-cadmium battery. In this study, the effects of pulsatile discharge loads on the operating time and cycle life of Ni-MH batteries at 39 degrees C were studied. Two battery cells (TH-3M, 1,200 mAh, phi 14.5 x 49 mm; Toshiba, Tokyo, Japan) in series were charge/discharge cycled at 39 degrees C using a charge current of 1CA (1,200 mA) and then were fully discharged to 1.0 V/cell under either pulsatile discharge loads, which mimicked a systole (1 A for 0.3 sec) and a diastole (0.4 A for 0.3 sec), or a non pulsatile discharge load equivalent to the average of the pulsatile loads (0.7 A). Each cycle life test was interrupted on the 482nd cycle under pulsatile load, and on the 423rd cycle under non pulsatile load, because of malfunction of each battery charger. The tests showed that the pulsatile discharge cells had significantly (p < 0.001) less operating time (74.0 +/- 7.15 min) throughout the test period (up to 482 days) compared to the cells under equivalent non pulsatile discharge loads (93.7 +/- 7.74 min). The pulsatile-discharged Ni-MH cells provide significantly less operating time than the constantly discharged cells; the Ni-MH battery has an operating time of over 78 min and a cycle life of almost 500 cycles at 39 degrees C. In conclusion, the Ni-MH battery is feasible as an implantable back-up battery for a totally implantable artificial heart system. PMID:8944901

  14. A new transcutaneous bidirectional communication for monitoring implanted artificial heart using the human body as a conductive medium.

    PubMed

    Okamoto, Eiji; Kato, Yoshikuni; Seino, Kazuyuki; Miura, Hidekazu; Shiraishi, Yasuyuki; Yambe, Tomoyuki; Mitamura, Yoshinori

    2012-10-01

    A transcutaneous communication system (TCS) is a key technology for monitoring and controlling artificial hearts and other artificial organs in the body. In this study, we developed a new TCS that uses the human body as a conductive medium. Direct data exchange provides a higher level of communication security compared to that of wireless methods without physical constraints such as an external wire. The external and internal units of the new TCS each consist mainly of a data transmitter and a data receiver. The data transmitter has an amplitude shift keying (ASK) modulator (carrier frequencies: 4 and 10 MHz) and an electrode. The ASK-modulated data current is led into the body through the electrode, and it flows back to the energy source through the body, the data receiver, and the earth ground that includes all conductors and dielectrics in the environment that are in close proximity to the patient. Performance of the TCS was evaluated by a communication test on the surface of the human body and in an animal experiment using a goat. The TCS was able to transmit data concurrently for 4 weeks between everywhere on the surface of the body and everywhere inside the body under full-duplex communication at a transmission rate of 115 kbps. The power consumption of each TCS unit was 125 mW with an ASK-modulated current of 7 mA (root-mean-square). While further study is required to secure its safety, the newly developed TCS has promise to be a next-generation transcutaneous communication device. PMID:22812488

  15. Artificial Molecular Devices and Machines Driven by Light

    SciTech Connect

    Semeraro, Monica; Silvi, Serena; Credi, Alberto

    2007-12-26

    Light-induced processes are at the basis of fundamental natural phenomena as well as of a variety of applications. Since the functions that can arise from the interaction between light and matter depend on the degree of complexity and organization of the receiving 'matter', the research on these processes has progressively moved from molecular to supramolecular (multicomponent) systems, thereby originating the field of supramolecular photochemistry. In this context, examples of photochemical molecular devices and machines - that is, multicomponent chemical systems capable to perform specific functions under light stimulation - have been developed. Here we describe two recent examples of such systems based on pseudorotaxane and rotaxane species. These studies are of interest not only for the growth of nanoscience, but also for increasing the basic understanding and testing current theoretical treatments of photoinduced processes.

  16. Ultra-flexible Piezoelectric Devices Integrated with Heart to Harvest the Biomechanical Energy

    PubMed Central

    Lu, Bingwei; Chen, Ying; Ou, Dapeng; Chen, Hang; Diao, Liwei; Zhang, Wei; Zheng, Jun; Ma, Weiguo; Sun, Lizhong; Feng, Xue

    2015-01-01

    Power supply for medical implantable devices (i.e. pacemaker) always challenges not only the surgery but also the battery technology. Here, we report a strategy for energy harvesting from the heart motion by using ultra-flexible piezoelectric device based on lead zirconate titanate (PZT) ceramics that has most excellent piezoelectricity in commercial materials, without any burden or damage to hearts. Experimental swine are selected for in vivo test with different settings, i.e. opened chest, close chest and awake from anesthesia, to simulate the scenario of application in body due to their hearts similar to human. The results show the peak-to-peak voltage can reach as high as 3 V when the ultra-flexible piezoelectric device is fixed from left ventricular apex to right ventricle. This demonstrates the possibility and feasibility of fully using the biomechanical energy from heart motion in human body for sustainably driving implantable devices. PMID:26538375

  17. Ultra-flexible Piezoelectric Devices Integrated with Heart to Harvest the Biomechanical Energy

    NASA Astrophysics Data System (ADS)

    Lu, Bingwei; Chen, Ying; Ou, Dapeng; Chen, Hang; Diao, Liwei; Zhang, Wei; Zheng, Jun; Ma, Weiguo; Sun, Lizhong; Feng, Xue

    2015-11-01

    Power supply for medical implantable devices (i.e. pacemaker) always challenges not only the surgery but also the battery technology. Here, we report a strategy for energy harvesting from the heart motion by using ultra-flexible piezoelectric device based on lead zirconate titanate (PZT) ceramics that has most excellent piezoelectricity in commercial materials, without any burden or damage to hearts. Experimental swine are selected for in vivo test with different settings, i.e. opened chest, close chest and awake from anesthesia, to simulate the scenario of application in body due to their hearts similar to human. The results show the peak-to-peak voltage can reach as high as 3 V when the ultra-flexible piezoelectric device is fixed from left ventricular apex to right ventricle. This demonstrates the possibility and feasibility of fully using the biomechanical energy from heart motion in human body for sustainably driving implantable devices.

  18. Ultra-flexible Piezoelectric Devices Integrated with Heart to Harvest the Biomechanical Energy.

    PubMed

    Lu, Bingwei; Chen, Ying; Ou, Dapeng; Chen, Hang; Diao, Liwei; Zhang, Wei; Zheng, Jun; Ma, Weiguo; Sun, Lizhong; Feng, Xue

    2015-01-01

    Power supply for medical implantable devices (i.e. pacemaker) always challenges not only the surgery but also the battery technology. Here, we report a strategy for energy harvesting from the heart motion by using ultra-flexible piezoelectric device based on lead zirconate titanate (PZT) ceramics that has most excellent piezoelectricity in commercial materials, without any burden or damage to hearts. Experimental swine are selected for in vivo test with different settings, i.e. opened chest, close chest and awake from anesthesia, to simulate the scenario of application in body due to their hearts similar to human. The results show the peak-to-peak voltage can reach as high as 3 V when the ultra-flexible piezoelectric device is fixed from left ventricular apex to right ventricle. This demonstrates the possibility and feasibility of fully using the biomechanical energy from heart motion in human body for sustainably driving implantable devices. PMID:26538375

  19. Implantation technique of the 50-cm3 SynCardia Total Artificial Heart: does size make a difference?

    PubMed

    Spiliopoulos, Sotirios; Guersoy, Dilek; Dimitriou, Alexandros Merkourios; Koerfer, Reiner; Tenderich, Gero

    2015-01-01

    Despite downsizing, implantation technique of the 50-cm(3) SynCardia Total Artificial Heart and settings of the Companion driver remain unchanged. Owing to the absence of de-airing nipples, de-airing procedure is even more crucial and has to be performed carefully. PMID:26438624

  20. Current state-of-the-art of device therapy for advanced heart failure

    PubMed Central

    Lee, Lawrence S.; Shekar, Prem S.

    2014-01-01

    Heart failure remains one of the most common causes of morbidity and mortality worldwide. The advent of mechanical circulatory support devices has allowed significant improvements in patient survival and quality of life for those with advanced or end-stage heart failure. We provide a general overview of past and current mechanical circulatory support devices encompassing options for both short- and long-term ventricular support. PMID:25559828

  1. Flow field of a novel implantable valveless counterpulsation heart assist device.

    PubMed

    Berthe, A; Gärtlein, S; Lederer, Ch; Kertzscher, U; Affeld, K; Goubergrits, L

    2012-09-01

    Flow fields are one of the key factors associated with the life threatening formation of thrombi in artificial organs. Therefore, knowledge of flow field is crucial for the design and optimization of a long-term blood pump performance. The blood chamber flow of a novel counterpulsation heart assist device (CPD) has been investigated using laser Doppler velocimetry (LDV), particle image velocimetry (PIV), and near-wall PIV (wall-PIV). The wall-PIV is an in-house developed technique assessing wall shear rates (WSR). These experimental techniques analyzed complex transient three-dimensional (3D) flow fields including major and secondary structures during the whole CPD cycle (ejection, filling, and hold time). PIV measurements in the central plane investigated an evolution (development and destruction) of the blood chamber fully filling vortex as the major CPD flow structure. The wall-PIV measurements identified areas of blood stagnation (vortex center and jet impingements) and quantified WSR at the front housing. Maximal mean WSR of 2,045 ± 605 s(-1) were found at the end of the filling. The LDV, which identified helical flow structure at the outer region of the pump, was used to complete 3D flow analysis and to combine PIV and wall-PIV results. The results suggest good washing behavior of the CPD regarding thrombus formation. PMID:22527012

  2. Estimation of Filling and Afterload Conditions by Pump Intrinsic Parameters in a Pulsatile Total Artificial Heart.

    PubMed

    Cuenca-Navalon, Elena; Laumen, Marco; Finocchiaro, Thomas; Steinseifer, Ulrich

    2016-07-01

    A physiological control algorithm is being developed to ensure an optimal physiological interaction between the ReinHeart total artificial heart (TAH) and the circulatory system. A key factor for that is the long-term, accurate determination of the hemodynamic state of the cardiovascular system. This study presents a method to determine estimation models for predicting hemodynamic parameters (pump chamber filling and afterload) from both left and right cardiovascular circulations. The estimation models are based on linear regression models that correlate filling and afterload values with pump intrinsic parameters derived from measured values of motor current and piston position. Predictions for filling lie in average within 5% from actual values, predictions for systemic afterload (AoPmean , AoPsys ) and mean pulmonary afterload (PAPmean ) lie in average within 9% from actual values. Predictions for systolic pulmonary afterload (PAPsys ) present an average deviation of 14%. The estimation models show satisfactory prediction and confidence intervals and are thus suitable to estimate hemodynamic parameters. This method and derived estimation models are a valuable alternative to implanted sensors and are an essential step for the development of a physiological control algorithm for a fully implantable TAH. PMID:26634983

  3. Steady state hemodynamic and energetic characterization of the Penn State/3M Health Care Total Artificial Heart.

    PubMed

    Weiss, W J; Rosenberg, G; Snyder, A J; Pierce, W S; Pae, W E; Kuroda, H; Rawhouser, M A; Felder, G; Reibson, J D; Cleary, T J; Ford, S K; Marlotte, J A; Nazarian, R A; Hicks, D L

    1999-01-01

    Total Artificial Heart (TAH) development at Penn State University and 3M Health Care has progressed from design improvements and manufacturing documentation to in vitro and in vivo testing to characterize the system's hemodynamic response and energetic performance. The TAH system is completely implantable and intended for use as an alternative to transplantation. It includes a dual pusher plate pump and rollerscrew actuator, welded electronics and battery assembly, transcutaneous energy transmission system, telemetry, and a compliance chamber. In vitro testing was conducted on a Penn State mock circulatory loop with glycerol/water solution at body temperature. Tests were performed to characterize the preload and afterload response, left atrial pressure control, and power consumption. A sensitive preload response was demonstrated with left atrial pressure safely maintained at less than 15 mm Hg for flow rates up to 7.5 L/min. Variations in aortic pressure and pulmonary vascular resistance were found to have minimal effects on the preload sensitivity and left atrial pressure control. In vivo testing of the completely implanted system in its final configuration was carried out in two acute studies using implanted temperature sensors mounted on the electronics, motor, and energy transmission coil in contact with adjacent tissue. The mean temperature at the device-tissue interface was less than 4 degrees C above core temperature. PMID:10360721

  4. Image based evaluation of mediastinal constraints for the development of a pulsatile total artificial heart

    PubMed Central

    2013-01-01

    Background Good anatomical compatibility is an important aspect in the development of cardiovascular implants. This work analyzes the interaction of the pump unit of an electrically driven pulsatile Total Artificial Heart (TAH) and the mediastinum. For an adequate compliance, both overall dimensions and alignment of inlets and outlets must be matched. Methods Cross-sectional medical image data of 27 individuals, including male and female patients suffering from end stage heart failure, was segmented and reconstructed to three dimensional (3D) surface models. Dimensions and orientations of relevant structures were identified and analyzed. The TAH surface model was virtually placed in orthotopic position and aligned with atrioventricular valves and big vessels. Additionally seven conventional cadaver studies were performed to validate different pump chamber designs based on virtual findings. Thereby 3D-coordinates were captured and introduced to the virtual environment to allow quantitative comparison between different individuals. Results Spatial parameters varied more in male patients with higher values if heart failure persists. Good correlation of the virtual analysis both to literature data and conventional cadaver studies could be shown. The full data of the 27 individuals as well as the summarized values found in literature are enclosed in the appendix. By superimposing the TAH-volume model to the anatomy, various misalignments were found and the TAH-design was adjusted. Conclusions Virtual fitting allows implant design adjustments in realistic anatomy which has not been influenced by thoracotomy. Higher numbers of relevant individuals can be reasonably investigated in the virtual environment and quantitatively correlated. Using this approach, conventional cadaver studies can be significantly reduced but not obviated, due to the unavailable haptic feedback and immobility of potentially compressed structures. PMID:23941400

  5. Artificial Synaptic Devices Based on Natural Chicken Albumen Coupled Electric-Double-Layer Transistors

    PubMed Central

    Wu, Guodong; Feng, Ping; Wan, Xiang; Zhu, Liqiang; Shi, Yi; Wan, Qing

    2016-01-01

    Recent progress in using biomaterials to fabricate functional electronics has got growing attention for the new generation of environmentally friendly and biocompatible electronic devices. As a kind of biological material with rich source, proteins are essential natural component of all organisms. At the same time, artificial synaptic devices are of great significance for neuromorphic systems because they can emulate the signal process and memory behaviors of biological synapses. In this report, natural chicken albumen with high proton conductivity was used as the coupling electrolyte film for organic/inorganic hybrid synaptic devices fabrication. Some important synaptic functions including paired-pulse facilitation, dynamic filtering, short-term to long-term memory transition and spatial summation and shunting inhibition were successfully mimicked. Our results are very interesting for biological friendly artificial neuron networks and neuromorphic systems. PMID:27008981

  6. Artificial Synaptic Devices Based on Natural Chicken Albumen Coupled Electric-Double-Layer Transistors

    NASA Astrophysics Data System (ADS)

    Wu, Guodong; Feng, Ping; Wan, Xiang; Zhu, Liqiang; Shi, Yi; Wan, Qing

    2016-03-01

    Recent progress in using biomaterials to fabricate functional electronics has got growing attention for the new generation of environmentally friendly and biocompatible electronic devices. As a kind of biological material with rich source, proteins are essential natural component of all organisms. At the same time, artificial synaptic devices are of great significance for neuromorphic systems because they can emulate the signal process and memory behaviors of biological synapses. In this report, natural chicken albumen with high proton conductivity was used as the coupling electrolyte film for organic/inorganic hybrid synaptic devices fabrication. Some important synaptic functions including paired-pulse facilitation, dynamic filtering, short-term to long-term memory transition and spatial summation and shunting inhibition were successfully mimicked. Our results are very interesting for biological friendly artificial neuron networks and neuromorphic systems.

  7. Artificial Synaptic Devices Based on Natural Chicken Albumen Coupled Electric-Double-Layer Transistors.

    PubMed

    Wu, Guodong; Feng, Ping; Wan, Xiang; Zhu, Liqiang; Shi, Yi; Wan, Qing

    2016-01-01

    Recent progress in using biomaterials to fabricate functional electronics has got growing attention for the new generation of environmentally friendly and biocompatible electronic devices. As a kind of biological material with rich source, proteins are essential natural component of all organisms. At the same time, artificial synaptic devices are of great significance for neuromorphic systems because they can emulate the signal process and memory behaviors of biological synapses. In this report, natural chicken albumen with high proton conductivity was used as the coupling electrolyte film for organic/inorganic hybrid synaptic devices fabrication. Some important synaptic functions including paired-pulse facilitation, dynamic filtering, short-term to long-term memory transition and spatial summation and shunting inhibition were successfully mimicked. Our results are very interesting for biological friendly artificial neuron networks and neuromorphic systems. PMID:27008981

  8. A moving-actuator type electromechanical total artificial heart--Part I: Linear type and mock circulation experiments.

    PubMed

    Min, B G; Kim, H C; Lee, S H; Kim, J W; Kim, J T; Kim, I Y; Kim, S W; Diegel, P D; Olsen, D B

    1990-12-01

    A new type of motor-driven total artificial heart system with a moving-actuator mechanism has been developed. The prototype system consists of a brushless dc motor inside of a rolling-cylinder, two arc-shaped pusher-plates and two polyurethane sacs. The moving-actuator type electromechanical pump has structural advantages of small size and light weight, as compared to other reported motor-driven pumps with fixed-actuator mechanisms. The results of the mock circulation tests are reported in this paper with a cardiac output of 9 L/min at an aortic pressure of 120 mmHg and a heart rate of 120 bpm. The fulfillment of the basic control requirements of the artificial heart was also confirmed, i.e., preload sensitive and afterload insensitive cardiac output response and balanced right and left ventricular outputs. PMID:2289792

  9. Application of an unstructured grid algorithm to artificial heart valve simulations.

    PubMed

    Hsu, A T; Yun, J X; Hwang, N H

    1999-01-01

    The time varying flow pattern in the vicinity of mechanical heart valves (MHV) is fairly complex: it involves multiple passages and moving leaflets. The numeric simulation of unsteady flows in these multiple passages with moving boundaries presents a major challenge to computational fluid dynamics (CFD). Two major difficulties in the numeric simulation of MHV flows are 1) the generation of a body fitted grid within the multipassage device and 2) moving leaflets. The conventional finite difference and finite volume scheme obtained by using a structured grid have serious deficiencies in these applications. To fit the grid lines with the various angles of the moving MHV, the grid may often become too skewed for accurate numeric solution. To overcome these deficiencies, significant effort and attention should be placed on the grid generation and moving grid scheme. We present an unstructured moving grid finite volume method for heart valve simulations. The Navier-Stokes equations are discretized on a general tetrahedral mesh by using a finite volume scheme. With this scheme, the mesh can be automatically generated with any commercial software. The method is applied to a tilting disk (Medtronic Hall 29mm, Medtronic, Inc., Minneapolis, MN) heart valve, and results are compared with that of the steady flow solutions. Significant differences between steady and unsteady flow solutions are observed. PMID:10593690

  10. Assessment of heart rate variability based on mobile device for planning physical activity

    NASA Astrophysics Data System (ADS)

    Svirin, I. S.; Epishina, E. V.; Voronin, V. V.; Semenishchev, E. A.; Solodova, E. N.; Nabilskaya, N. V.

    2015-05-01

    In this paper we present a method for the functional analysis of human heart based on electrocardiography (ECG) signals. The approach using the apparatus of analytical and differential geometry and correlation and regression analysis. ECG contains information on the current condition of the cardiovascular system as well as on the pathological changes in the heart. Mathematical processing of the heart rate variability allows to obtain a great set of mathematical and statistical characteristics. These characteristics of the heart rate are used when solving research problems to study physiological changes that determine functional changes of an individual. The proposed method implemented for up-to-date mobile Android and iOS based devices.

  11. First Report of 90-Day Support of Two Calves with a Continuous-Flow Total Artificial Heart

    PubMed Central

    Karimov, Jamshid H.; Moazami, Nader; Kobayashi, Mariko; Sale, Shiva; Such, Kimberly; Byram, Nicole; Sunagawa, Gengo; Horvath, David; Gao, Shengqiang; Kuban, Barry; Golding, Leonard A.; Fukamachi, Kiyotaka

    2015-01-01

    Objective The Cleveland Clinic continuous-flow total artificial heart (CFTAH) is a compact, single-piece, valveless, pulsatile pump providing self-regulated hemodynamic output to left/right circulation. We evaluated chronic in vivo pump performance, physiologic and hemodynamic parameters, and biocompatibility of the CFTAH in a well-established calf model. Methods CFTAH pumps have been implanted in 17 calves total. Hemodynamics, pump performance, and device-related adverse events were evaluated during studies and at necropsy. Results In vivo experiments demonstrated good hemodynamic performance (pump flow, 7.3 ± 0.7 L/min; left atrial pressure [LAP], 16 ± 3 mm Hg; right atrial pressure [RAP], 17 ± 3 mm Hg; RAP-LAP difference, 1 ± 2 mm Hg; mean arterial pressure, 103 ± 7 mm Hg; arterial pulse pressure, 30 ± 11 mm Hg; pulmonary arterial pressure, 34 ± 5 mm Hg). The CFTAH has operated within design specifications and never failed. With ever-improving pump design, the implants have shown no chronic hemolysis. Three recent animals with the CFTAH recovered well, with no postoperative anticoagulation, during planned in vivo durations of 30, 90, and 90 days (last two were intended to be 90-day studies). All these longest-surviving cases showed good biocompatibility, with no thromboembolism in organs. Conclusions The current CFTAH has demonstrated reliable self-regulation of hemodynamic output and acceptable biocompatibility without anticoagulation throughout 90 days of chronic implantation in calves. Meeting these milestones is in accord with our strategy to achieve transfer of this unique technology to surgical practice, thus filling the urgent need for cardiac replacement devices as destination therapy. PMID:26173607

  12. The MAVID heart holder: a demonstration device to anchor cadaver hearts for surgical simulation and practical education.

    PubMed

    Mavroudis, Constantine; Idriss, Rachid; Klaus, Kristen E

    2015-12-01

    Performing open heart surgery involves learning challenging techniques and a need for realistic training models to achieve and maintain a high level of surgical skills. The MAVID heart holder is an organ holder primarily designed to hold the heart in its anatomic position for the purpose of surgical simulation and education, thereby closing the gap between surgical performance in the laboratory and in the operating room. The device is simple to use, can be adjusted to organ size, and has the necessary instrumentation to be used with any solid organ. The MAVID heart holder also provides a platform for presentation and assists in advancing the research sphere. The advantage over other existing models is that the MAVID heart holder uses real tissue and does not distort the organ at the attachment sites. Further, it offers superior stability as well as the ability to manipulate the organ during presentation and dissection. Training with the MAVID heart holder has the potential to shorten training time to acquire surgical skills and proficiency before performing these techniques in the operating room and in so doing enhance patient safety. PMID:26675615

  13. Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare.

    PubMed

    Sawa, Yoshiki

    2015-06-01

    Recently, left ventricular assist devices (LVADs) have become a viable therapeutic approach as a bridge to cardiac transplantation, as well as destination therapy or as part of the bridge to recovery. In Japan, paracorporeal pneumatic devices are the only choice for such therapy, as implantable LVADs are not yet generally available due to device lag, which represents a serious problem in this field. Clinical trials of four different continuous-flow pumps, both axial and centrifugal flow types, were completed at about the same time, and two of those devices, DuraHeart and EVAHEART, have already been approved for use in Japan. Thus, reports of advanced treatment for severe heart failure with these devices are expected. The DuraHeart (Terumo Heart, Ann Arbor, MI, USA) and another device named the HeartWare (HeartWare Inc, Miami Lakes, FL, USA) are so-called third-generation devices, as they have achieved miniaturization and improvements in performance from the use of magnetic levitation. Based on our experiences from both clinical research and experimental use, we herein discuss the DuraHeart and HeartWare devices, with a focus on the clinical outcomes and management strategies. Because of the long waiting period for heart transplantation in Japan, these two devices are considered to have important roles in the near future for the treatment of severe heart failure, and a comprehensive strategy for LVAD therapy including such third-generation implantable devices is expected. PMID:25139211

  14. Current Approaches to Device Implantation in Pediatric and Congenital Heart Disease Patients

    PubMed Central

    Miller, Jacob R; Lancaster, Timothy S; Eghtesady, Pirooz

    2015-01-01

    Summary The pediatric ventricular assist device (VAD) has recently shown substantial improvements in survival as a bridge to heart transplant for patients with end-stage heart failure. Since that time, its use has become much more frequent. With increasing utilization, additional questions have arisen including patient selection, timing of VAD implantation and device selection. These challenges are amplified by the uniqueness of each patient, the recent abundance of literature surrounding VAD use, as well as the technological advancements in the devices themselves. Ideal strategies for device placement must be sought, for not only improved patient care, but for optimal resource utilization. Here, we review the most relevant literature to highlight some of the challenges facing the heart failure specialist, and any physician, who will care for a child with a VAD. PMID:25732410

  15. Passive constraint and new shape-change devices for heart failure.

    PubMed

    Kaplon, Richard; Lombardi, Pierluca

    2002-04-01

    Lessons learned from ventricular remodeling procedures have shown that Laplace mechanics, whereby mural tension is related to ventricular diameter, may be beneficially applied to the left ventricle (LV). Recently developed devices, predicated on the Law of Laplace, are directed at interrupting the heart-failure cascade without removing functioning myocardium. The Acorn cardiac support device is a polyester-mesh jacket placed snugly around the heart to provide end-diastolic support and prevent LV dilation. The Myosplint device uses transmural tension members to bisect the dilated LV to create a bilobed LV with decreased mural tension in each cavity. Preclinical and early clinical data with both devices appears promising and may offer a new surgical alternative for patients with worsening heart failure. PMID:11988954

  16. Designing artificial photosynthetic devices using hybrid organic-inorganic modules based on polyoxometalates.

    PubMed

    Symes, Mark D; Cogdell, Richard J; Cronin, Leroy

    2013-08-13

    Artificial photosynthesis aims at capturing solar energy and using it to produce storable fuels. However, while there is reason to be optimistic that such approaches can deliver higher energy conversion efficiencies than natural photosynthetic systems, many serious challenges remain to be addressed. Perhaps chief among these is the issue of device stability. Almost all approaches to artificial photosynthesis employ easily oxidized organic molecules as light harvesters or in catalytic centres, frequently in solution with highly oxidizing species. The 'elephant in the room' in this regard is that oxidation of these organic moieties is likely to occur at least as rapidly as oxidation of water, meaning that current device performance is severely curtailed. Herein, we discuss one possible solution to this problem: using self-assembling organic-polyoxometalate hybrid structures to produce compartments inside which the individual component reactions of photosynthesis can occur without such a high incidence of deleterious side reactions. PMID:23816903

  17. Total Artificial Heart as Bridge to Transplantation for Severe Culture-Negative Prosthetic Valve Endocarditis due to Gemella haemolysans

    PubMed Central

    Ramchandani, Meena S.; Rakita, Robert M.; Freeman, Rosario V.; Levy, Wayne C.; Von Homeyer, Peter; Mokadam, Nahush A.

    2015-01-01

    We report a rare case of a patient with prosthetic valve endocarditis requiring implantation of a total artificial heart (TAH) as a bridge to heart transplantation. Gemella haemolysans, an unusual cause of PVE, was identified as the organism responsible only by 16s rRNA PCR analysis of surgical tissue samples. We also describe one of the first uses of combined TAH and veno-venous extracorporeal membrane oxygenation therapy in the setting of severe respiratory and cardiac failure. Implantation of a TAH may be considered in situations where more traditional reconstructive methods are not feasible. PMID:24727539

  18. Continuous flow total artificial heart: modeling and feedback control in a mock circulatory system.

    PubMed

    Khalil, Hassan A; Kerr, Daniel T; Franchek, Matthew A; Metcalfe, Ralph W; Benkowski, Robert J; Cohn, William E; Tuzun, Egemen; Radovancevic, Branislav; Frazier, O H; Kadipasaoglu, Kamuran A

    2008-01-01

    We developed a mock circulatory loop and used mathematical modeling to test the in vitro performance of a physiologic flow control system for a total artificial heart (TAH). The TAH was constructed from two continuous flow pumps. The objective of the control system was to maintain loop flow constant in response to changes in outflow resistance of either pump. Baseline outflow resistances of the right (pulmonary vascular resistance) and the left (systemic vascular resistance) pumps were set at 2 and 18 Wood units, respectively. The corresponding circuit flow was 4 L/min. The control system consisted of two digital integral controllers, each regulating the voltage, hence, the rotational speed of one of the pumps. The in vitro performance of the flow control system was validated by increasing systemic and pulmonary vascular resistances in the mock loop by 4 and 8 Wood units (simulating systemic and pulmonary hypertension conditions), respectively. For these simulated hypertensive states, the flow controllers regulated circuit flow back to 4 L/min within seconds by automatically adjusting the rotational speed of either or both pumps. We conclude that this multivariable feedback mechanism may constitute an adequate supplement to the inherent pressure sensitivity of rotary blood pumps for the automatic flow control and left-right flow balance of a dual continuous flow pump TAH system. PMID:18496274

  19. New concepts and new design of permanent maglev rotary artificial heart blood pumps.

    PubMed

    Qian, K X; Zeng, P; Ru, W M; Yuan, H Y

    2006-05-01

    According to tradition, permanent maglev cannot achieve stable equilibrium. The authors have developed, to the contrary, two stable permanent maglev impeller blood pumps. The first pump is an axially driven uni-ventricular assist pump, in which the rotor with impeller is radially supported by two passive magnetic bearings, but has one point contact with the stator axially at standstill. As the pump raises its rotating speed, the increasing hydrodynamic force of fluid acting on the impeller will make the rotor taking off from contacting point and disaffiliate from the stator. Then the rotor becomes fully suspended. The second pump is a radially driven bi-ventricular assist pump, i.e., an impeller total artificial heart. Its rotor with two impellers on both ends is supported by two passive magnetic bearings, which counteract the attractive force between rotor magnets and stator coil iron core. The rotor is affiliated to the stator radially at standstill and becomes levitated during rotation. Therefore, the rotor keeps concentric with stator during rotation but eccentric at standstill, as is confirmed by rotor position detection with Honeywell sensors. It concludes that the permanent maglev needs action of a non-magnetic force to achieve stability but a rotating magnetic levitator with high speed and large inertia can maintain its stability merely with passive magnetic bearings. PMID:16183322

  20. Octreotide for the Management of Gastrointestinal Bleeding in a Patient with a HeartWare Left Ventricular Assist Device

    PubMed Central

    Dang, Geetanjali; Grayburn, Ryan; Lamb, Geoffrey; Umpierrez De Reguero, Adrian; Gaglianello, Nunzio

    2014-01-01

    HeartWare is a third generation left ventricular assist device (LVAD), widely used for the management of advanced heart failure patients. These devices are frequently associated with a significant risk of gastrointestinal (GI) bleeding. The data for the management of patients with LVAD presenting with GI bleeding is limited. We describe a 56-year-old lady, recipient of a HeartWare device, who experienced recurrent GI bleeding and was successfully managed with subcutaneous (SC) formulations of octreotide. PMID:25587457

  1. Berlin Heart EXCOR Ventricular Assist Device: Multilayer Membrane Rupture in a Pediatric Patient.

    PubMed

    Di Molfetta, Arianna; Filippelli, Sergio; Ferrari, Gianfranco; Secinaro, Aurelio; Zielinski, Krystzof; Amodeo, Antonio

    2016-08-01

    A 2-year-old child was implanted with an Berlin Heart EXCOR Ventricular Assist Device (Berlin Heart, Berlin, Germany) as a bridge to heart transplantation for idiopathic dilated cardiomyopathy. At postoperative day 296, a significant reduction of membrane movement was observed. The device was explanted and tested on a hydronumerical circulation simulator. Findings suggested that the integrity of the multilayered membrane had been compromised. This was confirmed by a computed tomography scan of the device. The computed tomography evidenced a detachment of the 3-layered membrane, with a thinner, convex layer on the side of the air chamber and an opposite convexity of the remaining membranes. These showed an additional air space within the layers. PMID:27449447

  2. Acquisition of Visual Perception in Blind Adults Using the BrainPort Artificial Vision Device

    PubMed Central

    Pintar, Christine; Arnoldussen, Aimee; Fisher, Christopher

    2015-01-01

    OBJECTIVE. We sought to determine whether intensive low vision rehabilitation would confer any functional improvement in a sample of blind adults using the BrainPort artificial vision device. METHOD. Eighteen adults ages 28–69 yr (n = 10 men and n = 8 women) who had light perception only or worse vision bilaterally spent up to 6 hr per day for 1 wk undergoing structured rehabilitation interventions. The functional outcomes of object identification and word recognition were tested at baseline and after rehabilitation training. RESULTS. At baseline, participants were unable to complete the two functional assessments. After participation in the 1-wk training protocol, participants were able to use the BrainPort device to complete the two tasks with moderate success. CONCLUSION. Without training, participants were not able to perform above chance level using the BrainPort device. As artificial vision technologies become available, occupational therapy practitioners can play a key role in clients’ success or failure in using these devices. PMID:25553750

  3. Numerical Model of Full Cardiac Cycle Hemodynamics in a Total Artificial Heart and the Effect of Its Size on Platelet Activation

    PubMed Central

    Marom, Gil; Chiu, Wei-Che; Crosby, Jessica R.; DeCook, Katrina J.; Prabhakar, Saurabh; Horner, Marc; Slepian, Marvin J.; Bluestein, Danny

    2014-01-01

    The SynCardia total artificial heart (TAH) is the only FDA approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1,300 patients, its size precludes implantation in smaller patients. This study’s aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac-cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress-accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac-cycle. Increased stress-accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable. PMID:25354999

  4. Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation.

    PubMed

    Marom, Gil; Chiu, Wei-Che; Crosby, Jessica R; DeCook, Katrina J; Prabhakar, Saurabh; Horner, Marc; Slepian, Marvin J; Bluestein, Danny

    2014-12-01

    The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study's aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable. PMID:25354999

  5. Update on Renal Replacement Therapy: Implantable Artificial Devices and Bioengineered Organs.

    PubMed

    Attanasio, Chiara; Latancia, Marcela T; Otterbein, Leo E; Netti, Paolo A

    2016-08-01

    Recent advances in the fields of artificial organs and regenerative medicine are now joining forces in the areas of organ transplantation and bioengineering to solve continued challenges for patients with end-stage renal disease. The waiting lists for those needing a transplant continue to exceed demand. Dialysis, while effective, brings different challenges, including quality of life and susceptibility to infection. Unfortunately, the majority of research outputs are far from delivering satisfactory solutions. Current efforts are focused on providing a self-standing device able to recapitulate kidney function. In this review, we focus on two remarkable innovations that may offer significant clinical impact in the field of renal replacement therapy: the implantable artificial renal assist device (RAD) and the transplantable bioengineered kidney. The artificial RAD strategy utilizes micromachining techniques to fabricate a biohybrid system able to mimic renal morphology and function. The current trend in kidney bioengineering exploits the structure of the native organ to produce a kidney that is ready to be transplanted. Although these two systems stem from different technological approaches, they are both designed to be implantable, long lasting, and free standing to allow patients with kidney failure to be autonomous. However, for both of them, there are relevant issues that must be addressed before translation into clinical use and these are discussed in this review. PMID:26905099

  6. Neurological Complications and Outcomes in the Berlin Heart EXCOR® Pediatric Investigational Device Exemption Trial

    PubMed Central

    Jordan, Lori C.; Ichord, Rebecca N.; Reinhartz, Olaf; Humpl, Tilman; Pruthi, Sumit; Tjossem, Christine; Rosenthal, David N.

    2015-01-01

    Background The Berlin Heart EXCOR® ventricular assist device has been approved for use in the United States as a bridge to heart transplantation in children. We sought to characterize neurological events in children supported with the Berlin Heart EXCOR® device. Methods and Results The multicenter prospective cohort consisted of all 204 children implanted with the Berlin Heart EXCOR® device at 47 centers in North America between May 2007 and December 2010. There were 73 neurological events in 59 patients, with 29% of the cohort experiencing ≥1 neurological event. Events included 52 strokes in 43 patients (21% of the cohort). The neurological event rate was 0.51 events per 100 patient‐days. Many of the neurological events occurred early in the course of support, with 30 events recorded during the first 14 days of support. The mortality rate in participants with at least 1 neurological event was 42% (25 of 59), significantly higher than the 18% mortality rate (26 of 145) for those who did not have a neurological event (P=0.0006). Risk‐factor analysis did not identify significant preimplantation predictors of neurological injury. Conclusions Of children treated with the Berlin Heart EXCOR® device as a bridge to transplant, 29% experienced at least 1 neurological event. The majority of neurological events were ischemic strokes, and many of those occurred early in the course of support. Neurological injury was the leading cause of death after implantation of the Berlin Heart EXCOR® device. Risk stratification for stroke or neurological injury is not possible based on baseline preimplantation characteristics. Clinical Trial Registration URL: www.clinicaltrials.gov. Unique Identifier: NCT00583661. PMID:25613996

  7. Eight-year experience with a continuous-flow total artificial heart in calves.

    PubMed

    Cohn, William E; Handy, Kelly M; Parnis, Steven M; Conger, Jeffrey L; Winkler, Jo Anna; Frazier, O H

    2014-01-01

    Over the last 8 years, we have developed and evaluated a continuous-flow total artificial heart (CFTAH) comprising two rotary blood pumps. To understand the physiologic effects of nonpulsatile circulation, we evaluated the CFTAH in 65 calves for 90 days or less. We describe our experience with 29 calves that survived for 7 days or more. The calves received dual axial-flow (n = 24) or centrifugal-flow (n = 5) pumps. Several iterations of customized atrial cuffs were developed to facilitate an adequate anatomical fit. Pressures (arterial pressure [AoP], pulmonary artery pressure [PAP], left atrial pressure [LAP], and right atrial pressure [RAP]) and pump parameters were continuously monitored. Hematologic and biochemistry values were analyzed. After each case, a necropsy was performed. The calves survived for 7-92 days (mean, 24 days). Pressures were 94 ± 14 (AoP), 25 ± 8 (PAP), 14 ± 6 (RAP), and 16 ± 6 (LAP) mm Hg. Pump flow was maintained at 9.1 ± 1.7 L/minute (right) and 9.4 ± 1.9 L/minute (left). Hematologic and biochemistry values remained acceptable. Eight animals underwent treadmill evaluations, in which oxygen consumption (VO2) was comparable with physiologic total-body VO2. In the two animals that survived to 90 days, the end-organs appeared unremarkable at autopsy, and the CFTAH circuits were free of thrombus. Our results show that a CFTAH can maintain a large animal physiologically and hemodynamically for up to 90 days with continuous flow. PMID:24281122

  8. Does exposure to an artificial ULF magnetic field affect blood pressure, heart rate variability and mood?

    PubMed

    Mitsutake, Gen; Otsuka, Kuniaki; Oinuma, Sachiko; Ferguson, Ian; Cornélissen, Germaine; Wanliss, James; Halberg, Franz

    2004-10-01

    The aim of this study was to determine whether an artificial magnetic field with an amplitude and frequency equivalent to those of geomagnetic pulsations during geomagnetic storms could affect physiology and psychology. Three healthy volunteers wore anambulatory BP monitor and an ECG recorder around the clock for 12 consecutive weekends in Winnipeg, Manitoba, Canada. In a room shielded against ELF and VLF waves, they were exposed for 8 hours per week to either a 50 nT 0.0016 Hz or a sham magnetic field at one of six circadian stages. Real exposure randomly alternated with sham exposure. They provided saliva and recorded mood and reaction time every 4 hours while awake. Systolic (S) and diastolic (D) blood pressure (BP), and heart rate (HR) were recorded every 30 minutes. Spectral analysis of HR variability (HRV) was performed using the maximum entropy method and a complex demodulation method. For these variables, daily means were compared between real and sham exposure, using paired t-tests. Their circadian MESOR, amplitude, and acrophase were analyzed and summarized using single cosinor and population-mean cosinor. Circadian rhythms were demonstrated for HR, SBP, DBP for sham exposure, salivary flow rate, positive affect, vigor, and subjective alertness (p < 0.001, -0.02). One participant showed higher HR, lower LF, HF, and VLF powers, and a steeper power-law slope (p < 0.005, -0.0001) in an early night exposure to the real magnetic field, but not in other circadian stages. There was no significant difference between circadian responses to real and sham exposure in any variable at any circadian stage. PMID:15754834

  9. A transcutaneous energy transmission system for artificial heart adapting to changing impedance.

    PubMed

    Fu, Yang; Hu, Liang; Ruan, Xiaodong; Fu, Xin

    2015-04-01

    This article presents a coil-coupling-based transcutaneous energy transmission system (TETS) for wirelessly powering an implanted artificial heart. Keeping high efficiency is especially important for TETS, which is usually difficult due to transmission impedance changes in practice, which are commonly caused by power requirement variation for different body movements and coil-couple malposition accompanying skin peristalsis. The TETS introduced in this article is designed based on a class-E power amplifier (E-PA), of which efficiency is over 95% when its load is kept in a certain range. A resonance matching and impedance compressing functions coupled network based on parallel-series capacitors is proposed in the design, to enhance the energy transmission efficiency and capacity of the coil-couple through resonating, and meanwhile compress the changing range of the transmission impedance to meet the load requirements of the E-PA and thus keep the high efficiency of TETS. An analytical model of the designed TETS is built to analyze the effect of the network and also provide bases for following parameters determination. Then, according algorithms are provided to determine the optimal parameters required in the TETS for good performance both in resonance matching and impedance compressing. The design is tested by a series of experiments, which validate that the TETS can transmit a wide range of power with a total efficiency of at least 70% and commonly beyond 80%, even when the coil-couple is seriously malpositioned. The design methodology proposed in this article can be applied to any existing TETS based on E-PA to improve their performance in actual applications. PMID:25349072

  10. Analysis, design, and control of a transcutaneous power regulator for artificial hearts.

    PubMed

    Qianhong Chen; Siu Chung Wong; Tse, C K; Xinbo Ruan

    2009-02-01

    Based on a generic transcutaneous transformer model, a remote power supply using a resonant topology for use in artificial hearts is analyzed and designed for easy controllability and high efficiency. The primary and secondary windings of the transcutaneous transformer are positioned outside and inside the human body, respectively. In such a transformer, the alignment and gap may change with external positioning. As a result, the coupling coefficient of the transcutaneous transformer is also varying, and so are the two large leakage inductances and the mutual inductance. Resonant-tank circuits with varying resonant-frequency are formed from the transformer inductors and external capacitors. For a given range of coupling coefficients, an operating frequency corresponding to a particular coupling coefficient can be found, for which the voltage transfer function is insensitive to load. Prior works have used frequency modulation to regulate the output voltage under varying load and transformer coupling. The use of frequency modulation may require a wide control frequency range which may extend well above the load insensitive frequency. In this paper, study of the input-to-output voltage transfer function is carried out, and a control method is proposed to lock the switching frequency at just above the load insensitive frequency for optimized efficiency at heavy loads. Specifically, operation at above resonant of the resonant circuits is maintained under varying coupling-coefficient. Using a digital-phase-lock-loop (PLL), zero-voltage switching is achieved in a full-bridge converter which is also programmed to provide output voltage regulation via pulsewidth modulation (PWM). A prototype transcutaneous power regulator is built and found to to perform excellently with high efficiency and tight regulation under variations of the alignment or gap of the transcutaneous transformer, load and input voltage. PMID:23853160

  11. Development of data communication system with ultra high frequency radio wave for implantable artificial hearts.

    PubMed

    Tsujimura, Shinichi; Yamagishi, Hiroto; Sankai, Yoshiyuki

    2009-01-01

    In order to minimize infection risks of patients with artificial hearts, wireless data transmission methods with electromagnetic induction or light have been developed. However, these methods tend to become difficult to transmit data if the external data transmission unit moves from its proper position. To resolve this serious problem, the purpose of this study is to develop a prototype wireless data communication system with ultra high frequency radio wave and confirm its performance. Due to its high-speed communication rate, low power consumption, high tolerance to electromagnetic disturbances, and secure wireless communication, we adopted Bluetooth radio wave technology for our system. The system consists of an internal data transmission unit and an external data transmission unit (53 by 64 by 16 mm, each), and each has a Bluetooth module (radio field intensity: 4 dBm, receiver sensitivity: -80 dBm). The internal unit also has a micro controller with an 8-channel 10-bit A/D converter, and the external unit also has a RS-232C converter. We experimented with the internal unit implanted into pig meat, and carried out data transmission tests to evaluate the performance of this system in tissue thickness of up to 3 mm. As a result, data transfer speeds of about 20 kbps were achieved within the communication distance of 10 m. In conclusion, we confirmed that the system can wirelessly transmit the data from the inside of the body to the outside, and it promises to resolve unstable data transmission due to accidental movements of an external data transmission unit. PMID:19964616

  12. Electron microscopic stereology of capillary endothelial cells and cardiomyocytes in artificially arrested canine hearts.

    PubMed

    Schmiedl, A.; Schnabel, P. A.; Marten, K.; Kausch Blecken Von Schmeling, H.; Richter, J.

    1999-12-01

    In open heart surgery and transplantation, sufficient structural preservation of the myocardium immediately following cardioplegic arrest is a precondition for overcoming ischemia and for resumption of postischemic function. Therefore, we compared the protective effect of three clinically applied cardioplegic solutions with fibrillating and beating hearts using structural criteria. Left ventricular samples were taken from (1) beating, or (2) fibrillating or arrested hearts following coronary perfu-sion with (3) St. Thomas' Hospital solution, (4) histidine tryptophane ketoglutalate (HTK) (Custodiol), or (5) University of Wisconsin (UW) solution and fixed by immersion. Ultrastructural differences in the swelling of capillary endothelial cells and myocytes were quantitatively evaluated using stereological methods. Endothelial cells were somewhat more swollen after St. Thomas perfusion than those in beating and fibrillating hearts. HTK-arrested hearts showed significantly lower values for cellular edema than beating hearts. UW perfusion resulted in the (significantly) lowest degree of endothelial cell edema. Edematous changes in myocytes were significantly greater in St. Thomas-arrested hearts than in UW- or HTK-arrested hearts. Cardiomyocyte edema in beating and fibrillating hearts was comparable to that in St. Thomas-perfused hearts. Thus, the stereol-ogical analysis revealed significant differences between cardioplegic solutions in structural preservation of myocardial ultrastructure. PMID:11810439

  13. Digital image correlation of coated and uncoated Religa Heart_Ext ventricular assist device.

    PubMed

    Kopernik, Magdalena; Gawlikowski, Maciej; Milenin, Andrij; Altyntsev, Ievgenii; Kustosz, Roman; Kąc, Sławomir

    2015-01-01

    The digital image correlation is used to estimate influence of deposited heamocompatible coatings (gold and titanium nitride) on mechanical response of ventricular assist device Religa Heart_Ext made of Bionate II (thermoplastic polycarbonate urethane) under working conditions by comparison of the coated Religa Heart_Ext with uncoated Religa Heart_Ext. The DIC is applied for experimental investigation of the strains and displacements distribution on external surface of the blood chamber of ventricular assist device during loading. The experiment was conducted in a hydraulic system with water at operating temperatures of 25 and 37 °C, as well as under static pressures: 80, 120, 180, 220 and 280 mmHg, and static underpressures: -25, -45, -75 mmHg. The subsequent images were taken after stabilization of pressure on a set level. The applied research method shows that the nano-coating of 30 nm in thickness significantly affects deformation of the blood chamber of Religa Heart_Ext in macro scale. The proposed composition of coatings increases strain on external surface of the ventricular assist device. PMID:26899910

  14. Surgical considerations for the explantation of the Parachute left ventricular partitioning device and the implantation of the HeartMate II left ventricular assist device

    PubMed Central

    Bansal, Shelley; Rosas, Paola C.; Mazzaferri, Ernest L.; Sai-Sudhakar, Chittoor B.

    2016-01-01

    Chronic heart failure is the leading cause of death in the world. With newer therapies, the burden of this disease has decreased; however, a significant number of patients remain refractive to existing therapies. Myocardial infarction often leads to ventricular remodeling and eventually contributes to heart failure. The Parachute™ (Cardiokinetix, Menlo Park, CA) is the first device designed for percutaneous ventricular restoration therapy, which reduces left ventricular volume and minimizes the risk of open surgical procedures. For the first time, we report a case of explantation of the Parachute ventricular partitioning device and transition to a HeartMate II™ left ventricular assist device and the surgical considerations for a successful outcome. PMID:27034560

  15. Surgical considerations for the explantation of the Parachute left ventricular partitioning device and the implantation of the HeartMate II left ventricular assist device.

    PubMed

    Ravi, Yazhini; Bansal, Shelley; Rosas, Paola C; Mazzaferri, Ernest L; Sai-Sudhakar, Chittoor B

    2016-04-01

    Chronic heart failure is the leading cause of death in the world. With newer therapies, the burden of this disease has decreased; however, a significant number of patients remain refractive to existing therapies. Myocardial infarction often leads to ventricular remodeling and eventually contributes to heart failure. The Parachute™ (Cardiokinetix, Menlo Park, CA) is the first device designed for percutaneous ventricular restoration therapy, which reduces left ventricular volume and minimizes the risk of open surgical procedures. For the first time, we report a case of explantation of the Parachute ventricular partitioning device and transition to a HeartMate II™ left ventricular assist device and the surgical considerations for a successful outcome. PMID:27034560

  16. Cardiopulmonary exercise testing responses to different external portable drivers in a patient with a CardioWest Total Artificial Heart.

    PubMed

    Tarzia, Vincenzo; Braccioni, Fausto; Bortolussi, Giacomo; Buratto, Edward; Gallo, Michele; Bottio, Tomaso; Vianello, Andrea; Gerosa, Gino

    2016-06-01

    Management of patients treated with CardioWest Total Artificial Heart (CW-TAH) as a bridge to heart transplantation (HTx) is complicated by difficulties in determining the optimal timing of transplantation. We present a case of a 53-year-old man supported as an outpatient with a CW-TAH, whose condition deteriorated following exchange of the portable driver. The patient was followed-up with serial cardiopulmonary exercise testing (CPET) which demonstrated a fall of peak VO2 to below 12 ml/kg/min following driver substitution, and the patient was subsequently treated with urgent orthotopic HTx. This case highlights the potential utility of CPET as a means for monitoring and indicating timing of HTx in patients with CW-TAH, as well as the potential for clinical deterioration following portable driver substitution. PMID:26497137

  17. Electrical energy converters for practical human total artificial hearts--an opinion in support of electropneumatic systems.

    PubMed

    Jarvik, R K

    1983-02-01

    Until recently, most artificial hearts have served as research tools to acquire further knowledge necessary ultimately to design practical systems for human use. Transcutaneous systems or percutaneous systems utilizing permanently implanted energy converters, batteries, and electronics packages have a number of substantial problems that would not exist if most system elements were kept outside the body. These problems include physiologic control, fit and fixation, foreign body infection, hermetic sealing, cable insulation and fatigue, inherent system complexity, stringent requirements for maintenance-free operation with long-term high reliability, and high cost. Percutaneous systems, particularly those in which only the blood pump is implanted, are an attractive choice for practical systems in the near future. A wearable, battery-powered electropneumatic total heart system should be developed. PMID:6838405

  18. Home Discharge and Out-of-Hospital Follow-Up of Total Artificial Heart Patients Supported by a Portable Driver System

    PubMed Central

    2014-01-01

    To enhance ambulation and facilitate hospital discharge of total artificial heart (TAH)–supported patients, we adapted a mobile ventricular assistance device (VAD) driver (Excor) for TAH use and report on the performance of Excor-driven TAH patients discharged home. Ten patients stabilized on a TAH, driven by the CSS (“Circulatory Support System”), were progressively switched over to the Excor in hospital over 14 days as a pilot, with daily hemodynamics and laboratory parameters measured. Twenty-two stable TAH patients were subsequently placed on the Excor, trained, and discharged home. Clinical and hemodynamic parameters were followed. All pilot study patients were clinically stable on the Excor, with no decrease in TAH output noted (6.3 + 0.3 L/min [day 1] vs. 5.8 + 0.2 L/min [day 14], p = 0.174), with a trend suggesting improvement of both hepatic and renal function. Twenty-two TAH patients were subsequently successfully discharged home on the portable driver and were supported out of hospital for up to 598 days (range, 2–598; mean = 179 ± 140 days), remaining ambulatory, New York Heart Association (NYHA) class I or II, and free of readmission for 88.5% of the time of support. TAH patients may be effectively and safely supported by a mobile drive system. As such, the utility of the TAH may be extended to support patients beyond the hospital, at home, with overall ambulatory freedom. PMID:24577369

  19. [Flowmetric assessment of coronary bypass grafts in the conditions of artificial circulation and on the beating heart].

    PubMed

    Bazylev, V V; Nemchenko, E V; Karnakhin, V A; Pavlov, A A; Mikulyak, A I

    2016-01-01

    Advantages and shortcomings of aortocoronary bypass grafting on the beating heart and in the conditions of artificial circulation (AC) have long been discussed. The data on patency of bypass grafts in the remote period are indicative of comparable results of operations with and without AC or advantages of using AC. In order to determine benefits of each method it is necessary to reveal intraoperative predictors of bypass grafts occlusion in the remote period. We analyzed the results of ultrasound flowmetry of the blood flow through the left internal thoracic artery during bypass grafting of the anterior descending artery with the use of AC and on the beating heart. A retrospective study included a total of 352 patients subdivided into 2 groups: Group One was composed of 120 patients undergoing surgery in the conditions of AC and Group Two comprised 232 patients subjected to similar operations on the beating heart. Blood flow was measured with the help of flowmeter VeryQ MediStim® after termination of AC and inactivation of heparin by protamine, with systolic pressure of 100-110 mm Hg. There were no statistically significant differences between the groups by the diameter and degree of stenosis of the anterior descending artery, diameter of the left internal thoracic artery. The mean volumetric blood flow velocity (Qmean) along the shunts in Group One was higher (p=0.01). No statistically significant differences by the pulsatility index (PI) between the groups were revealed (p=0.2). A conclusion was drawn that coronary bypass grafting of the anterior descending artery by the left internal thoracic artery in the conditions of artificial circulation made it possible to achieve higher volumetric velocity of blood flow through the conduit as compared with operations on the beating heart, with similar resistance index. The immediate results of the operations with the use of the both techniques did not differ. PMID:27100540

  20. Pulsatile mechanical cardiac assistance in pediatric patients with the Berlin heart ventricular assist device.

    PubMed

    Merkle, Frank; Boettcher, Wolfgang; Stiller, Brigitte; Hetzer, Roland

    2003-06-01

    Mechanical cardiac assistance for neonates, infants, children and adolescents may be accomplished with pulsatile ventricular assist devices (VAD) instead of extracorporeal membrane oxygenation or centrifugal pumps. The Berlin Heart VAD consists of extracorporeal, pneumatically driven blood pumps for pulsatile univentricular or biventricular assistance for patients of all age groups. The blood pumps are heparin-coated. The stationary driving unit (IKUS) has the required enhanced compressor performance for pediatric pump sizes. The Berlin Heart VAD was used in a total number of 424 patients from 1987 to November 2001 at our institution. In 45 pediatric patients aged 2 days-17 years the Berlin Heart VAD was applied for long-term support (1-111 days, mean 20 days). There were three patient groups: Group I: "Bridge to transplantation" with various forms of cardiomyopathy (N = 21) or chronic stages of congenital heart disease (N = 9); Group II: "Rescue" in intractable heart failure after corrective surgery for congenital disease (N = 7) or in early graft failure after heart transplantation (N = 1); and Group III: "Acute myocarditis" (N = 7) as either bridge to transplantation or bridge to recovery. Seventeen patients were transplanted after support periods of between 4 and 111 days with 12 long-term survivors, having now survived for up to 10 years. Five patients (Groups I and III) were weaned from the system with four long-term survivors. In Group II only one patient survived after successful transplantation. Prolonged circulatory support with the Berlin Heart VAD is an effective method for bridging until cardiac recovery or transplantation in the pediatric age group. Extubation, mobilization, and enteral nutrition are possible. For long-term use, the Berlin Heart VAD offers advantages over centrifugal pumps and ECMO in respect to patient mobility and safety. PMID:12939019

  1. "And the Beat Goes Ona... Building Artificial Hearts in the Classroom.

    ERIC Educational Resources Information Center

    Brock, David L.

    2000-01-01

    Among the many ideas and theories in anatomy and physiology, one particular topic provides all the potential benefits of learning about the human body: the circulatory system, specifically the heart. Describes a distinctive way to study circulation and the heart that allows students to explore the basic principles of vertebrate anatomy and…

  2. Continuous-Flow Total Heart Replacement Device Implanted in a 55-Year-Old Man with End-Stage Heart Failure and Severe Amyloidosis

    PubMed Central

    Frazier, O. H.; Cohn, William E.

    2012-01-01

    We implanted a continuous-flow total heart replacement device in a 55-year-old man who had severe end-stage heart failure due to amyloidosis and no other options for treatment. The device was composed of 2 modified HeartMate II ventricular assist pumps. After the implantation, our patient recovered normal neurologic function and was able to converse with his family and work on his computer. He died of multisystem organ failure caused by severe amyloidosis 5 weeks after the implantation. During the past 6 years, we have been developing and testing various technological iterations for total heart replacement in our animal laboratory and have achieved survival periods as long as 90 days in calves. We describe the development, preclinical trials, and adaptation for human use of the modified HeartMate II apparatus, as well as its role in our patient's survival. PMID:22949774

  3. Evolvement of left ventricular assist device: the implications on heart failure management.

    PubMed

    Chair, Sek Ying; Yu, Doris Sf; Ng, Michael Timothy; Wang, Qun; Cheng, Ho Yu; Wong, Eliza Ml; Sit, Janet Wh

    2016-07-01

    Heart failure (HF) is a potentially fatal disease that affects increasing number of people worldwide. Although heart transplant is the "gold standard" therapy for HF, due to the limited availability of organs, many patients died when waiting for the transplant. Left ventricular assist device (LVAD), as a mechanical circulatory support, has become a new light for patients with HF. With the technical advancements, LVADs work not only as a bridge to transplant, but also assist heart recovery and even as a destination therapy in long-term treatment. This observation paper reviewed the development of LVAD and its clinical roles. The challenges and possible solutions in nursing care for patients with LVAD at different stage of implantation were discussed. The healthcare professionals could obtain a better understanding about the LVAD treatment for HF patients. PMID:27594870

  4. Evolvement of left ventricular assist device: the implications on heart failure management

    PubMed Central

    Chair, Sek Ying; Yu, Doris SF; Ng, Michael Timothy; Wang, Qun; Cheng, Ho Yu; Wong, Eliza ML; Sit, Janet WH

    2016-01-01

    Heart failure (HF) is a potentially fatal disease that affects increasing number of people worldwide. Although heart transplant is the “gold standard” therapy for HF, due to the limited availability of organs, many patients died when waiting for the transplant. Left ventricular assist device (LVAD), as a mechanical circulatory support, has become a new light for patients with HF. With the technical advancements, LVADs work not only as a bridge to transplant, but also assist heart recovery and even as a destination therapy in long-term treatment. This observation paper reviewed the development of LVAD and its clinical roles. The challenges and possible solutions in nursing care for patients with LVAD at different stage of implantation were discussed. The healthcare professionals could obtain a better understanding about the LVAD treatment for HF patients. PMID:27594870

  5. Speed Modulation of the Continuous-Flow Total Artificial Heart to Simulate a Physiologic Arterial Pressure Waveform

    PubMed Central

    Shiose, Akira; Nowak, Kathleen; Horvath, David J.; Massiello, Alex L.; Golding, Leonard A.R.; Fukamachi, Kiyotaka

    2010-01-01

    This study demonstrated the concept of using speed modulation in a continuous-flow total artificial heart (CFTAH) to shape arterial pressure waveforms and to adjust pressure pulsatility. A programmable function generator was used to determine the optimum pulsatile speed profile. Three speed profiles (sinusoidal, rectangular, and optimized [a profile optimized for generation of a physiologic arterial pressure waveform]) were evaluated using the CFTAH mock circulatory loop. Hemodynamic parameters were recorded at average pump speeds of 2,700 rpm and a modulation cycle of 60 beats per minute. The effects of varying physiologically relevant vascular resistance and lumped compliance on the hemodynamics were assessed. The feasibility of using speed modulation to manipulate systemic arterial pressure waveforms, including a physiologic pressure waveform, was demonstrated in vitro. The additional pump power consumption needed to generate a physiologic pulsatile pressure was 16.2% of the power consumption in nonpulsatile continuous-flow mode. The induced pressure waveforms and pulse pressure were shown to be very responsive to changes in both systemic vascular resistance and arterial compliance. This system also allowed pulsatile pulmonary arterial waveform. Speed modulation in the continuous-flow total artificial heart could enable physicians to obtain desired pressure waveforms by simple manual adjustment of speed control input waveforms. PMID:20616704

  6. Mechanical and Electrical Characterization of Piezoelectric Artificial Cochlear Device and Biocompatible Packaging

    PubMed Central

    Jung, Youngdo; Kwak, Jun-Hyuk; Kang, Hanmi; Kim, Wan Doo; Hur, Shin

    2015-01-01

    This paper presents the development of a piezoelectric artificial cochlea (PAC) device capable of analyzing vibratory signal inputs and converting them into electrical signal outputs without an external power source by mimicking the function of human cochlea within an audible frequency range. The PAC consists of an artificial basilar membrane (ABM) part and an implantable packaged part. The packaged part provides a liquid environment through which incoming vibrations are transmitted to the membrane part. The membrane part responds to the transmitted signal, and the local area of the ABM part vibrates differently depending on its local resonant frequency. The membrane was designed to have a logarithmically varying width from 0.97 mm to 8.0 mm along the 28 mm length. By incorporating a micro-actuator in an experimental platform for the package part that mimics the function of a stapes bone in the middle ear, we created a similar experimental environment to cochlea where the human basilar membrane vibrates. The mechanical and electrical responses of fabricated PAC were measured with a laser Doppler vibrometer and a data acquisition system, and were compared with simulation results. Finally, the fabricated PAC in a biocompatible package was developed and its mechanical and electrical characteristics were measured. The experimental results shows successful frequency separation of incoming mechanical signal from micro-actuator into frequency bandwidth within the 0.4 kHz–5 kHz range. PMID:26263995

  7. Exercise Rehabilitation for Chronic Heart Failure Patients with Cardiac Device Implants

    PubMed Central

    Haennel, Robert G.

    2012-01-01

    In the past decade a significant development in the management and rehabilitation of people with chronic heart failure (CHF) has been the utilization of cardiac devices. The use of biventricular pacemakers, referred to as Cardiac Resynchronization Therapy (CRT) can yield improvements in functional abilities for a select group of CHF patients and the inclusion of implantable cardiac defibrillators (ICDs) may reduce the risk of sudden death. This review provides physical therapists with a basic understanding of how to prescribe exercise for people with CHF who have these device implants. PMID:22993499

  8. [PULMONARY COMPLICATIONS IN CHILDREN, OPERATED ON FOR INBORN HEART FAILURES IN THE ARTIFICIAL BLOOD CIRCULATION ENVIRONMENT].

    PubMed

    Moshkivska, L V; Nastenko, E A; Golovenko, O S; Lazoryshynets, V V

    2015-11-01

    The risk factors of pulmonary complications occurrence were analyzed in children, operated on for inborn heart failures in atrificial blood circulation environment. Pulmonary complications rate and the risk factors of their occurrence were analyzed. PMID:26939427

  9. Nanocrystal quantum dots as building blocks for artificial solids and their applications in optoelectronic devices

    NASA Astrophysics Data System (ADS)

    Choi, Joshua Jongwoo

    Nanocrystal quantum dots exhibit size-dependent optoelectronic properties and provide intriguing scientific and technological opportunities. Most proposed technologies based nanocrystals depend on macroscopic functional assemblies of nanocrystals in which the nanocrystals interact with each other to give rise to new collective properties - also called as artificial solids. As in the analogous atomic crystals, the optoelectronic properties of artificial solids are governed by (1) the energy levels of nanocrystals, (2) electronic coupling between nanocrystals, and (3) the symmetry of the nanocrystal superlattice. These issues add many levels of complexity to the design of artificial solids and, for the successful development of nanocrystal based technologies, it is crucial to gain deep understanding on the structure-property relationship of nanocrystals on multiple length scales. In this dissertation, I will present studies that show insights into the three governing factors of the optoelectronic properties of artificial solids mentioned above. (1) Nanocrystal energy levels: a direct correlation between interfacial energy level offsets between lead chalcogenide nanocrystals and ZnO layers with photovoltaic device performance is presented. Based on obtained insights on the size dependent photovoltaic properties of lead chalcogenide nanocrystals, first demonstration of solution processed nanocrystal tandem solar cells was achieved. (2) Inter-nanocrystal electronic coupling: rates of photogenerated exciton dissociation in nanocrystal assemblies as a function of inter-nanocrystal spacing are probed. The results show that excitons dissociate via tunneling induced delocalization among neighboring nanocrystals. Based on insights obtained from this work, drastically improved performance of solution processed nanocrystal infrared light emitting diodes is demonstrated. (3) Nanocrystal superlattice symmetry: interaction between ligand molecules on the surface of nanocrystals

  10. Incorporating an Exercise Detection, Grading, and Hormone Dosing Algorithm Into the Artificial Pancreas Using Accelerometry and Heart Rate.

    PubMed

    Jacobs, Peter G; Resalat, Navid; El Youssef, Joseph; Reddy, Ravi; Branigan, Deborah; Preiser, Nicholas; Condon, John; Castle, Jessica

    2015-11-01

    In this article, we present several important contributions necessary for enabling an artificial endocrine pancreas (AP) system to better respond to exercise events. First, we show how exercise can be automatically detected using body-worn accelerometer and heart rate sensors. During a 22 hour overnight inpatient study, 13 subjects with type 1 diabetes wearing a Zephyr accelerometer and heart rate monitor underwent 45 minutes of mild aerobic treadmill exercise while controlling their glucose levels using sensor-augmented pump therapy. We used the accelerometer and heart rate as inputs into a validated regression model. Using this model, we were able to detect the exercise event with a sensitivity of 97.2% and a specificity of 99.5%. Second, from this same study, we show how patients' glucose declined during the exercise event and we present results from in silico modeling that demonstrate how including an exercise model in the glucoregulatory model improves the estimation of the drop in glucose during exercise. Last, we present an exercise dosing adjustment algorithm and describe parameter tuning and performance using an in silico glucoregulatory model during an exercise event. PMID:26438720

  11. In vitro perfusion of hybrid artificial pancreas devices at low flow rates.

    PubMed

    Ramírez, C A; López, M; Stephens, C L

    1992-01-01

    Type I diabetes is characterized by insulin insufficiency due to lack of functional beta cells. To replace injection therapy, schemes such as the Hybrid Artificial Pancreas (HAP) were developed. This consists of an acrylic housing enclosing a semipermeable hollow fiber membrane. Donor islets can be seeded in the annular space through a port in the housing, and thus are separated from the recipient's bloodstream or perfusate. Before scaling the HAP to human size, the dynamics of its insulin response to a perfusion glucose challenge must be better understood. In this study, the HAP's insulin response after a step increase in the lumenal glucose concentration was determined as a function of the radial thickness of the annular space (0.173-0.973 mm) and islet distribution at a flow rate of 1 ml/min. Devices containing a single, 65 mm long fiber were used. Rat islets were isolated using standard collagenase digestion techniques. In unseeded HAP perfusions, the washout time for glucose and insulin from the annular space was dependent on flow rate and radial thickness. Both solutes were removed in < 3 min from the smallest devices when perfused at 10 ml/min. Thus, solute transport within the HAP is very fast. In the seeded HAP perfusions, the devices were subjected to a step increase in the lumenal glucose concentration. Sequential samples of the HAP effluent were collected and assayed for glucose and insulin. The spatial distribution of the islets in the annular space was one of the most important factors in determining the HAP's insulin response.(ABSTRACT TRUNCATED AT 250 WORDS) PMID:1457899

  12. Cost comparison of heart transplant vs. left ventricular assist device therapy at one year.

    PubMed

    Marasco, Silvana F; Summerhayes, Robyn; Quayle, Margaret; McGiffin, David; Luthe, Marco

    2016-05-01

    With the worldwide shortage of donor organs, use of ventricular assist device (VAD) therapy is rapidly increasing in both the bridge to transplant and destination therapy settings. However, the high cost of VADs and VAD care is a cause for concern for policy makers who have relied on the limited supply of donor hearts to naturally cap health expenditure on heart transplantation (HTx). We sought to compare costs of the first 12 months of care of VADs vs. HTx. Single center retrospective study utilizing real generated costs over a three yr span from 2010-2012. Only patients with 12 months of costing data were included. Costs of 28 HTx patients and 24 VAD patients were analyzed. Index admission costs were more than double in the VAD group compared to the HTx group and this was driven by the procurement costs and length of stay which increased almost all aspects of in hospital care costs. Subsequent costs were six times higher in the HTx group and this was driven largely by pharmaceuticals. VAD therapy remains a very expensive treatment option for end stage heart failure patients. Device prices need to reduce substantially to make this a more widely applicable and cost effective treatment option. PMID:26913688

  13. Artificial Limbs

    MedlinePlus

    ... you are missing an arm or leg, an artificial limb can sometimes replace it. The device, which ... activities such as walking, eating, or dressing. Some artificial limbs let you function nearly as well as ...

  14. Apical access and closure devices for transapical transcatheter heart valve procedures.

    PubMed

    Ferrari, Enrico

    2016-01-01

    The majority of transcatheter aortic valve implantations, structural heart procedures and the newly developed transcatheter mitral valve repair and replacement are traditionally performed either through a transfemoral or a transapical access site, depending on the presence of severe peripheral vascular disease or anatomic limitations. The transapical approach, which carries specific advantages related to its antegrade nature and the short distance between the introduction site and the cardiac target, is traditionally performed through a left anterolateral mini-thoracotomy and requires rib retractors, soft tissue retractors and reinforced apical sutures to secure, at first, the left ventricular apex for the introduction of the stent-valve delivery systems and then to seal the access site at the end of the procedure. However, despite the advent of low-profile apical sheaths and newly designed delivery systems, the apical approach represents a challenge for the surgeon, as it has the risk of apical tear, life-threatening apical bleeding, myocardial damage, coronary damage and infections. Last but not least, the use of large-calibre stent-valve delivery systems and devices through standard mini-thoracotomies compromises any attempt to perform transapical transcatheter structural heart procedures entirely percutaneously, as happens with the transfemoral access site, or via a thoracoscopic or a miniaturised video-assisted percutaneous technique. During the past few years, prototypes of apical access and closure devices for transapical heart valve procedures have been developed and tested to make this standardised successful procedure easier. Some of them represent an important step towards the development of truly percutaneous transcatheter transapical heart valve procedures in the clinical setting. PMID:26900765

  15. The influence of preoperative use of ventricular assist devices on survival after heart transplantation: propensity score matched analysis

    PubMed Central

    Hur, Kwan; Gibbons, Robert

    2010-01-01

    Objective To determine the influence of the preoperative placement of a left ventricular assist device on survival after heart transplantation. Design Prospective cohort study. Setting Organ sharing database with patient level data on heart transplants in the United States. Participants 2786 adults aged 18 or older in status 1A or 1B (highest priority for heart transplantation with either some form of ventricular assist device, intravenous inotrope, or life expectancy of less than seven days), based on the United Network for Organ Sharing Registry, 1996-2004. Main outcome measure Survival after heart transplantation in patients who did and did not receive a left ventricular assist device. Results The left ventricular assist device was not associated with decreased survival, even after the data were stratified by propensity score (the odds of being a treated patient). Inspection of the strata showed no difference in survival between patients who received the device and those who did not. The hazard ratios in strata 1 to 5 were 0.69, 1.37, 1.55, 0.75, and 1.19, respectively, and none was statistically significant. Conclusion Overall, survival after heart transplantation in patients who received a left ventricular assist device before transplantation was comparable to those who did not receive the device. PMID:20147346

  16. A novel passive left heart platform for device testing and research.

    PubMed

    Leopaldi, A M; Vismara, R; van Tuijl, S; Redaelli, A; van de Vosse, F N; Fiore, G B; Rutten, M C M

    2015-04-01

    Integration of biological samples into in vitro mock loops is fundamental to simulate real device's operating conditions. We developed an in vitro platform capable of simulating the pumping function of the heart through the external pressurization of the ventricle. The system consists of a fluid-filled chamber, in which the ventricles are housed and sealed to exclude the atria from external loads. The chamber is connected to a pump that drives the motion of the ventricular walls. The aorta is connected to a systemic impedance simulator, and the left atrium to an adjustable preload. The platform reproduced physiologic hemodynamics, i.e. aortic pressures of 120/80 mmHg with 5 L/min of cardiac output, and allowed for intracardiac endoscopy. A pilot study with a left ventricular assist device (LVAD) was also performed. The LVAD was connected to the heart to investigate aortic valve functioning at different levels of support. Results were consistent with the literature, and high speed video recordings of the aortic valve allowed for the visualization of the transition between a fully opening valve and a permanently closed configuration. In conclusion, the system showed to be an effective tool for the hemodynamic assessment of devices, the simulation of surgical or transcatheter procedures and for visualization studies. PMID:25666402

  17. Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges.

    PubMed

    Hawkins, Nathaniel M; Virani, Sean A; Sperrin, Matthew; Buchan, Iain E; McMurray, John J V; Krahn, Andrew D

    2016-08-01

    Cardiac implantable electronic devices include remote monitoring tools intended to guide heart failure management. The monitoring focus has been on averting hospitalizations by predicting worsening heart failure. However, although device measurements including intrathoracic impedance correlate with risk of decompensation, they individually predict hospitalizations with limited accuracy. Current 'crisis detection' methods involve repeatedly screening for impending decompensation, and do not adhere to the principles of diagnostic testing. Complex substrate, limited test performance, low outcome incidence, and long test to outcome times inevitably generate low positive and high negative predictive values. When combined with spectrum bias, the generalizability, incremental value, and cost-effectiveness of device algorithms are questionable. To avoid these pitfalls, remote monitoring may need to shift from crisis detection to health maintenance, keeping the patient within an ideal physiological range through continuous 'closed loop' interaction and dynamic therapy adjustment. Test performance must also improve, possibly through combination with physiological sensors in different dimensions, static baseline characteristics, and biomarkers. Complex modelling may tailor monitoring to individual phenotypes, and thus realize a personalized medicine approach. Future randomized controlled trials should carefully consider these issues, and ensure that the interventions tested are generalizable to clinical practice. PMID:26663507

  18. Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs

    PubMed Central

    Elorriaga, Natalia; Garay, Osvaldo U; Poggio, Rosana; Caporale, Joaquin; Matta, Maria G; Augustovski, Federico; Pichon-Riviere, Andres; Mozaffarian, Dariush

    2015-01-01

    Abstract Objective To estimate the impact of Argentine policies to reduce trans fatty acids (TFA) on coronary heart disease (CHD), disability-adjusted life years (DALYs) and associated health-care costs. Methods We estimated the baseline intake of TFA before 2004 to be 1.5% of total energy intake. We built a policy model including baseline intake of TFA, the oils and fats used to replace artificial TFAs, the clinical effect of reducing artificial TFAs and the costs and DALYs saved due to averted CHD events. To calculate the percentage of reduction of CHD, we calculated CHD risks on a population-based sample before and after implementation. The effect of the policies was modelled in three ways, based on projected changes: (i) in plasma lipid profiles; (ii) in lipid and inflammatory biomarkers; and (iii) the results of prospective cohort studies. We also estimated the present economic value of DALYs and associated health-care costs of coronary heart disease averted. Findings We estimated that projected changes in lipid profile would avert 301 deaths, 1066 acute CHD events, 5237 DALYs and 17 million United States dollars (US$) in health-care costs annually. Based on the adverse effects of TFA intake reported in prospective cohort studies, 1517 deaths, 5373 acute CHD events, 26 394 DALYs and US$ 87 million would be averted annually. Conclusion Even under the most conservative scenario, reduction of TFA intake had a substantial effect on public health. These findings will help inform decision-makers in Argentina and other countries on the potential public health and economic impact of this policy. PMID:26478625

  19. Ovalis TAH: development and in vitro testing of a new electromechanical energy converter for a total artificial heart.

    PubMed

    Sauer, I M; Frank, J; Spiegelberg, A; Bücherl, E S

    2000-01-01

    A new electromechanical energy converting system has been developed to yield an efficient and durable orthotopic total artificial heart (TAH). The energy converter we developed transforms the unidirectional rotational motion of the motor into a longitudinal forward-reverse movement of an internal geared oval, linked directly to pusher plates on both sides. To ensure a permanent positive connection between the drive gear and the internally geared wheel, a ball bearing runs inside an oval shaped guide track. Motor, gear unit, and conical pusher plates are seated between alternately ejecting and filling ventricles. The unidirectional motion of the brushless DC motor affords easier motor control, reduces energy demand, and ensures longer life of the motor when compared with a bidirectional motion system. In vitro testing has been performed on a mock circulation loop. The overall system efficiency of the TAH Ovalis was 27-39% (mean, 36%) for the pump output range of 2-7 L/min. The maximum output of 7 L/min can be obtained with a pump rate of 130 min(-1) and an afterload pressure of 140 mm Hg. For an average sized human with a mean cardiac output of 6 L/min at a mean aortic pressure of 120 mm Hg, 5 watts of input power would be required. The size of the prototype is 560 cm3, the weight is 950 g. Our first in vitro studies demonstrated the excellent efficiency and pump performance of this new electromechanical energy converter. The results prove the feasibility of this new concept's use as an energy converter for a total artificial heart. PMID:11110274

  20. Veno-venous extracorporeal membrane oxygenation with a bicaval dual-lumen catheter in a SynCardia total artificial heart patient.

    PubMed

    Spiliopoulos, Sotirios; Dogan, Guenes; Guersoy, Dilek; Serrano, Maria Rosario; Koerfer, Reiner; Tenderich, Gero

    2013-01-01

    We report the case of a 55 years old caucasian male patient with cardiogenic shock due to an extended myocardial infarction who underwent SynCardia Total Artificial Heart implantation and veno-venous extracorporeal membrane oxygenation with a bicaval dual-lumen cannula for the treatment of adult respiratory distress syndrome. PMID:23915497

  1. Veno-venous extracorporeal membrane oxygenation with a bicaval dual-lumen catheter in a SynCardia total artificial heart patient

    PubMed Central

    2013-01-01

    We report the case of a 55 years old caucasian male patient with cardiogenic shock due to an extended myocardial infarction who underwent SynCardia Total Artificial Heart implantation and veno-venous extracorporeal membrane oxygenation with a bicaval dual-lumen cannula for the treatment of adult respiratory distress syndrome. PMID:23915497

  2. Mechanical ventilation and the total artificial heart: optimal ventilator trigger to avoid post-operative autocycling - a case series and literature review

    PubMed Central

    2010-01-01

    Many patients with end-stage cardiomyopathy are now being implanted with Total Artificial Hearts (TAHs). We have observed individual cases of post-operative mechanical ventilator autocycling with a flow trigger, and subsequent loss of autocycling after switching to a pressure trigger. These observations prompted us to do a retrospective review of all TAH devices placed at our institution between August 2007 and May 2009. We found that in the immediate post-operative period following TAH placement, autocycling was present in 50% (5/10) of cases. There was immediate cessation of autocycling in all patients after being changed from a flow trigger of 2 L/minute to a pressure trigger of 2 cm H2O. The autocycling group was found to have significantly higher CVP values than the non-autocycling group (P = 0.012). Our data suggest that mechanical ventilator autocycling may be resolved or prevented by the use of a pressure trigger rather than a flow trigger setting in patients with TAHs who require mechanical ventilation. PMID:20478064

  3. Adhesion control by inflation: implications from biology to artificial attachment device

    NASA Astrophysics Data System (ADS)

    Dening, Kirstin; Heepe, Lars; Afferrante, Luciano; Carbone, Giuseppe; Gorb, Stanislav N.

    2014-08-01

    There is an increasing demand for materials that incorporate advanced adhesion properties, such as an ability to adhere in a reversible and controllable manner. In biological systems, these features are known from adhesive pads of the tree frog, Litoria caerulea, and the bush-cricket, Tettigonia viridissima. These species have convergently developed soft, hemispherically shaped pads that might be able to control their adhesion through active changing the curvature of the pad. Inspired by these biological systems, an artificial model system is developed here. It consists of an inflatable membrane clamped to the metallic cylinder and filled with air. Pull-off force measurements of the membrane surface were conducted in contact with the membrane at five different radii of curvature r c with (1) a smooth polyvinylsiloxane membrane and (2) mushroom-shaped adhesive microstructured membrane made of the same polymer. The hypothesis that an increased internal pressure, acting on the membrane, reduces the radius of the membrane curvature, resulting in turn in a lower pull-off force, is verified. Such an active control of adhesion, inspired by biological models, will lead to the development of industrial pick-and-drop devices with controllable adhesive properties.

  4. High-Intensity Transient Signals in the Outflow Graft and Thrombosis of a HeartWare Left Ventricular Assist Device.

    PubMed

    Dimitrov, Kamen; Riebandt, Julia; Haberl, Thomas; Wiedemann, Dominik; Simon, Paul; Laufer, Günther; Schima, Heinrich; Zimpfer, Daniel

    2016-03-01

    We report the echocardiographic detection of microbubbles in the outflow prosthesis of a HeartWare HVAD left ventricular assist device using transthoracic echocardiography. In this case it was a specific sign associated with device thrombosis that resolved after successful treatment with systemic thrombolysis. PMID:26897237

  5. RF communication with implantable wireless device: effects of beating heart on performance of miniature antenna

    PubMed Central

    Borghi, Alessandro; Bahmanyar, Mohammad Reza; McLeod, Christopher N.; Navaratnarajah, Manoraj; Yacoub, Magdi; Toumazou, Christofer

    2014-01-01

    The frequency response of an implantable antenna is key to the performance of a wireless implantable sensor. If the antenna detunes significantly, there are substantial power losses resulting in loss of accuracy. One reason for detuning is because of a change in the surrounding environment of an antenna. The pulsating anatomy of the human heart constitutes such a changing environment, so detuning is expected but this has not been quantified dynamically before. Four miniature implantable antennas are presented (two different geometries) along with which are placed within the heart of living swine the dynamic reflection coefficients. These antennas are designed to operate in the short range devices frequency band (863–870 MHz) and are compatible with a deeply implanted cardiovascular pressure sensor. The measurements recorded over 27 seconds capture the effects of the beating heart on the frequency tuning of the implantable antennas. When looked at in the time domain, these effects are clearly physiological and a combination of numerical study and posthumous autopsy proves this to be the case, while retrospective simulation confirms this hypothesis. The impact of pulsating anatomy on antenna design and the need for wideband implantable antennas is highlighted. PMID:26609377

  6. How to face emergencies in heart failure patients with ventricular assist device.

    PubMed

    Pistono, Massimo; Corrà, Ugo; Gnemmi, Marco; Imparato, Alessandro; Temporelli, Pier Luigi; Tarro Genta, Franco; Giannuzzi, Pantaleo

    2013-10-15

    Ventricular assist device (VAD) technology has rapidly evolved, and VADs are now seen as a reliable lifesaving option to support the failing heart in the short- and long-term: in some cases, VAD therapy represents a well-accepted treatment option for advanced heart failure that can obviate the need for heart transplantation. In the near future, more and more cardiologists will encounter VAD patients in their clinical practice and need to know how to handle the inherent risks associated with VAD use. The emergency care of a VAD patient differs from that of conventional practice and specific expertise is required to avoid inappropriate management that could lead to inefficient treatment and/or dangerous consequences. Here, we describe two emergency scenarios in VAD patients, two paradigmatic clinical in-hospital situations, in different settings. Following a brief overview of the role of cardiopulmonary resuscitation maneuvers in VAD patients, we propose a working algorithm that might help to ensure a timely and efficient response to acute demands in this setting. PMID:23992932

  7. Risk Factors Influencing Complications of Cardiac Implantable Electronic Device Implantation: Infection, Pneumothorax and Heart Perforation

    PubMed Central

    Lin, Yu-Sheng; Hung, Sheng-Ping; Chen, Pei-Rung; Yang, Chia-Hung; Wo, Hung-Ta; Chang, Po-Cheng; Wang, Chun-Chieh; Chou, Chung-Chuan; Wen, Ming-Shien; Chung, Chang-Ming; Chen, Tien-Hsing

    2014-01-01

    Abstract As the number of cardiac implantable electronic devices (CIEDs) is increasing annually, CIED-related complications are becoming increasingly important. The aim of the study was to assess the risks associated with CIEDs by a nationwide database. Patients were selected from the Taiwan National Health Insurance Database. Admissions for CIED implantation, replacement, and revision were evaluated and the evaluation period was 14 years. Endpoints included CIED-related infection, pneumothorax, and heart perforation. The study included 40,608 patients with a mean age of 71.8 ± 13.3 years. Regarding infection, the incidence rate was 2.45 per 1000 CIED-years. Male gender, younger age, device replacement, and previous infection were risks for infection while old age and high-volume centers (>200 per year) were protectors. The incidence of pneumothorax was 0.6%, with an increased risk in individuals who had chronic obstructive lung disease (COPD) and cardiac resynchronized therapy (CRT). The incidence of heart perforation was 0.09%, with an increased risk in individuals who had pre-operation temporal pacing and steroid use. High-volume center was found to decrease infection rate while male gender, young people, and individuals who underwent replacements were associated with an increased risk of infection. Additionally, pre-operation temporal pacing and steroid use should be avoided if possible. Furthermore, COPD patients or those who accept CRTs should be monitored closely. PMID:25501080

  8. Surgical ablation for atrial fibrillation: The efficacy of a novel bipolar pen device in the cardioplegically arrested and beating heart

    PubMed Central

    Sakamoto, Shun-ichiro; Voeller, Rochus K.; Melby, Spencer J.; Lall, Shelly C.; Chang, Nai-lun; Schuessler, Richard B.; Damiano, Ralph J.

    2009-01-01

    Objective The introduction of ablation technology has simplified surgical intervention for atrial fibrillation. However, most ablation devices cannot create focal transmural lesions on the beating heart and have difficulty ablating specific regions of the atria, such as the atrioventricular isthmus, coronary sinus, and ganglionated plexus. The purpose of this study was to examine the efficacy of a pen-type bipolar radiofrequency ablation device on both arrested and beating hearts. Methods Endocardial and epicardial atrial tissues in the free wall, left atrial roof, atrioventricular annuli, and coronary sinus were ablated for varying time intervals (2.5–15 seconds) in porcine cardioplegically arrested (n = 6) and beating (n = 9) hearts. The hearts were stained with 1%2,3,5-triphenyl-tetrazolium chloride solution and sectioned to determine lesion depth and width. In 5 animals epicardial fat pads containing ganglionated plexus were stimulated and ablated. Results Lesion depth increased with ablation time similarly in both arrested and beating hearts. Transmurality was fully achieved in the thin atrial tissue (<4 mm) at 10 seconds in the beating and arrested hearts. The device had a maximal penetration depth of 6.1 mm. Epicardial ablation of the coronary sinus showed complete penetration through the left posterior atrium only in the arrested heart. Seven of 17 fat pads demonstrated a vagal response. All vagal responses were eliminated after ablation. Conclusion The bipolar pen effectively ablated atrial tissue in both arrested and beating hearts. This device might allow the surgeon to ablate tissue in regions not accessible to other devices during atrial fibrillation surgery. PMID:19026819

  9. Intelligent postoperative morbidity prediction of heart disease using artificial intelligence techniques.

    PubMed

    Hsieh, Nan-Chen; Hung, Lun-Ping; Shih, Chun-Che; Keh, Huan-Chao; Chan, Chien-Hui

    2012-06-01

    Endovascular aneurysm repair (EVAR) is an advanced minimally invasive surgical technology that is helpful for reducing patients' recovery time, postoperative morbidity and mortality. This study proposes an ensemble model to predict postoperative morbidity after EVAR. The ensemble model was developed using a training set of consecutive patients who underwent EVAR between 2000 and 2009. All data required for prediction modeling, including patient demographics, preoperative, co-morbidities, and complication as outcome variables, was collected prospectively and entered into a clinical database. A discretization approach was used to categorize numerical values into informative feature space. Then, the Bayesian network (BN), artificial neural network (ANN), and support vector machine (SVM) were adopted as base models, and stacking combined multiple models. The research outcomes consisted of an ensemble model to predict postoperative morbidity after EVAR, the occurrence of postoperative complications prospectively recorded, and the causal effect knowledge by BNs with Markov blanket concept. PMID:21184153

  10. Apoptotic self-organized electronic device using thin-film transistors for artificial neural networks with unsupervised learning functions

    NASA Astrophysics Data System (ADS)

    Kimura, Mutsumi; Miyatani, Tomoaki; Fujita, Yusuke; Kasakawa, Tomohiro

    2015-03-01

    Artificial neural networks are promising systems for information processing with many advantages, such as self-teaching and parallel distributed computing. However, conventional networks consist of extremely intricate circuits to guarantee accurate behaviors of the neurons and synapses. We demonstrate an apoptotic self-organized electronic device using thin-film transistors for artificial neural networks with unsupervised learning functions. First, we formed a “neuron” from only eight transistors and reduced a “synapse” to only one transistor by employing the characteristic degradations of the synapse transistors to adjust the synaptic connection strength. Second, we classified the synapses into two types, “concordant” and “discordant” synapses, and composed a local interconnective network optimized for integrated electronic circuits. Finally, we confirmed that the device is feasible and can learn multiple logical operations, including AND, OR, and XOR.

  11. The hemostatic history of a 15-month-old child implanted with a Berlin heart left ventricular assist device.

    PubMed

    Steenwyk, Brad L; Kirklin, James K; Gurley, William Q; Nielsen, Vance G

    2007-03-01

    We documented the hemostatic changes associated with placement of a EXCOR Berlin Heart left ventricular assist device in a 15-month-old child before heart transplantation. The development of hypercoagulability was rapid, manifested first by a plasmatic and subsequently platelet-mediated increase in coagulation kinetics and strength that persisted for weeks. The patient had no thrombotic complications for 6 wk before transplant but required extraordinary blood product administration to achieve hemostasis secondary to aggressive, multimodal anticoagulation. In summary, when proscribing anesthetic and surgical management of patients with a Berlin Heart, consideration of hypercoagulable features and anticoagulant therapy must be made to maximize patient safety. PMID:17312204

  12. Pulmonary Hypertension and Congenital Heart Disease.

    PubMed

    Roth, Todd S; Aboulhosn, Jamil A

    2016-08-01

    Pulmonary arterial hypertension in congenital heart disease (PAH-CHD) is a frequent complication in adults with congenital heart disease. Regardless of etiology, the optimal treatment strategy for this difficult population is challenging. The new frontier of targeted PAH therapies has demonstrated improved functional capacity in the various phenotypes of PAH-CHD, with work currently in progress scrutinizing outcomes. In those who fail conventional medical therapy, heart and heart-lung (block) transplantation become the final therapeutic options, with the role of ventricular assist devices and the total artificial heart still under investigation in this group. PMID:27443136

  13. Long-term continuous-flow left ventricular assist devices (LVAD) as bridge to heart transplantation

    PubMed Central

    Pozzi, Matteo; Giraud, Raphaël; Tozzi, Piergiorgio; Bendjelid, Karim; Robin, Jacques; Meyer, Philippe; Obadia, Jean François

    2015-01-01

    Heart transplantation (HTx) is the treatment of choice for end-stage heart failure but the limited availability of heart’s donors still represents a major issue. So long-term mechanical circulatory support (MCS) has been proposed as an alternative treatment option to assist patients scheduled on HTx waiting list bridging them for a variable time period to cardiac transplantation—the so-called bridge-to-transplantation (BTT) strategy. Nowadays approximately 90% of patients being considered for MCS receive a left ventricular assist device (LVAD). In fact, LVAD experienced several improvements in the last decade and the predominance of continuous-flow over pulsatile-flow technology has been evident since 2008. The aim of the present report is to give an overview of continuous-flow LVAD utilization in the specific setting of the BTT strategy taking into consideration the most representative articles of the scientific literature and focusing the attention on the evolution, clinical outcomes, relevant implications on the HTx strategy and future perspectives of the continuous-flow LVAD technology. PMID:25922736

  14. Sex Differences in Device Therapy for Heart Failure: Utilization, Outcomes, and Adverse Events

    PubMed Central

    Herz, Naomi D.; Engeda, Joseph; Zusterzeel, Robbert; Sanders, William E.; O'Callaghan, Kathryn M.; Strauss, David G.; Jacobs, Samantha B.; Selzman, Kimberly A.; Piña, Ileana L.

    2015-01-01

    Abstract Background: Multiple studies of heart failure patients demonstrated significant improvement in exercise capacity, quality of life, cardiac left ventricular function, and survival from cardiac resynchronization therapy (CRT), but the underenrollment of women in these studies is notable. Etiological and pathophysiological differences may result in different outcomes in response to this treatment by sex. The observed disproportionate representation of women suggests that many women with heart failure either do not meet current clinical criteria to receive CRT in trials or are not properly recruited and maintained in these studies. Methods: We performed a systematic literature review through May 2014 of clinical trials and registries of CRT use that stratified outcomes by sex or reported percent women included. One-hundred eighty-three studies contained sex-specific information. Results: Ninety percent of the studies evaluated included ≤35% women. Fifty-six articles included effectiveness data that reported response with regard to specific outcome parameters. When compared with men, women exhibited more dramatic improvement in specific parameters. In the studies reporting hazard ratios for hospitalization or death, women generally had greater benefit from CRT. Conclusions: Our review confirms women are markedly underrepresented in CRT trials, and when a CRT device is implanted, women have a therapeutic response that is equivalent to or better than in men, while there is no difference in adverse events reported by sex. PMID:25793483

  15. Real time heart rate variability assessment from Android smartphone camera photoplethysmography: Postural and device influences.

    PubMed

    Guede-Fernandez, F; Ferrer-Mileo, V; Ramos-Castro, J; Fernandez-Chimeno, M; Garcia-Gonzalez, M A

    2015-08-01

    The aim of this paper is to present a smartphone based system for real-time pulse-to-pulse (PP) interval time series acquisition by frame-to-frame camera image processing. The developed smartphone application acquires image frames from built-in rear-camera at the maximum available rate (30 Hz) and the smartphone GPU has been used by Renderscript API for high performance frame-by-frame image acquisition and computing in order to obtain PPG signal and PP interval time series. The relative error of mean heart rate is negligible. In addition, measurement posture and the employed smartphone model influences on the beat-to-beat error measurement of heart rate and HRV indices have been analyzed. Then, the standard deviation of the beat-to-beat error (SDE) was 7.81 ± 3.81 ms in the worst case. Furthermore, in supine measurement posture, significant device influence on the SDE has been found and the SDE is lower with Samsung S5 than Motorola X. This study can be applied to analyze the reliability of different smartphone models for HRV assessment from real-time Android camera frames processing. PMID:26737985

  16. Analysis of current density and specific absorption rate in biological tissue surrounding transcutaneous transformer for an artificial heart.

    PubMed

    Shiba, Kenji; Nukaya, Masayuki; Tsuji, Toshio; Koshiji, Kohji

    2008-01-01

    This paper reports on the current density and specific absorption rate (SAR) analysis of biological tissue surrounding an air-core transcutaneous transformer for an artificial heart. The electromagnetic field in the biological tissue is analyzed by the transmission line modeling method, and the current density and SAR as a function of frequency, output voltage, output power, and coil dimension are calculated. The biological tissue of the model has three layers including the skin, fat, and muscle. The results of simulation analysis show SARs to be very small at any given transmission conditions, about 2-14 mW/kg, compared to the basic restrictions of the International Commission on nonionizing radiation protection (ICNIRP; 2 W/kg), while the current density divided by the ICNIRP's basic restrictions gets smaller as the frequency rises and the output voltage falls. It is possible to transfer energy below the ICNIRP's basic restrictions when the frequency is over 250 kHz and the output voltage is under 24 V. Also, the parts of the biological tissue that maximized the current density differ by frequencies; in the low frequency is muscle and in the high frequency is skin. The boundary is in the vicinity of the frequency 600-1000 kHz. PMID:18232363

  17. [The influence of hereditary thrombophilic mechanisms on the degree of permanent intravascular coagulation in patients with artificial heart valves].

    PubMed

    Vavilova, T V; Sirotkina, O V; Razorenov, G I; Razorenova, T S; Emanuél', V L; Gritsenko, V V; Orlovskiĭ, P I; Doĭnikov, D N; Sharafutdinov, V E; Karpov, S A; Kuznetsov, A A; Kadinskaia, M I

    2004-01-01

    The genotyping of 40 patients with artificial heart valves (AHV) was performed after prosthesis of the mitral and aotic valves with bicuspid AHV (Medinzh-2 and CarboMedics). The patients took phenylin and varfarin. The patients' genotype was estimated by the thrombophylic genes: factor V Leiden (FVL), prothrombin G20210A, methylene tetrahydrofolate reductase C677T, G/A--455FGB, 4G/5G PAI-1, PI A1/A2 GPIIIa. The genes determining the thrombocytic activity or the vascular wall state substantially influence the third degree of the intensity of the permanent intravascular coagulation (PIC-3) independent of the degree of correction of hemostasis of oral anticoagulants. The addition of anti-aggregants to therapy is the only that can normalize functional activity of thrombocytes in patients with AHV having such defects. The laboratory detection of the genetic defects is of great practical importance for the determination of risk groups of formation of PIC-3 and the strategy of antithrombotic protection of patients with AHV. PMID:15651704

  18. IN VIVO ACUTE PERFORMANCE OF THE CLEVELAND CLINIC SELF-REGULATING CONTINUOUS-FLOW TOTAL ARTIFICIAL HEART

    PubMed Central

    Fumoto, Hideyuki; Horvath, David J.; Rao, Santosh; Massiello, Alex L.; Horai, Tetsuya; Takaseya, Tohru; Arakawa, Yoko; Mielke, Nicole; Chen, Ji-Feng; Dessoffy, Raymond; Fukamachi, Kiyotaka; Golding, Leonard A. R.

    2009-01-01

    Background The purpose of this study was to evaluate the acute in vivo pump performance of a unique valveless, sensorless, pulsatile, continuous flow total artificial heart (CFTAH) that passively self-balances left and right circulations without electronic intervention. Methods The CFTAH was implanted in two calves with pump and hemodynamic data recorded at baseline over the full range of pump operational speeds (2,000-3,000 rpm) in 200-rpm increments, pulsatility variance, and under a series of induced hemodynamic states created by varying circulating blood volume and systemic and pulmonary vascular resistance (SVR and PVR). Results Sixty of the 63 induced hemodynamic states in Case #1 and 73 of 78 states in Case #2 met our design goal of a balanced flow and maximum atrial pressure difference of 10 mm Hg. The correlation of calculated vs. measured flow and SVR was high (R2 = 0.857 and 0.832, respectively), allowing validation of an additional level of automatic active control. By varying the amplitude of sinusoidal modulation of the speed waveform, 9 mm Hg of induced pulmonary and 18 mm Hg of systemic arterial pressure pulsation were achieved. Conclusions These results validated CFTAH self-balancing of left and right circulation, induced arterial flow and pressure pulsatility, accurate calculated flow and SVR parameters and the performance of an automatic active control mode in an acute in vivo setting in response to a wide range of imposed physiologic perturbations. PMID:19782590

  19. Wireless photoplethysmographic device for heart rate variability signal acquisition and analysis.

    PubMed

    Reyes, Ivan; Nazeran, Homer; Franco, Mario; Haltiwanger, Emily

    2012-01-01

    The photoplethysmographic (PPG) signal has the potential to aid in the acquisition and analysis of heart rate variability (HRV) signal: a non-invasive quantitative marker of the autonomic nervous system that could be used to assess cardiac health and other physiologic conditions. A low-power wireless PPG device was custom-developed to monitor, acquire and analyze the arterial pulse in the finger. The system consisted of an optical sensor to detect arterial pulse as variations in reflected light intensity, signal conditioning circuitry to process the reflected light signal, a microcontroller to control PPG signal acquisition, digitization and wireless transmission, a receiver to collect the transmitted digital data and convert them back to their analog representations. A personal computer was used to further process the captured PPG signals and display them. A MATLAB program was then developed to capture the PPG data, detect the RR peaks, perform spectral analysis of the PPG data, and extract the HRV signal. A user-friendly graphical user interface (GUI) was developed in LabView to display the PPG data and their spectra. The performance of each module (sensing unit, signal conditioning, wireless transmission/reception units, and graphical user interface) was assessed individually and the device was then tested as a whole. Consequently, PPG data were obtained from five healthy individuals to test the utility of the wireless system. The device was able to reliably acquire the PPG signals from the volunteers. To validate the accuracy of the MATLAB codes, RR peak information from each subject was fed into Kubios software as a text file. Kubios was able to generate a report sheet with the time domain and frequency domain parameters of the acquired data. These features were then compared against those calculated by MATLAB. The preliminary results demonstrate that the prototype wireless device could be used to perform HRV signal acquisition and analysis. PMID:23366333

  20. Comparison of intraplatelet reactive oxygen species, mitochondrial damage, and platelet apoptosis after implantation of three continuous flow left ventricular assist devices: HeartMate II, Jarvik 2000, and HeartWare.

    PubMed

    Mondal, Nandan K; Sorensen, Erik N; Feller, Erika D; Pham, Si M; Griffith, Bartley P; Wu, Zhongjun J

    2015-01-01

    Differences in device design may have an effect on platelet damage and associated clinical complications. We aimed to compare device-specific platelet functionality in 26 heart failure patients supported with three continuous-flow left ventricular assist devices: HeartMate II (n = 8), Jarvik 2000 (n = 9), and HeartWare (n = 9). Intraplatelet reactive oxygen species (ROS) generation, mitochondrial damage, and platelet apoptosis were compared between device types before and after the implantation at every week up to 1 month. Overall, the baseline characteristics, demographics, routine laboratory values were comparable between the three device groups. Intraplatelet ROS, mitochondrial damage, and platelet apoptosis significantly elevated in the HeartWare group in comparison with the other two device groups after implantation. The major bleeding, infections, systemic inflammatory response syndrome, and right ventricular failure were found to be more common among the HeartWare group than others. Intraplatelet ROS and platelet damage levels were returned to baseline in both the HeartMate II and the Jarvik groups, whereas in HeartWare group they remained elevated. The patients with the Jarvik and the HeartMate II experienced less clinical complications and the platelet functionality is not compromised by these devices. Data from this study suggests that the continuous-flow left ventricular assist devices design may exert different effects on platelet function. PMID:25757140

  1. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials

    PubMed Central

    Howlett, Jonathan G; McKelvie, Robert S; Arnold, J Malcolm O; Costigan, Jeannine; Dorian, Paul; Ducharme, Anique; Estrella-Holder, Estrellita; Ezekowitz, Justin A; Giannetti, Nadia; Haddad, Haissam; Heckman, George A; Herd, Anthony M; Isaac, Debra; Jong, Philip; Kouz, Simon; Liu, Peter; Mann, Elizabeth; Moe, Gordon W; Tsuyuki, Ross T; Ross, Heather J; White, Michel

    2009-01-01

    The Canadian Cardiovascular Society published a comprehensive set of recommendations on the diagnosis and management of heart failure in January 2006. Based on feedback obtained through a national program of heart failure workshops and through active solicitation of stakeholders, several topics were identified because of their importance to the practicing clinician. Topics chosen for the present update include best practices for the diagnosis and management of right-sided heart failure, myocarditis and device therapy, and a review of recent important or landmark clinical trials. These recommendations were developed using the structured approach for the review and assessment of evidence adopted and previously described by the Society. The present update has been written from a clinical perspective to provide a user-friendly and practical approach. Specific clinical questions that are addressed include: What is right-sided heart failure and how should one approach the diagnostic work-up? What other clinical entities may masquerade as this nebulous condition and how can we tell them apart? When should we be concerned about the presence of myocarditis and how quickly should patients with this condition be referred to an experienced centre? Among the myriad of recently published landmark clinical trials, which ones will impact our standards of clinical care? The goals are to aid physicians and other health care providers to optimally treat heart failure patients, resulting in a measurable impact on patient health and clinical outcomes in Canada. PMID:19214293

  2. Numerical analysis of blood flow in the clearance regions of a continuous flow artificial heart pump.

    PubMed

    Anderson, J; Wood, H G; Allaire, P E; Olsen, D B

    2000-06-01

    The CFVAD3 is the third prototype of a continuous flow ventricular assist device being developed for implantation in humans. The pump consists of a fully shrouded 4-blade impeller supported by magnetic bearings. On either side of this suspended rotating impeller is a small clearance region through which the blood flows. The spacing and geometry of these clearance regions are very important to the successful operation of this blood pump. Computational fluid dynamics (CFD) solutions for this flow were obtained using TascFlow, a software package available from AEA Technology, U.K. Flow in these clearance regions was studied parametrically by varying the size of the clearance, the blood flow rate into the pump, and the rotational speed of the pump. The numerical solutions yield the direction and magnitude of the flow and the dynamic pressure. Experimentally measured pump flow rates are compared to the numerical study. The results of the study provide guidance for improving pump efficiency. It is determined that current clearances can be significantly reduced to improve pump efficiency without negative impacts. PMID:10886072

  3. Exercise in heart failure patients supported with a left ventricular assist device.

    PubMed

    Jung, Mette Holme; Gustafsson, Finn

    2015-04-01

    After implantation of a continuous-flow left ventricular assist device (CF-LVAD), exercise capacity in heart failure patients remains reduced with peak oxygen uptake (peak VO2) values averaging from 11 to 20 ml/kg/min. Total cardiac output in CF-LVAD patients during exercise is predominantly determined by pump speed, the pressure difference across the pump, and in some cases ejection through the aortic valve. Fixed pump speed utilized in CF-LVADs may provide insufficient support, resulting in a moderate cardiac output increase during increased physical strain. Ongoing studies are evaluating whether pump speed changes in response to varied loading conditions may enable LVADs to provide sufficient support even during strenuous exercise. In the currently used devices, evidence suggests that focus on optimizing non-cardiac peripheral parameters is vital. Extra-cardiac potentially reversible factors are anemia with low oxygen-carrying capacity, obesity and general deconditioning with low muscle mass. In addition, exercise training in CF-LVAD patients can improve peak VO2. To design interventions to improve functional capacity in patients treated with modern durable LVADs, a detailed understanding of exercise physiology in a continuous-flow circulatory system is necessary. In this review we address the different components of exercise physiology in LVAD patients and point out potential solutions or areas of future research. PMID:25577562

  4. Biventricular mechanical support devices - clinical perspectives.

    PubMed

    Shehab, Sajad; Newton, Phillip J; Allida, Sabine M; Jansz, Paul C; Hayward, Christopher S

    2016-04-01

    Cardiac transplantation remains the optimal treatment for end stage heart failure in selected patients. However, the shortage of donor hearts, rigorous eligibility criteria and long waiting lists have increased the demand for alternative treatment strategies such as mechanical circulatory support. While many patients are adequately supported with left ventricular assist devices, frequently there is right heart failure or involvement of the right ventricle, requiring biventricular support. Pulsatile flow biventricular devices and total artificial hearts approved for temporary biventricular support have limitations including size, high rates of adverse events and restricted mobility which makes them unsuitable for long term support. A number of centres have reported dual continuous flow left ventricular assist devices as a means of supporting the left and right heart. This review will summarise the literature on the outcomes and complications from current biventricular support devices and assess the role of dual continuous flow VAD therapy, and the new continuous flow total heart replacement devices. PMID:26894825

  5. Acute Effects of a Therapeutic Mobility Device on Physical Activity and Heart Rate in Children with Down Syndrome

    ERIC Educational Resources Information Center

    Hauck, Janet L.; Ulrich, Dale A.

    2015-01-01

    Purpose: The purpose of this feasibility study was to provide an opportunity to increase physical activity (PA) and heart rate (HR) for children with Down syndrome (DS) during unstructured group exercise utilizing a riding device called the Power Pumper®. Method: Twenty-four children aged 5 to 7 years old participated in this case-control study,…

  6. Preload Sensitivity in Cardiac Assist Devices

    PubMed Central

    Fukamachi, Kiyotaka; Shiose, Akira; Massiello, Alex; Horvath, David J.; Golding, Leonard A. R.; Lee, Sangjin; Starling, Randall C.

    2013-01-01

    With implantable cardiac assist devices increasingly proving their effectiveness as therapeutic options for end-stage heart failure, it is important for clinicians to understand the unique physiology of device-assisted circulation. Preload sensitivity as it relates to cardiac assist devices is derived from the Frank-Starling relationship between human ventricular filling pressures and ventricular stroke volume. In this review, we stratify the preload sensitivity of 17 implantable cardiac assist devices relative to the native heart and discuss the effect of preload sensitivity on left ventricular volume unloading, levels of cardiac support, and the future development of continuous-flow total artificial heart technology. PMID:23272869

  7. Surface modification of polyurethane films by plasma and ultraviolet light to improve haemocompatibility for artificial heart valves.

    PubMed

    Alves, P; Cardoso, R; Correia, T R; Antunes, B P; Correia, I J; Ferreira, P

    2014-01-01

    Prosthetic cardiac valves implantation is a common procedure used to treat heart valve diseases. Although there are different prostheses already available in the market (either mechanical or bioprosthetic), their use presents several problems, specifically concerning thrombogenicity and structural failure. Recently, some progresses have been achieved in developing heart valves based on synthetic materials with special emphasis in polymers. Among them, polyurethanes are one of the most commonly used for the production of these devices. Herein, Elastollan(®)1180A50, a thermoplastic polyurethane (TPU), was used to formulate films whose surfaces were modified by grafting 2-hydroxyethylmethacrylate (HEMA) either by ultra-violet (UV) or by plasma treatment. All films were analyzed before and after grafting. X-ray photoelectron spectroscopy (XPS) measurements were used to evaluate TPU surfaces functionalization. HEMA grafting was confirmed by the increase of the hydroxyl (OH) groups' concentration at the surface of the films. Atomic force microscopy (AFM) analysis was done to evaluate the surface topography of the biomaterials. Results showed that the roughness of the surface decreased when HEMA was grafted, especially for plasma treated samples. After grafting the films' hydrophilicity was improved, as well as the polar component of the surface energy, by 15-30%. Hydrophobic recovery studies using milli Q water or PBS were also performed to characterize the stability of the modified surface, showing that the films maintained their surface properties along time. Furthermore, blood-contact tests were performed to evaluate haemolytic and thrombogenic potential. The results obtained for HEMA grafted surfaces, using plasma treatment, confirmed biomaterials biocompatibility and low thrombogenicity. Finally, the cytotoxicity and antibacterial activity of the materials was assessed through in vitro assays for both modified films. The obtained results showed enhanced

  8. In vivo performance evaluation of a transcutaneous energy and information transmission system for the total artificial heart.

    PubMed

    Ahn, J M; Kang, D W; Kim, H C; Min, B G

    1993-01-01

    As part of an electromechanical total artificial heart (TAH) program, an integrated transcutaneous energy and information transmission (TEIT) system has been developed. In vivo performance of the developed system was evaluated through a simplified animal model without implant of a TAH. The design features include the small size of the implanted part, and dual coil structure of the external part. In the transcutaneous energy transmission (TET) system based on magnetic induction, the external primary and implanted secondary coils have the shape of a truncated cone, 7.0 and 3.8 cm in diameter, and 23 and 12 turns of Litz wire, respectively. The external coil is driven by a 350 to 410 kHz tuned class E amplifier that has a minimum switching loss of power transistor. In vitro test results using 1 cm thick dog's skin showed a flat total efficiency (DC to DC) of 75% for 20 to 30 W of delivered mean power. In order to achieve bidirectional communication between implanted and external components, a small circuit board containing four light emitting diodes and a photodiode was incorporated in each TET coil facing each other across the skin. Unmodulated optical pulse transmitted digital data (9600 baud, RS-232 protocol) in error free condition through an up to 15 mm thick dog's skin patch accommodated 18 degrees of misalignment. Three subacute in vivo studies were conducted in dogs to evaluate performance of the developed system. The secondary set was implanted in the mild flank region of the dog, and the output was percutaneously connected to the control system to drive the external TAH on the mock circulatory system.(ABSTRACT TRUNCATED AT 250 WORDS) PMID:8268530

  9. Device therapy in advanced heart failure: what to put in and what to turn off: remote telemonitoring and implantable hemodynamic devices for advanced heart failure monitoring in the ambulatory setting and the evolving role of cardiac resynchronization therapy.

    PubMed

    Smith, Sakima A; Abraham, William T

    2011-01-01

    Despite evidence based medical and pharmacologic advances the management of heart failure remains challenging, especially in the ambulatory setting. There is an urgent need to develop strategies to reduce hospitalizations and re-admission rates for heart failure in general. This focused review illustrates the potential role for remote telemonitoring and implantable hemodynamic devices to address this significant issue. We also explore the growth of cardiac resynchronization therapy and how it has evolved into another tool in our armamentarium for hemodynamic monitoring. PMID:21906246

  10. Ultrathin, Stretchable, Multiplexing pH Sensor Arrays on Biomedical Devices With Demonstrations on Rabbit and Human Hearts Undergoing Ischemia

    PubMed Central

    Chung, Hyun-Joong; Sulkin, Matthew S.; Kim, Jong-Seon; Goudeseune, Camille; Chao, Hsin-Yun; Song, Joseph W.; Yang, Sang Yoon; Hsu, Yung-Yu; Ghaffari, Roozbeh

    2014-01-01

    Stable pH is an established biomarker of health, relevant to all tissues of the body, including the heart. Clinical monitoring of pH in a practical manner, with high spatiotemporal resolution, is particularly difficult in organs such as the heart due to its soft mechanics, curvilinear geometry, heterogeneous surfaces and continuous, complex rhythmic motion. The results presented here illustrate that advanced strategies in materials assembly and electrochemical growth can yield interconnected arrays of miniaturized IrOx pH sensors encapsulated in thin, low-modulus elastomers to yield conformal monitoring systems capable of non-invasive measurements on the surface of the beating heart. A thirty channel custom data acquisition system enables spatiotemporal pH mapping with a single potentiostat. In-vitro testing reveals super-Nernstian sensitivity with excellent uniformity (69.9 ± 2.2 mV/pH), linear response to temperature (−1.6 mV/°C), and minimal influence of extracellular ions (< 3.5 mV). Device examples include sensor arrays on balloon catheters and on skin-like stretchable membranes. Real-time measurement of pH on the surfaces of explanted rabbit hearts and a donated human heart during protocols of ischemia-reperfusion illustrate some of the capabilities. Envisioned applications range from devices for biological research, to surgical tools and long-term implants. PMID:23868871